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9General introduction
In societies from all over the world, we find human beings afflicted with a mental 
illness. The group of mental disorders can be divided into two main subgroups: 
neurodegenerative diseases and neurodevelopmental disorders. Neurodegeneration 
is the state in which cells of the brain and spinal cord are damaged or lost. Alzheimer's 
disease, Huntington's disease and Creutzfeldt-Jakob disease (mad cow disease) are 
examples of neurodegenerative diseases. In this thesis, the focus will be on the other 
subgroup, the neurodevelopmental disorders. The study will deal with a rat model 
for neurodevelopmental disorders (part A) and translational research in human (part 
B). This introductory chapter summarizes the current knowledge of the aetiology 
of complex neurodevelopmental disorders and the strategies followed to unravel its 
causes. Besides the genetic component that is clearly involved, also the environmental 
and epigenetic factors contributing to the pathology of neurodevelopmental disorders 
are briefly addressed. 
Neurodevelopmental disorders and genetic aetiology 
The relatively new term neurodevelopmental disorder includes a group of disorders 
with severely affected behavioral features caused by alterations in early brain 
development. Most neurodevelopmental disorders are associated with a life-
long endurance and have a severe impact on normal brain functioning, leading 
to affected behavior often resulting in large economical, emotional and physical 
problems, not only for the individual but also for the family and society as a whole. 
The various neurodevelopmental disorders show similar features, including brain 
dysfunctioning (such as difficulties in sensor and motor systems, problems with 
speech and language) and a number of cognitive impairments (e.g. in learning and 
organizational skills). Schizophrenia, autistic disorders, attention deficit hyperactivity 
disorder (ADHD), bipolar disorder, mental retardation and Tourette’s syndrome are 
some of the more common neurodevelopmental disorders, but also Rett syndrome, 
immunodeficiency, centromeric region instability, facial anomalies (ICF) syndrome 
and X-linked alpha thalassemia/mental retardation (ATR-X) syndrome are considered 
neurodevelopmental disorders (table 1). 
Neurodevelopmental disorders can be divided into four subgroups, based on their 
(mostly hypothetical) genetic aetiology (table 1). The first subgroup is characterized 
by aneuploidy (an abnormal number of chromosomes). The most well-known 
neurodevelopmental aneuploidy is Down’s syndrome with a trisomy of chromosome 
21. Disorders of the second subgroup contain chromosomal micro-deletions, such 
as the deletion of chromosomal region 7q11.2 (which harbours more than 20 genes) 
in William’s-Beuren syndrome. In each neurodevelopmental disorder of the third 
subgroup, only a single gene is affected. For example, the fragile X syndrome is a 
genetic disorder caused by a mutation (CGG repeat expansion) of the fragile X mental 
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Table 1. Neurodevelopmental disorders and their genetic aetiologies
Group Disorder Genetic aetiology
I (Aneuploidy)
Down’s syndrome Trisomy of chromosome 21 (OMIM #190685).
II (Micro-deletion)
Prader-Willi syndrome / 
Angelman syndrome
~4 Mb deletion (~7 genes) of chromosome 
15q11-q13 (OMIM #176270 and #105830).
Smith-Magenis syndrome Deletion (3.7 Mb) of chromosome 17p11.2 (OMIM 
#182290).
DiGeorge/velo-cardio-
facial syndrome
Hemizygous deletion (1.5 to 3.0-Mb) of 
chromosome 22q11.2 (OMIM #188400 and 
#192430).
William’s-Beuren 
syndrome
Deletion of chromosomal region 7q11.2 (OMIM 
#194050).
III (Single-gene defect)
ATR-X syndrome Mutations in the ATR-X gene on the X-chromosome 
(OMIM #301040)
Barth syndrome (X-linked 
cardioskeletal myopathy 
and neutropenia)
Mitochondrial functional impairments due to the 
tafazzin (TAZ) gene on chromosome Xq28 (OMIM 
#302060).
Fragile-X syndrome CCG repeat expansion of the FMR1 gene (OMIM 
#300624).
ICF syndrome Mutations in the DNA methyltransferase 3B 
(DNMT3B) gene on chromosome 20 (OMIM 
#242860).
Neurofibromatosis Mutations or deletion (~1.5 Mb) in the neurofibromin 
gene on chromosome 17q11.2 (OMIM +162200).
Rett syndrome Mutations in the MeCP2 gene on the 
X-chromosome (OMIM #312750).
Smith-Lemli-Opitz 
syndrome
Mutations in the gene encoding sterol delta-7-
reductase (DHCR7) on chromosome 11q12-q13 
(OMIM #270400).
IV (Multifactorial)
Addictive disorders
Attention deficit 
(hyperactivity) disorders 
Anxiety disorders
Asperger’s disorder
Autistic disorders
Bipolar disorder
Depressive illness
Dyslexia        Multiple genes (?)
Eating disorders
Epilepsy (seizure disorder)
Fetal alcohol syndrome
Hydrocephalus
Mental retardation
Schizophrenia
Spina bifida
Tourette’s syndrome
OMIM: Online Mendelian Inheritance in Man
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retardation 1 (FMR1) gene on the X chromosome. The neurodevelopmental disorders 
with a complex aetiology, such as autism and schizophrenia, comprise the fourth 
subgroup and are thought to be caused by (a combination of) genetic, environmental 
and epigenetic factors. This chapter focuses on the neurodevelopmental disorders 
with a complex aetiology and the current thoughts on their genetic, environmental 
and epigenetic aetiologies. 
 
Identification of susceptibility loci and genes 
Twin, family and adoption studies have revealed an unambiguous role for genetic 
factors in the aetiology of complex neurodevelopmental disorders that can even 
exceed an estimated heritability of 90% (in autism; table 2). Although a genetic 
component is thus clearly involved in the aetiology of a complex neurodevelopmental 
disorder, it is still elusive which gene (or genes) is responsible for its pathogenesis. 
Historically, the dopamine and also the glutamate neurotransmission system have 
often been implicated to play a role in neurodevelopmental pathogenesis. However, 
since many recently identified susceptibility genes have been found not to be 
related to either of the two neurotransmitter systems, restriction to these systems 
is no longer justified. To identify susceptibility genes and to better understand the 
pathophysiology of complex neurodevelopmental disorders, many studies utilizing 
genetic, biochemical, pharmacological, neurological and cognitive neuroscience 
techniques have been performed. In this section, the genetic approaches that have 
been used to identify risk factors at specific loci and genes are summarized. 
Linkage studies
Linkage analysis is a method to locate disease-related loci using DNA markers across 
the genome that travel with a disease within families. The main advantage of linkage 
analysis is that it involves family-based analysis, and thus eliminates the problem of 
ethnical stratification. However, linkage analysis has a relatively low power to detect 
small-effect variations (Risch and Merikangas, 1996).
 
Association studies
Numerous association studies have been performed to test for association between 
genetic variations and neurodevelopmental disorders (Craddock and Owen, 1996; 
Owen and Craddock, 1996). Compared to linkage analysis, one important advantage 
of association studies concerns its improved power when equal cohort sizes are used 
(Risch, 2000). In association studies, the genotype or allele frequencies of genetic 
variations between patients and controls (non-related individuals; case-control 
design) or between parents and their offspring (related individuals; family-based 
design) is compared. For the case-control design, a more than by chance predicted 
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difference in the frequency of a single-nucleotide polymorphism (SNP) between 
the cases and controls indicates that the specific polymorphism may increase or 
decrease risk for the disorder, or is in linkage disequilibrium with a nearby genetic 
variant. The frequencies of genetic varations may vary among individuals from a 
different geographical or ethnical background and therefore a well-defined cohort is 
necessary. For family-based association studies, the parents function as the controls 
for the affected offspring (so-called trio-study). If the SNP is transmitted from the 
parents to the offspring as expected by chance alone, no association with the disorder 
is present. Transmission of the SNP at a higher degree than expected by chance 
suggests association of the genetic marker with the affected phenotype. 
Having decided on the study design and study samples, the next step is to select 
appropriate candidate genes. In general, a gene is selected with some a priori 
relationship with the disorder, based on its localization (i.e. the gene is located 
in a chromosomal region with a significant linkage), or proposed function in the 
pathogenesis of the disorder (e.g. the gene belongs to the dopamine or serotonin 
pathway in association studies for schizophrenia pathogenesis). Genome-wide 
association (GWA) studies can now also be performed, whereby large numbers of 
DNA polymorphisms are analyzed in one experiment. 
Genomic copy number variations
Recently, it became clear that besides mutations and SNPs (both coding and non-
coding alterations) also genomic rearrangements and gene-dosage imbalances 
(duplications, deletions and inversions) play a role in the pathogenesis of a number 
of nervous system disorders (reviewed by Lee and Lupski, 2006) (figure 1). These 
structural variants are common and ubiquitous in the genome and can range from 
kilobases to megabases in size. The human genome contains at least 1447 copy-
number variants (CNVs), covering 360 megabases and comprising 12% of the 
genome (Redon et al., 2006). Previous knowledge of CNVs in relation to diseases 
was limited due to insufficient methods to detect CNVs. Only large CNVs detected 
with cytogenetic techniques, such as G-banding (Giemsa staining) and fluorescence 
in situ hybridization, have been previously identified. The advent of high-resolution 
genome-wide methods has significantly improved the power to detect CNVs. 
At present, one of the most attractive techniques to detect CNVs is comparative genome 
hybridization (CGH) using DNA microarrays containing genomic DNA probes (e.g. 
bacterial artificial chromosome clones, cDNA clones or oligonucleotides). The 
CGH technology allows a genome-wide screening with a relatively high resolution 
(with the resolution depending on the number, distribution and lengths of the probes 
present on the array), and may be particularly useful for the identification of CNVs 
that are too small to detect via routine cytogenetic analyses. Another type of array 
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that can be used for detecting CNVs is the genome-wide SNP array. Besides normal 
SNP analysis (i.e. the identification of a single-base polymorphism), these arrays 
also give intensity information and thereby the corresponding copy number of a 
genomic region. Once CNVs have been detected, studies for locus-specific CNV 
association have to be designed, such as targeted quantitative and semiquantitative 
PCR, multiplex ligation-dependent probe amplification or dynamic allele-specific 
hybridization.
Figure 1. Genetic and epigenetic variations in the genome. (A) A single-nucleotide polymorphism 
(SNP) or mutation (indicated by an asterix) represents a variation of a single base pair in the genome. 
SNPs are thought to be mutations that have been successful enough to remain within a population 
with a significant prevalence (>1%). The epigenetic variation DNA methylation (indicated by a star) 
represents addition of a methyl group to the cytosine within the sequence CG. (B) Copy number 
variations (CNVs) include genomic rearrangements and gene-dosage imbalances, and can range from 
kilobases to megabases in size (figure B based on Check, 2005).  
mRNA and protein expression profiling 
The principle of mRNA and protein profiling is to identify genes that are differentially 
expressed in selected tissues of cases and (matched) controls. One of the promising 
strategies is the use of human post-mortem brain tissues, from which nowadays 
good quality mRNA can be extracted for microarray analysis (Tkachev et al., 2003). 
However, when performing such studies one has to be aware of the possibility that 
14
General introduction
the differential expression could be caused by years of medicine usage or by pre- or 
post-mortem artifacts. 
Animal models
The use of animal models for the analysis of complex neurodevelopmental disorders 
appears to be an attractive alternative to circumvent the problems encountered when 
human material is used for mRNA or protein profiling. However, animals do not 
exhibit higher-order functions, some of which may be associated with complex 
human disorders. Nevertheless, one can take advantage of specific characteristics 
(endophenotypes) of an animal model to study the genetic and environmental factors 
that lead to a particular phenotypic outcome. 
Several categories of animal models may be employed, including models based 
on a behavioral selection (e.g. the endophenotype prepulse inhibition), on a 
pharmacological selection (e.g. the psychotic effects of drugs, such as amphetamine) 
or on brain lesions (e.g. animal models with disconnections of the hippocampus). In 
addition, genetic animal models – with targeted genetic manipulations of specific 
genes - can be used, including knockout, knockin and transgenic models. Genetically 
modified animals can be subjected to a whole battery of behavioral tests to understand 
the role of a gene in neurodevelopmental aetiology. Furthermore, such models can 
be used to study environmental manipulations, including maternal or chronic stress 
paradigms. An example of an animal model for neurodevelopmental disorders 
represent the so-called APO-SUS/-UNSUS rats, a model based on a pharmacological 
selection (Cools et al., 1990). A more detailed description of this model will be given 
at the end of this chapter.
Susceptibility loci and genes of complex neurodevelopmental disorders 
In the past decades, an impressive amount of linkage and association studies have 
been performed. However, conclusive evidence from the numerous genetic linkage 
and association studies has not yet been obtained. The studies have continuously led to 
inconsistent and controversial findings. In the next paragraphs, the genetic aetiology 
of the complex neurodevelopmental disorders is summarized. However, because 
positive associations are often published more easily one has to realize publication 
bias and the fact that even results obtained by meta-analysis may represent false 
positives. 
Autism
Autism has a prevalence of ~0.6% in the general population and is four times more 
prevalent in boys than in girls. Together with four other disorders (Asperger’s 
disorder, childhood disintegrative disorder, Rett syndrome and Personality Disorder 
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Not Otherwise Specified) it belongs to the group of Pervasive Developmental 
Disorders (PDD). Autism is the most common PDD and usually appears during the 
first three years of life. Its symptoms include impairments in verbal and nonverbal 
communication, lack of social interaction, and restricted and stereotypical behaviour 
(Montes and Halterman, 2006). Though autism is one of the most hereditary disorders 
in psychiatry, with an estimated heritability of up to 90% (table 2) (Freitag, 2007), 
the search for susceptibility genes has proven to be complex.  Until now, a number 
of chromosomal loci have been identified that may represent regions predisposing 
to autism, including regions on chromosome 1p12-p21.1, 1q21-q44, 2q24.1-q33.1, 
3q21.3-q29, 4q21.3-q35.1, 5p12-p15.33, 6q14.3-q23.2, 7q21.2-q36.2, 10p12.1-p14, 
10q23.3-q26.3, 13q12.13-q33.1, 15q13.1-q26.1, 16p12.1-p13.3, 17q11.1-q21.2, 
19p13.11-p13.3 and 19q12-q13.12 (reviewed by  Yang and Gill, 2007). Although 
most susceptibility regions have been studied in more detail via the candidate-gene 
approach (e.g. the Reelin gene on chromosome 7q22 and the serotonin transporter 
gene (SLC6A4) on chromosome 17q11.1-q12), no gene has been found to clearly 
contribute to autism susceptibility. Recently, the first GWA studies for autism have 
been reported with significant associations, including CNVs, found in several genetic 
loci (Lauritsen et al., 2006; Sebat et al., 2007; Szatmari et al., 2007), but the results 
have been inconclusive. Thus, despite the high heritability estimates for autism, its 
genetic aetiology still needs to be elucidated.
Table 2. Estimated heritability of complex neurodevelopmental disorders
Disorder Estimated 
heritability
References
Autism >90% (Freitag, 2007)
Schizophrenia 80% (Cardno et al., 1999)
ADHD 70% (Faraone and Khan, 2006)
Epilepsy 70% (Kjeldsen et al., 2002)
Drug addiction 70% (Sullivan and Kendler, 1999)
Spina bifida 70% (Jorde et al., 1983)
Bipolar disorder 63% (Smoller and Finn, 2003)
Eating disorders 48-74% (Bulik et al., 1998; Kortegaard et al., 2001)
Dyslexia 50-70% (Hawke et al., 2006)
Alcohol addiction 50-60% (Hiroi and Agatsuma, 2005) 
Panic disorder 30-46% (Fyer et al., 2006)
Posttraumatic stress disorder 30% (True et al., 1993)
Obsessive-compulsive disorder 26-47% (Clifford et al., 1984; Jonnal et al., 2000)
Anxiety disorders 30-40% (Hettema et al., 2001)
Depressive illness 37% (Kendler and Karkowski-Shuman, 1997)
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Schizophrenia 
Schizophrenia is a common mental disorder affecting approximately 1% of the 
population (Jablensky et al., 1987). It generally emerges between 16 and 30 years of 
age and is characterized by three main symptoms: cognitive disturbances, psychosis 
and negative symptoms (Kay and Opler, 1987). Unfortunately, there are no genetic 
markers available for diagnosing schizophrenia. Therefore, diagnosis can only be 
based on clinical symptoms using the Diagnostic and Statistical manual for mental 
disorders version IV (DSM-IV, 2000) or the International Classification of Disease 
version 10 (ICD-10, 1992). 
The first genetic studies on schizophrenia date back from 1916 and addressed the 
question whether the disorder has a genetic aetiology. Many subsequent family, 
twin and adoption studies clearly revealed the importance of a genetic component 
in schizophrenia (Gottesman, 1991) with an estimated heritability of around 80% 
(table 2) (Cardno et al., 1999), but the responsible gene (or genes) is still elusive. 
Although many susceptibility loci have been identified, numerous inconsistent and 
controversial findings have been reported. The genes most often reported to be 
related to schizophrenia are the genes encoding disrupted in schizophrenia 1 (DISC1; 
1q42.1), neuregulin-1 (NRG1; 8p12), dysbindin (DTNBP1; 6p22.3), D-amino acid 
oxidase activator (DAOA or G72; 13q34), D-amino-acid oxidase (DAO; 12q24), 
regulator of G-protein signaling 4 (RGS4; 1q23.3) and the dopamine-catabolizing 
enzyme catechol-O-methyl transferase (COMT; 22q11.21) (reviewed by Owen et 
al., 2005; Ross et al., 2006). However, relative risk effects of the variations range 
between 1.5 to 2.0, indicating only small-effect sizes. Recently, the first GWA study 
for schizophrenia using the Affymetrix GeneChip 500K Mapping Array Set on 178 
schizophrenic patients and 144 controls has been reported. One SNP (rs4129148) 
close to the colony stimulating factor 2 receptor alpha chain gene (CSF2RA) on 
chromosome Xp22.32 and Yp11.3 showed association beyond the genome-wide 
significance threshold (Lencz et al., 2007). Independent replications to confirm this 
finding are however necessary. 
Bipolar disorder
Bipolar disorder, also known as manic-depressive illness, is a severe mental disorder 
characterized by recurrent manic and depressive episodes causing dramatic mood 
swings. The prevalence of bipolar disorder is estimated to be 0.8-2.6% (Kato, 2007). 
Although some have their first symptoms in childhood, most patients develop episodes 
in late adolescence or early adulthood. Bipolar disorder patients show many clinical 
features that are similar to those of schizophrenic patients, such as age of onset, 
psychotic symptoms, episodic courses of illness and a lifelong endurance. However, 
also clear distinctions exist between the two disorders. For example, bipolar disorder 
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manifests as an impairment of mood, whereas schizophrenia is a primary disorder of 
cognition. Furthermore, most bipolar patients benefit from lithium therapy, whereas 
schizophrenics seldom do. 
Twin and family studies have shown that bipolar disorder tends to run in families 
with an estimated genetic hereditary of 63% (Smoller and Finn, 2003). Interestingly, 
besides the shared clinical symptoms, bipolar disorder and schizophrenia may also 
share a genetic background (Berrettini, 2003). A number of promising susceptibility 
genes for schizophrenia have been reported to associate with bipolar disorder as well, 
including G72, DAO, DISC1, NRG1, RGS4, COMT, neural cell adhesion molecule 
1 (NCAM1; 11q23.1), brain-derived neurotrophic factor (BDNF; 11p13) glutamate 
receptor, metabotropic 3 and 4 (GRM3; 7q21.1-q21.2 and GRM4; 6p21.3), glutamate 
receptor, ionotropic, N-methyl D-aspartate 2B (GRIN2B; 12p12), megalencephalic 
leukoencephalopathy with subcortical cysts 1 (MLC1; 22q13.33), synaptogyrin 1 
(SYNGR1; 22q13.1) and solute carrier family 12 (potassium/chloride transporters), 
member 6 (SLC12A6; 15q13-q15) (reviewed by Farmer et al., 2007; Kato, 2007). 
Recently, The Wellcome Trust Case Control Consortium reported a GWA study on 
bipolar disorder using the Affymetrix GeneChip 500K Mapping Array Set and found 
one chromosomal region with strong evidence of association (16p12) and 13 regions 
with moderate association (2p25, 2q12, 2q14, 2q37, 3p23, 3q27, 6p21, 8p12, 9q32, 
14q22, 14q32, 16q12 and 20p13) (Consortium WTCC, 2007). 
Major depression
Like bipolar disorder, depression is a major mood disorder. Although many clinical 
aspects are comparable between major depression and bipolar disorder, a number 
of characteristics are different between the two disorders: depression is much more 
heterogeneous, has a higher environmental contribution and has a higher prevalence 
with an overall lifetime risk of 16.2% in the United States (Kessler et al., 2003). 
Since the genetic contribution to major depression is only ~37% (Kendler and 
Karkowski-Shuman, 1997) and the illness is highly heterogeneous, unravelling its 
genetic pathogenesis is extremely difficult. To date, no clear genetic risk factors for 
major depression have been identified. Most studies have focused on well-known 
polymorphisms that have been hypothesized to associate with other psychiatric disorders. 
For example, the Val66Met variant in the BDNF gene, the short allele of the SLC6A4 
gene, and the Val158Met variation in the COMT gene have been studied in depression 
cohorts (Caspi et al., 2003; Massat et al., 2005; Schumacher et al., 2005), but the results 
are contradictory (Frisch et al., 1999; Gillespie et al., 2005; Surtees et al., 2007). 
ADHD
ADHD was first described in 1845 and affects up to 1 in 20 children (Comings, 
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2001; Faraone et al., 2003). The principal problem for children with ADHD is 
the impairment to control their behaviour, due to inattention, hyperactivity and 
impulsivity. According to the DSM-IV guidelines, these symptoms should appear 
early in a child’s life, before age 7, and should continue for at least 6 months, 
otherwise the diagnosis ADHD is not justified. Other disorders often accompany 
ADHD, including learning disabilities, oppositional defiant disorder, conduct 
disorder, Tourette’s syndrome and/or depressive illness.  
Twin studies have indicated a relatively high genetic contribution reaching an 
average of 70% (Faraone and Khan, 2006). Thus far, many candidate gene studies 
on ADHD have focused on the dopamine and serotonin pathways. Meta-analyses of 
the available data have suggested several of the genes belonging to either pathway to 
be involved in ADHD pathogenesis, including the dopamine receptors D4 (DRD4; 
11p15.5) and D5 (DRD5; 4p16.1), SLC6A4, the dopamine transporter (DAT or 
SLC6A3; 5p15.3), the 5-hydroxytryptamine (serotonin) receptor 1B (HTR1B; 
6q13), dopamine beta-hydroxylase (DBH; 9q34) and synaptosomal-associated 
protein of 25kDa (SNAP25; 20p12-p11.2) (reviewed by  Faraone and Khan, 2006). 
In addition, recently a large candidate gene analysis was performed involving 1,038 
SNPs and spanning 51 candidate genes (belonging to the circadian rhythm genes 
and the dopamine, norepinephrine or serotonin pathways) that confirmed association 
with DRD4 and DAT1 (Brookes et al., 2006), the two most replicated associations. 
Tourette’s syndrome 
Tourette’s syndrome (also called Gilles de la Tourette syndrome) is a neuropsychiatric 
disorder that occurs with an estimated prevalence of 1% among school-age children 
(Robertson, 2003), is characterized by multiple chronic tics (involuntary movements 
and vocalizations) and is often accompanied by other behavioural disorders, 
including ADHD and obsessive-compulsive disorder (OCD) (Comings, 2001). 
Although family and twin studies have suggested a contribution of genetic factors 
in Tourette’s syndrome, its precise contribution rate remains unclear (Pauls, 2003). 
Until now, most association studies have focussed on candidate genes belonging to 
the dopaminergic pathway, and showed several positive associations for the DAT, 
monoamine oxidase A (MAOA; Xp11.3) and the dopamine receptors D2 (DRD2; 
11q23), D3 (DRD3; 3q13.3) and D4 (Comings et al., 1991; Comings et al., 1993; 
Comings et al., 1996b; Grice et al., 1996; Gade et al., 1998; Rowe et al., 1998; Tarnok 
et al., 2007; Yoon et al., 2007). However, since not all subsequent replication studies 
were positive (Gelernter et al., 1990; Brett et al., 1993; Gelernter et al., 1993; Brett 
et al., 1995; Barr et al., 1996, 1997) and other genes were found to associate as well 
(Abelson et al., 2005), the contribution of the dopaminergic pathway to Tourette’s 
syndrome remains to be established. 
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Dyslexia (reading disability)
Dyslexia affects 5–10% of school-age children (Shaywitz et al., 1990) and is 
characterized by problems with word recognition and spelling. Linkage studies 
have revealed a number of chromosomal susceptibility loci for dyslexia (1p34-p36, 
2p16-p15, 3p12-q12, 6p21, 6q13-q16, 11p15, 15q21, 18p11 and Xq27) (reviewed 
by Caylak, 2007). Within and near these loci several genes have been studied using 
association analyses, resulting in a few candidate genes for dyslexia: dyslexia 
susceptibility 1 candidate 1 (DYX1C1; 15q21) (Taipale et al., 2003), roundabout 
Drosophila homolog 1 (ROBO1; 3p12) (Hannula-Jouppi et al., 2005) and doublecortin 
domain-containing protein 2 (DCDC2; 6p22.1) (Meng et al., 2005), but again the 
results are not conclusive and therefore the genetic aetiology of dyslexia is currently 
still unclear.
Epilepsy (seizure disorder)
Epilepsy is a heterogeneous group of disorders with abnormal electrical brain activity. 
In adults, temporal lobe epilepsy (TLE) is the most common form of epilepsy with an 
age of onset in late childhood or adolescence. In childhood, the most common form 
of epilepsy is febrile seizures (FSs), with a prevalence of 2-5% in Western countries 
and an estimated heritability of 70% (Kjeldsen et al., 2002). Genetic linkage analyses 
have identified a number of loci for familial FS, including the loci on chromosome 
19p13.3, 2q23-q24, 5q14-q15 and 18p11.2 containing the genes encoding casein 
kinase I gamma 2 isoform (CSNK1G2; 19p13.3), sodium channel, voltage-gated, 
type I, alpha subunit (SCN1A; 2q24.3), G protein-coupled receptor 98 (GPR98; 
5q13) and inositol(myo)-1(or 4)-monophosphatase 2 (IMPA2; 18p11.2), respectively 
(Johnson et al., 1998; Peiffer et al., 1999; Nakayama et al., 2000; Nakayama et al., 
2004). Although linkage of these loci has been replicated in some other familial cases, 
only for CSNK1G2 and IMPA2 association was found in subsequent association 
analysis (Nakayama et al., 2004; Yinan et al., 2004). In addition, a number of other 
candidate genes have been identified via association studies, including the genes 
encoding cholinergic receptor nicotinic alpha 4 (CHRNA4; 20q13.2-q13.3), gamma-
aminobutyric acid A receptor gamma 2 (GABRG2; 5q31.1-q33.1) and -beta 3 
(GABRB3; 15q11.2-q12), interleukin 1 beta (IL1B; 2q14) and interleukin 1 receptor 
antagonist (IL1RN; 2q14.2) (Steinlein et al., 1997; Feucht et al., 1999; Kanemoto 
et al., 2000; Baulac et al., 2001; Tsai et al., 2002). However, the latter associations 
could not be replicated in subsequent cohorts (Tilgen et al., 2002; Nakayama et al., 
2003; Mulley et al., 2004; Haspolat et al., 2005; Hempelmann et al., 2007). 
Mental retardation
Mental retardation (MR) occurs in approximately 2-3% of the population in developed 
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countries (Chelly and Mandel, 2001). For the diagnosis MR a number of criteria have 
to be fulfilled, including an IQ lower than 70 and behavioural disabilities that are 
already evident in childhood. The underlying causes of MR can be diverse, varying 
from inborn causes such as Down’s syndrome, Fragile X syndrome and fetal alcohol 
syndrome (these three causes are responsible for 30% of the MR cases (Batshaw, 
1993)), but also malnutrition and problems during pregnancy or birth can increase 
the risk for MR (Hagberg and Kyllerman, 1983). 
Although it is evident that a genetic factor is involved in the aetiology of MR and the 
genetic cause of a number of subtypes has been identified (e.g. trisomy of chromosome 
21 in Down’s syndrome), the majority of cases have an unknown genetic aetiology. 
Since MR has a clearly X-linked inheritance pattern and is more often found in 
males than females, variations in the X-chromosome may increase the risk for MR. 
A number of X-linked genes have been identified as susceptibility genes for MR, 
including fragile X mental retardation 2 (FMR2; Xq28), oligophrenin 1 (OPHN1; 
Xq12), p21 (CDKN1A)-activated kinase 3 (PAK3; Xq22.3-23), GDP dissociation 
inhibitor 1 (GDI1; Xq28), Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 
(ARHGEF6; Xq26), ribosomal protein S6 kinase, 90kDa, polypeptide 3 (RPS6KA3; 
Xp22.2-p22.1), interleukin 1 receptor accessory protein-like 1 (IL1RAPL1; 
Xp22.1-p21.3), tetraspanin 7 (TSPAN7; Xp11.4), methyl CpG binding protein 
2 (MECP2; Xq28), acyl-CoA synthetase long-chain family member 4 (ACSL4; 
Xq22.3-q23) and aristaless related homeobox (ARX; Xp21) (Gecz et al., 1996; Allen 
et al., 1998; Billuart et al., 1998; D'Adamo et al., 1998; Carrie et al., 1999; Merienne 
et al., 1999; Kutsche et al., 2000; Zemni et al., 2000; Couvert et al., 2001; Meloni 
et al., 2002; Stromme et al., 2002). However, many other genes are likely linked to 
MR.
Addictive disorders
Many twin studies have been performed on addictive disorders (both alcohol and 
drug abuse), which indicated heritability levels of 50-60% in alcohol consumption 
(Hiroi and Agatsuma, 2005) and up to 70% in severe smoking (Sullivan and Kendler, 
1999). Since the dopaminergic pathway plays a central role in the reward system, the 
genes involved in this pathway are thought to be susceptibility genes for addictive 
disorders. Indeed, a number of studies have identified polymorphisms in this pathway 
that infer susceptibility to addiction: genetic variations in the DRD2, DRD3, COMT 
and DAT1 genes have been reported to associate with smoking, alcoholism, cocaine 
abuse and heroin addiction (Blum et al., 1990; Noble et al., 1993; Muramatsu and 
Higuchi, 1995; Duaux et al., 1998; Comings et al., 1999; Tiihonen et al., 1999; 
Horowitz et al., 2000; Xu et al., 2004; Guindalini et al., 2006; Timberlake et al., 
2006). Nevertheless, despite the large number of studies reporting association, meta-
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analyses have shown that the effects are only weak or not significant (Munafo et al., 
2004; Munafo et al., 2007). 
Fetal alcohol syndrome
During pregnancy, alcohol use by the mother may lead to fetal alcohol syndrome 
(FAS) that occurs at a rate of 0.5-2 individuals per 1000 live births. A number of family, 
twin and animal studies have suggested a genetic component in FAS pathogenesis, 
one of the main candidate genes being the alcohol dehydrogenase 1B (ADH1B) 
gene located on chromosome 4q21-q23. However, whereas some studies report a 
protective effect for a number of ADH1B subtypes, others were not successful in 
reproducing these results (reviewed by Green and Stoler, 2007). Besides ADH1B, 
other candidate genes have been suggested as risk factors for FAS pathogenesis, 
such as the cytochrome P450 2E1 gene (CYP2E1; 10q24.3-qter) (Boutelet-Bochan 
et al., 1997; Rasheed et al., 1997). 
Anxiety disorders
Panic disorder, OCD, separation anxiety, overanxious disorder, agoraphobia and 
other phobias all belong to the group of anxiety disorders and are relatively common 
(lifetime prevalence of 25% (Kessler et al., 1994)). Twin studies have indicated that 
a genetic factor is involved in anxiety disorders, but the genetic contribution to the 
disorders is only modest (30-40%) (Hettema et al., 2001). Yet, many linkage and 
association studies have been performed to determine the chromosomal locations 
or genes involved in the pathogenesis of the various subtypes of anxiety disorders. 
Panic disorder showed significant linkage to chromosomal regions 9q31, 13q and 
22q (Hamilton et al., 2003; Thorgeirsson et al., 2003), for OCD linkage was reported 
to chromosome 1q, 3q27-28, 6q, 7p, 9p24, 10p15, 14 and 15q (Hanna et al., 2002; 
Shugart et al., 2006; Hanna et al., 2007; Samuels et al., 2007), and for other anxiety 
disorders linkage was observed for chromosome 14p (simple phobia) (Gelernter 
et al., 2003), 16 (social phobia) (Gelernter et al., 2004), 1q, 4q, 7p, 12q and 13q 
(neuroticism) (Fullerton et al., 2003) and 8p21-23 (harm avoidance) (Cloninger et 
al., 1998). Recently, also genome-wide linkage analyses on individuals with a broad 
anxiety phenotype rather than based on the DSM-IV anxiety disorder diagnosis 
have been performed and significant linkage was observed for chromosome 14 
(Middeldorp et al., 2007) and 4q31-q34 (Kaabi et al., 2006).  
Besides linkage analysis, many case-control design studies on candidate genes 
for anxiety pathogenesis have been performed. For panic disorder, a positive 
association was found for the serotonin receptors HTR1A (5q11.2-q13) and HTR2A 
(13q14-q21) (Inada et al., 2003; Rothe et al., 2004), COMT (Domschke et al., 2004), 
the neuropeptide cholecystokinin (CCK; 3p22-p21.3) (Miyasaka et al., 2004), the 
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adenosine A2a receptor (ADORA2A; 22q11.23) (Deckert et al., 1998), MAOA (Deckert 
et al., 1999), the nuclear transcription factor cAMP-responsive element modulator 
(CREM; 10p11.21) (Domschke et al., 2003), the peripheral benzodiazepine receptor 
(PBR or TSPO; 22q13.31) (Nakamura et al., 2006), glutamic acid decarboxylase 1 
(GAD1; 2q31) (Hettema et al., 2006), diazepam binding inhibitor (DBI; 2q12-q21) 
(Thoeringer et al., 2007), calmodulin-dependent protein kinase kinase b (CaMKKb; 
12q24.2) (Erhardt et al., 2007) and angiotensin-converting enzyme (ACE; 17q23.3) 
(Olsson et al., 2004). In addition, an association analysis of 90 SNPs located in 21 
candidate genes revealed eight SNPs to be associated with panic disorder (located 
in the CCK, serotonin and dopamine systems), but all with a minor individual effect 
(Maron et al., 2005). 
Besides association with panic disorder, a number of susceptibility genes have been 
found to associate with other subtypes within anxiety disorders as well, such as 
the serotonin system in OCD and neuroticism (Lesch et al., 1996; Camarena et al., 
2004; Lochner et al., 2004; Meira-Lima et al., 2004; Schinka et al., 2004; Sen et al., 
2004), MAOA in generalized anxiety disorder and neuroticism (Eley et al., 2003; 
Tadic et al., 2003), COMT in neuroticism and phobic anxiety (Eley et al., 2003; 
McGrath et al., 2004) and BDNF in anxiety-related personality traits (Lang et al., 
2005; Hunnerkopf et al., 2007).  
Posttraumatic stress disorder 
Posttraumatic stress disorder (PTSD) can occur in a subset of individuals exposed 
to extreme traumatic events (Nemeroff et al., 2006), and has a lifetime incidence 
of ~9–15% (Kessler et al., 1995; Breslau et al., 1998), and an estimated genetic 
inheritance of ~30% (True et al., 1993). Susceptibility genes for PTSD have not yet 
been identified, but to date the number of individuals screened is low, while the few 
genetic studies that have been performed mainly focussed on key candidate genes, 
including BDNF, neuropeptide Y (NPY; 7p15.1), the glucocorticoid receptor (NR3C1; 
5q31.3), and components of the serotonin and dopamine pathways (Comings et al., 
1996a; Lappalainen et al., 2002; Bachmann et al., 2005; Lee et al., 2005; Zhang et 
al., 2006a).   
Eating disorders
Anorexia and bulimia nervosa are two major eating disorders with still unknown 
risk factors. For a long time, eating disorders have been considered to be caused by 
sociocultural factors. However, it has recently become clear that also genetics may 
play a substantial role in its aetiology. Family and twin studies have shown that 
heritability estimates for eating disorders vary from 48% to 74% in anorexia nervosa 
and from 55% to 83% in bulimia nervosa (Kendler et al., 1991; Bulik et al., 1998; 
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Klump et al., 2001; Kortegaard et al., 2001). Since serotonin plays an important role in 
mood and feeding, genetic variations in the serotonergic pathway are thought to lead 
to eating disturbances. Indeed, a number of positive associations with the serotonin 
receptors HTR2A and HTR2C (Xq24), and also with the serotonin transporter gene 
have been reported (Collier et al., 1997; Di Bella et al., 2000; Westberg et al., 2002), 
however, replication was not always successful (Campbell et al., 1998; Burnet et 
al., 1999). Furthermore, associations were found for BDNF (Koizumi et al., 2004; 
Ribases et al., 2004), the growth hormone secretagogue receptor (ghrelin receptor 
or GHSR; 3q26.31) (Miyasaka et al., 2006) and COMT (Frieling et al., 2006; 
Mikolajczyk et al., 2006).   
Spina bifida
Spina bifida is caused by unsuccessful closure of the neural tube during early 
development (between embryonic day 17 and 30) and occurs with a frequency of 1-2 
cases per 1000 births. The exact aetiology of spina bifida is poorly understood, but it 
is clear that both genetic and environmental factors are involved (Frey and Hauser, 
2003). Since individuals with spina bifida often die prenatal or early postnatal and 
thus hardly any families exist with several affected members, this disease could well 
be the most difficult complex disorder to study at the genetic level. Based on animal 
and epidemiological studies, genes involved in folic acid (folate), vitamin B12 and 
homocysteine metabolism, or genes involved in neurulation have been hypothesized 
to play a role in spina bifida genesis (reviewed by Padmanabhan, 2006). However, 
until now, only a few genes have been reported to represent risk factors for spina bifida, 
including 5,10-methylenetetrahydrofolate reductase (MTHFR; 1p36.3) (Whitehead 
et al., 1995), methionine synthase reductase (MTRR; 5p15.3-p15.2) (van der Linden 
et al., 2006), platelet-derived growth factor receptor alpha (PDGFRA; 4q11-q13) 
(Joosten et al., 2001) endothelial nitric oxide synthase 3 (NOS3; 7q36) (Brown et al., 
2004) protein-L-isoaspartate (D-aspartate) O-methyltransferase (PCMT1; 6q24-q25) 
(Zhu et al., 2006) and cofilin 1 (non-muscle) (CFL1; 11q13) (Zhu et al., 2007). 
Hydrocephalus
Hydrocephalus occurs at a frequency of approximately 0.5 in 1000 births (Fernell et 
al., 1986; Halliday et al., 1986) and is characterized by abnormal flow or resorption 
of cerebrospinal fluid. It is considered a heterogeneous complex disorder (Willems, 
1988) with genetic and environmental aetiologies (Stoll et al., 1992; Haverkamp 
et al., 1999). Although approximately 37% of the hydrocephalus cases have a 
possible genetic aetiology (Haverkamp et al., 1999), clear susceptibility genes for 
hydrocephalus have not been identified yet. Studies in animal models have suggested 
several loci as susceptibility regions for hydrocephalus, but these regions have not yet 
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been reported as susceptibility regions in human (reviewed by Zhang et al., 2006b). 
Complex neurodevelopmental disorders and the environment
Since in general complex neurodevelopmental disorders have an estimated 
heritability lower than 100% (table 2), their aetiology includes another component 
that is thought to be primarily the environment (e.g. stressful life events). Numerous 
factors acting during early development of a foetus may contribute to the genesis 
of a neurodevelopmental disorder, including insufficient maternal nutrition, daily 
smoking, viral infection and repeated psychological stress (Schroeder, 2000). Most 
environmental vulnerability factors are however difficult to assign and quantify.
The type and timing of the early environmental risk factors to which an organism 
is exposed appear to determine the phenotypic outcome. For example, a prenatal 
exposure of 9-days-pregnant mice to a sublethal intranasal administration of influenza 
virus led to both short-term and long-lasting deleterious effects on the developing 
brain structures and to abnormal behavior in the offspring of the mice (Fatemi et 
al., 2002). Besides risk factors during early (prenatal) development, also obstetrical 
complications, including the use of resuscitation or an incubator, premature membrane 
rupture, diabetes, rhesus incompatibility, bleeding, preterm birth or caesarean birth, 
may increase the vulnerability to neurodevelopmental disorders (Curatolo et al., 
1995; Boog, 2004).
One obvious gene-environment link concerns the season in which birth took place. 
An excess of winter-spring births in bipolar disorder and schizophrenia has been 
observed (Torrey et al., 1996). A similar tendency has been found in schizoaffective 
disorder (December-March), major depression (March-May) and autism (March) 
(Torrey et al., 1997). Besides the season of birth, also the place of birth is thought 
to be associated. Urban–born (and brought-up) subjects are more susceptible to 
neurodevelopmental disorders than rural-born (and brought-up) subjects (Torrey et 
al., 1997; Mortensen et al., 1999). Furthermore, risk factors like immigration and 
adoption may contribute to the development of psychiatric disorders (Cantor-Graae 
and Pedersen, 2007; Yearwood et al., 2007).
Gene-environment interactions in complex neurodevelopmental disorders
One of the reasons that the genetic and environmental factors in complex 
neurodevelopmental disorders are difficult to define is the fact that the two factors 
may interact. Moreover, such an interaction may be complex and act at various levels. 
For instance, genetic and environmental factors may have an additive effect, genetic 
factors may affect the influence of the environment on a phenotype or environmental 
factors may modulate the expression of genetic variants. 
An example of a gene-environment interaction concerns the influence of stressful 
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life events on depressive individuals with a functional polymorphism in the promoter 
region of the serotonin transporter gene. Individuals with the short allele have been 
found to respond differently to stressful life events (e.g. childhood maltreatment) 
and as such are more vulnerable to develop depressive symptoms than individuals 
with the long allele (Caspi et al., 2003). A second example of gene-environment 
interaction is the valine/methionine polymorphism (SNP rs4680) in the COMT 
gene. Upon cannabis use, individuals carrying the valine allele have a higher chance 
to exhibit psychotic symptoms and to develop schizophreniform disorders when 
compared to individuals with two methionine alleles (Caspi et al., 2005). 
Complex neurodevelopmental disorders and epigenetics
Epigenetics is defined as heritable changes in gene expression patterns that occur 
without changing the DNA sequence itself (Wolffe and Matzke, 1999), and includes 
DNA methylation and posttranslational modifications of histone proteins. DNA 
methylation, i.e. a covalent binding of a methyl group to the 5-position of the cytosine 
ring within the sequence 5’-CG-3’ (CpG), can be tissue- and cell-type specific and 
is found in all vertebrates, and many invertebrates and plants. CpG clusters with a 
minimum of 200 base pairs, a CG percentage greater than 50% and an observed/
expected CpG ratio greater than 0.6 are called CpG islands. These islands are often 
found in gene promoter regions and can protect single CpGs within a CpG island 
from DNA methylation. 
An apparent link between the methylation status and gene transcription levels has 
led to the speculation that alterations in the methylation pattern (epimutations) 
might contribute to altered gene expression. Such epimutations are thought to occur 
upon exposure to environmental risk factors, including early developmental stress. 
Since early embryos seem to be particularly sensitive to epimutations (Reik et al., 
1993; Rideout et al., 2001), this factor should be considered for the aetiology of 
neurodevelopmental disorders. For instance, epigenetic alterations are responsible 
for a number of neurodevelopmental disorders with single-gene defects, such as Rett 
Syndrome, ICF Syndrome, Fragile X Syndrome and ATR-X Syndrome (Amir et al., 
1999; Xu et al., 1999; Gibbons et al., 2000; Jin and Warren, 2000). A role for DNA 
methylation has also been proposed in connection with complex neurodevelopmental 
disorders. For example, spina bifida can be caused by a lack of folate (reviewed 
by Pitkin, 2007), a compound needed for the generation of S-adenosylmethionine 
(SAM) that donates the methyl group in the DNA methylation process. Also, some 
patients with depressive illness and schizophrenia display lower serum folate levels 
(Herran et al., 1999). Animal models further provide evidence for a possible link 
between epigenetics and neurodevelopmental disorders. Following a diet with 
L-methionine, a precursor in the biosynthesis of SAM, the reeler mouse (a model for 
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schizophrenia) showed increased promoter methylation of the reelin gene, reduced 
reelin expression and a declined prepulse inhibition of startle. These effects could 
subsequently be reversed by valproic acid, a mood-stabilizing drug used for treatment 
of epilepsy, bipolar disorder and schizophrenia (Tremolizzo et al., 2002). In addition, 
the adult offspring of rat mothers that showed high licking and grooming (LG) and 
arched-back nursing (ABN) (two forms of maternal behaviour in the rat that serve 
as the basis for the individuals programming of the stress response) are less fearful, 
have a lower hypothalamic-pituitary-adrenal response to stress, and have a lower 
DNA methylation status in the promoter region of the glucocorticoid receptor gene 
when compared to the offspring of low-LG and -ABN mothers (Weaver et al., 2004). 
Thus, alterations in epigenetic profiles may contribute to the generation of complex 
neurodevelopmental disorders. 
APO-SUS and APO–UNSUS rat model for complex neurodevelopmental 
disorders
The genetic, environmental and epigenetic contributions to the aetiology of 
neurodevelopmental disorders illustrate that unravelling the pathogenesis of these 
disorders is highly complex. Although insights into the degree of the genetic 
contribution to the aetiology of neurodevelopmental disorders have been obtained, 
the identities of the genes involved and thus diagnostic markers are mostly lacking. 
The use of an animal model with (aspects of) neurodevelopmental disorders 
represents an interesting strategy to identify new genes and pathways responsible 
for neurodevelopmental pathogenesis. An example of such an animal model is 
the APO-SUS/-UNSUS rat model already mentioned above, a model based on a 
pharmacological selection. Rats from an outbred Wistar population were selected on 
the basis of their response to the dopamine D2 receptor agonist apomorphine (Cools 
et al., 1990). Upon injection of this drug, a bimodal distribution of the stereotyped 
gnawing response can be found. Approximately 40% of the Wistar rats showed 
a weak gnawing response (<10 counts/45 min) and a similar percentage showed 
an intense gnawing response (>500 counts/45 min). Through a specific breeding 
program, two rat lines representing the two extremes have been created, named the 
APO-SUS rats (apomorphine susceptible rats with an intense gnawing response) 
and the APO-UNSUS rats (apomorphine unsusceptible rats with a weak gnawing 
response) (Cools et al., 1990; Ellenbroek et al., 2000) (figure 2). This breeding 
program has been carried out twice, with a ten-year interval, leading to the original 
APO-SUS and –UNSUS lines (with the breeding started in 1985) and the replicate 
APO-SUS and –UNSUS lines (breeding started in 1995). Extensive characterization 
of the APO-SUS and –UNSUS rat lines has revealed many differences which are not 
limited to the dopaminergic pathway, but also include behavioural, neurochemical, 
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immunological and endocrinological differences (table 3). 
Interestingly, several phenotypical features of the APO-SUS rats strongly resemble 
characteristics of patients suffering from a neurodevelopmental disorder, suggesting 
that the APO-SUS/-UNSUS model may be a good model to study (aspects of) 
neurodevelopmental disorders. For instance, APO-SUS rats show abnormalities in 
information processing (Ellenbroek et al., 1995), a phenomenon also observed in 
patients suffering from schizophrenia, bipolar disorder, obsessive compulsive disorder, 
Tourette's syndrome, temporal lobe epilepsy with psychosis and posttraumatic stress 
disorder (PTSD) (Braff and Geyer, 1990; Swerdlow et al., 1993; Castellanos et al., 
1996; Grillon et al., 1996; Pouretemad et al., 1998; Perry et al., 2001). In addition, 
APO-SUS rats have an altered hypothalamus-pituitary-adrenal (HPA) axis response 
to stress (Rots et al., 1995; Rots et al., 1996a), a characteristic also seen in patients 
with schizophrenia, mania, depressive illness, ADHD, anxiety disorders, PTSD and 
eating disorders (Carson et al., 1988; Kaye et al., 1988; Smith et al., 1989; Kaneko 
et al., 1993; Lammers et al., 1995; Schmider et al., 1995). Furthermore, it has been 
shown that both genetic and environmental factors can influence the APO-SUS/-
Figure 2. Schematic representation of the generation of the APO-SUS and –UNSUS rat model. Rats 
from the Wistar population were injected with the dopamine D2 receptor agonist apomorphine and 
tested for their gnawing responses. Rats with a low gnawing score (<10 times per 45 minutes) and 
rats with a high gnawing score (>500 times per 45 minutes) were selected and used for breeding of the 
apomorphine-unsusceptible (APO-UNSUS) and apomorphine-susceptible (APO-SUS) rat lines, res-
pectively (based on Cools et al., 1990).
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UNSUS phenotypes (Ellenbroek et al., 2000) as can also be seen in the pathogenesis 
of human neurodevelopmental disorders. Thus, the APO-SUS/-UNSUS rats may 
represent a valuable model in our attempt to unravel the genetic factors involved in 
the pathogenesis of disorders with a complex aetiology.  
Outline of this thesis
This thesis focuses on candidate gene and pathway discovery in disorders with a 
complex aetiology, especially the neurodevelopmental disorders. Although numerous 
studies suggest that genetic variants play a significant role in the aetiology of 
complex disorders, in almost all cases the precise genetic background remains to be 
identified. A better understanding of the genes and pathways involved may be useful 
for the development of specific medicines and the application of disease-preventing 
strategies. The goal of the research described in this thesis is twofold and the thesis 
is therefore divided into two parts. Part A concerns a search for the molecular basis 
of the APO-SUS and -UNSUS rats. On the basis of the results obtained in the rat, 
we describe in part B human genetic association analyses in a number of complex 
disorders.
Part A. Rat model
Chapter A1 describes the search for gene transcripts which are differentially 
expressed in brain regions from the APO-SUS/-UNSUS rats. The expression profiles 
of hippocampal APO-SUS and –UNSUS rats have been analysed using microarray 
technology and revealed only one transcript, Aph-1b, to be differently expressed. 
Aph-1b is a component of the g-secretase enzyme complex that is responsible for 
the proteolytic processing of a wide variety of type I transmembrane proteins and 
is involved in multiple (neuro)developmental pathways. The possibility of the 
g-secretase signalling cascade as a susceptibility pathway for neurodevelopmental 
disorders is discussed. 
Chapter A2 describes the expression levels of Aph-1b and its family members Aph-
1aS and -1aL in APO-SUS and –UNSUS rats during development (starting from 
embryonic day 13). Besides the ontogenic expression levels for the Aph-1 family, 
tissue- and time-specific cleavage of the g-secretase substrate APP is presented.
Chapter A3 shows the expression levels of the Aph-1 family in APO-SUS and 
–UNSUS rats in several tissues. In addition, cleavage of a number of g-secretase 
substrates, including the APP superfamily, p75 neurotrophin receptor, ErbB4 and 
neuregulin-2, was found to occur in a tissue-specific manner. 
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Table 3. Phenotypic characteristics of APO-SUS rats compared to those of APO-UNSUS rats
Phenotypic characteristics References
↑  apomorphine susceptibility (Cools et al., 1990)
↓  noradrenaline immunoreactivity in nucleus accumbens (Cools et al., 1990)
↑  hippocampal and pituitary mineralocorticoid receptor binding capacity (Sutanto et al., 1992)
↑  metabolic activity in hippocampal area (Cools et al., 1993)
↓  hippocampal dynorphin-B (Cools et al., 1993)
↓  sensitivity for encephalitis and rheumatoid arthritis (van de Langerijt et al., 
1994)
↑  hypothalamic corticotropin releasing hormone mRNA (Rots et al., 1995)
↑  basal plasma levels of ACTH (Rots et al., 1995)
↓  basal plasma levels of free corticosterone (Rots et al., 1995)
↑  ACTH and corticosterone plasma levels upon novelty (Rots et al., 1995)
↓  prepulse inhibition of the acoustic startle response (Ellenbroek et al., 1995)
↓  latent inhibition in a conditioned taste aversion paradigm (Ellenbroek et al., 1995)
↑  hypothalamic synaptic density (Mulders et al., 1995)
↑  TH mRNA in nigrostriatal and  tuberoinfundibular system (Rots et al., 1996b)
↑  dopaminergic D2 receptors in striatum (Rots et al., 1996b)
↑  susceptibility to behavioural effects of dexamphetamine (Cools et al., 1997)
↓  number of blood T cells (Kavelaars et al., 1997)
↑  number of blood B cells (Kavelaars et al., 1997)
↑  TH2 response upon infection (Kavelaars et al., 1997)
↑  incidence of involuntary muscular contractions upon GABA activation (Dirksen et al., 1997)
↓  hippocampal mossy fiber terminal fields (Spooren et al., 1999)
↑  sensitivity to periodontitis (Breivik et al., 2000)
↑  incidence of bursts of bilateral synchronous spike wave discharges (de Bruin et al., 2000)
↓  alcohol intake under non-challenged conditions (Sluyter et al., 2000)
↓  relaxation of mesenteric arteries upon b2-agonist stimulation (Smits et al., 2002)
↓  relaxation of mesenteric arteries upon a2-agonist stimulation (Smits et al., 2002)
↓  tumor growth (Teunis et al., 2002)
↓  angiogenesis (Teunis et al., 2002)
↓  contribution of nitric oxide to the vascular tone (Riksen et al., 2003)
↓  recovery from gastric ulcerations (Degen et al., 2003)
↓  number of natural killer cells in the spleen (Teunis et al., 2004)
↑  fiber network and varicosities in nucleus accumbens (van der Elst et al., 2005)
↓  speed of development (Degen et al., 2005)
↑  alcohol consumption after an acute challenge (van der Kam et al., 2005b)
↓  cocaine intake under habituated circumstances (van der Kam et al., 2005a)
↑  cocaine intake under stressful circumstances (van der Kam et al., 2005a)
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Chapter A4 identifies additional differences between the APO-SUS and –UNSUS 
rats using arbitrarily primed-polymerase chain reaction. Besides the gene-dosage 
imbalance of the Aph-1b locus, additional genetic and epigenetic variations have been 
found to segregate with the APO-SUS/-UNSUS lines. We discuss the possibility that 
these newly identified variations may contribute to the complex phenotype and, as 
a consequence, suggest that Aph-1b might not be the only genetic factor responsible 
for the complex APO-SUS phenotype. 
Chapter A5 describes CNVs other than the Aph-1b locus in the APO-SUS and 
–UNSUS rat genomes. By using CGH and (quantitative) genomic PCR analysis in 
APO-SUS and –UNSUS rats, we show eight new intragenic chromosomal regions to 
contain a CNV when comparing the genomes of the original and replicate APO-SUS 
and –UNSUS rats. A possible contribution of these CNVs to the complex APO-SUS 
phenotype is discussed.  
Part B. Human
Chapter B1 describes association analysis of the g-secretase pathway with 
premature atherosclerosis. A non-synonymous polymorphism in the human APH1B 
gene (Phe217Leu; rs1047552) was studied in a Caucasian case-control cohort 
for premature coronary atherosclerosis. Furthermore, the functional effect of this 
polymorphism in vitro is presented and the contribution of the g-secretase signalling 
cascade in vascular pathogenesis is discussed.
Chapter B2 examines association of the functional Phe217Leu polymorphism in the 
human APH1B gene with the neurodevelopmental disorder epilepsy. We discuss the 
contribution of this polymorphism in epileptic seizures.
Chapter B3 describes association analysis of the APH1B Phe217Leu polymorphism 
in human immunodeficiency virus type 1 (HIV-1) infection. The results of two ethnical 
(Caucasian and South African) case-control cohorts are presented and implications 
for the contribution of the g-secretase signalling cascade in susceptibility for HIV-1 
infection is discussed.
Chapter B4 examines the influence of the APH1B Phe217Leu polymorphism 
on a number of disorders with a complex aetiology. Its role in susceptibility for 
schizophrenia, bipolar disorder, autism, ADHD, dyslexia, depression, rheumatoid 
arthritis, celiac disease and cancer (colorectal, throat, prostate and lung cancer) is 
presented and discussed. 
In the general discussion, the results of the studies reported in this thesis are discussed 
and placed in a broader context.
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Abstract
A combination of genetic factors and early-life events is thought to determine the 
vulnerability of an individual to develop a complex neurodevelopmental disorder 
like schizophrenia. Pharmacogenetically selected, apomorphine-susceptible Wistar 
rats (APO-SUS) display a number of behavioural and pathophysiological features 
reminiscent of such disorders. Here we report microarray analyses revealing in 
APO-SUS rats, relative to their counterpart APO-UNSUS rats, a reduced expression 
of Aph-1b, a component of the g-secretase enzyme complex that is involved in 
multiple (neuro)developmental signalling pathways. The reduced expression is due 
to a duplicon-based genomic rearrangement event resulting in an Aph-1b dosage 
imbalance. The expression levels of the other γ-secretase components were not 
different. However, g-secretase cleavage activity was affected and the APO-SUS/-
UNSUS Aph-1b genotypes segregated with a number of behavioural phenotypes. 
Thus, a subtle imbalance in the expression of a single, developmentally important 
protein may be sufficient to cause a complex phenotype.
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Chapter A1
Introduction
We used the susceptibility of normal outbred Wistar rats for the dopaminergic agonist 
apomorphine as a criterion for the selection of two distinct types of individuals 
(Cools et al., 1990; Ellenbroek and Cools, 2002). Through systemic apomorphine 
administration and long-term pharmacogenetic selections we produced rats with a high 
or low susceptibility for this drug (referred to as APO-SUS and APO-UNSUS rats, 
respectively). Extensive phenotyping of the APO-SUS and -UNSUS rats over the last 
15 years has revealed differences in many aspects of behaviour, neuroanatomy, and 
their neurochemical, endocrine and immune systems (Cools et al., 1990; Ellenbroek 
and Cools, 2002). For example, they differ in brain information processing (prepulse 
inhibition and latent inhibition; (Ellenbroek et al., 1995)), locomotor activity in 
response to novelty, and fleeing and problem-solving behaviour (Cools, 1988; 
Cools et al., 1990). In addition, APO-SUS and -UNSUS rats show changes in their 
hypothalamus-pituitary-adrenal (HPA) axis response to stress (Rots et al., 1995), 
their sensitivity to dopamimetic drugs (Ellenbroek et al., 2000), their neuropeptide, 
steroid and steroid receptor levels (Cools et al., 1993; Rots et al., 1995; Rots et al., 
1996), their synaptic densities within hypothalamic nuclei (Mulders et al., 1995), their 
T
H2
 cell contents and their susceptibilities to inflammatory and infectious diseases, 
vasorelaxation and stress (Kavelaars et al., 1997). Crossbreeding experiments have 
shown that genetic factors play an important role in the development of the rat model 
(Ellenbroek et al., 2000). Furthermore, the propensity of the model to develop the 
specific features in adulthood is dependent on the timing and type of stressors to which 
the rats have been exposed during early life (Ellenbroek et al., 2000; Degen et al., 
2004). For example, when APO-SUS rats are reared from birth on by APO-UNSUS 
mothers their susceptibility to apomorphine is significantly reduced, whereas such 
crossfostering has no effect on APO-UNSUS rats. Conversely, a 24-h separation 
of the pups from their mother early in life enhances apomorphine susceptibility in 
APO-UNSUS rats, while this maternal deprivation does not affect APO-SUS rats 
(Ellenbroek et al., 2000). Interestingly, ten years after developing the original APO-
SUS and -UNSUS lines a separate, independent selection and breeding procedure 
for apomorphine susceptibility of Wistar rats resulted in replication of the APO-SUS 
and -UNSUS lines that displayed similar features as the original ones (Ellenbroek et 
al., 2000). In this study, we examined the molecular basis of the differences between 
the APO-SUS and -UNSUS rats.
Materials and methods
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Animals
Systemic administration of apomorphine (1.5 mg/kg s.c.) was used to select rats 
with a high or low susceptibility to this drug (APO-SUS and APO-UNSUS rats, 
respectively); the behaviour was quantified with the Ungerstedt box and the rats were 
classified on the basis of their gnawing scores (APO-SUS: >500 gnaws in 45 min; 
APO-UNSUS: <10 gnaws in 45 min) to select female and male rats for breeding the 
two distinct lines (Cools et al., 1990). We have avoided brother-sister pairings, and 
used a specific procedure that was aimed at selectively breeding for apomorphine 
susceptibility, while otherwise maintaining the genotypic heterogeneity of the initial 
Wistar strain. For the present study, we used APO-SUS and -UNSUS rats of the 13th 
to the 20th generation; genotyping of the original APO-SUS and -UNSUS lines was 
on rats of the 32nd generation. For the behavioural tests, adult male rats (PND60-70) 
were used, and separate I/I, II/II and III/III lines were generated by PCR-analysis 
of genomic DNA with specific primers and intermating each of the genotypes. The 
I/I and II/II sublines were produced from the APO-SUS line. Following its creation 
in 1994, the APO-SUS line has been maintained for 19 generations by random 
breeding. When we recently discovered the genomic recombination event reported 
here, we decided to select APO-SUS rats homozygous for one or two Aph-1b copies. 
The two rat populations were then intermated separately, resulting in the generation 
of the two APO-SUS sublines (I/I and II/II). Since no selection other than for Aph-
1b homozygosity was applied, apart from the Aph-1b locus these sublines have 
highly similar general genetic backgrounds. Rats were bred and reared in the Central 
Animal Facility of the Radboud University under approved animal protocols and in 
accordance with institutional guidelines.
Microarray experiments
For mRNA expression profiling, hippocampi were dissected from fresh brains of 
PND 9 and PND 60 APO-SUS and -UNSUS rats and the tissues were frozen in 
liquid nitrogen. Furthermore, hippocampi were isolated from PND 60 APO-SUS and 
-UNSUS rats three hours after they were injected with apomorphine (1.5 mg/kg, s.c.). 
Total RNA was prepared with the Trizol reagent (Gibco BRL Life Technologies), and 
RNAs from 5 hippocampi were pooled and used in the microarray analyses. The PND 
9 hippocampal samples were analysed using Affymetrix high-density oligonucleotide 
arrays (Rat Genome Set U34A containing ~7,000 full-length sequences and ~1,000 
EST clusters randomly selected from Rattus norvegicus database sequences) 
according to the manufacturer’s recommendations. Briefly, total RNA was purified 
on RNeasy columns (Qiagen) and 20 μg RNA was reverse transcribed (Superscript II; 
GibcoBRL Life Technologies) using a T7-dT24 primer (GenSet). Following second-
strand synthesis, the double-stranded cDNA was used in an in vitro transcription 
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reaction to generate biotinylated cRNA. Purified, fragmented cRNA (10 μg) was 
hybridised onto the Affymetrix arrays for 16 h at 45 °C. Standard post-hybridisation 
washes and double-stain protocols were performed on a GeneChip Fluidics Station 
400 (Affymetrix). Arrays were scanned on a Hewlett Packard Gene Array scanner and 
analysed using Microarray Suite version 5.0 software. For the PND 60 hippocampal 
samples, we used the Incyte high-density cDNA microarrays (Rat NeuroGEM 2.02 
containing 8,478 Sprague Dawley rat nervous system cDNAs representing 6746 
different genes). Isolation of mRNA, conversion to Cy3 or Cy5 fluorescently labelled 
cDNA, hybridisation and scanning were performed as described previously (Yue et 
al., 2001) and the data were analysed with GEMTools 2.5 software. All microarray 
experiments were performed with biological duplicates. With the oligonucleotide 
microarrays no differences were found that met the criteria (a difference in expression 
between PND 9 APO-SUS and -UNSUS hippocampus of >1.3-fold), while seven 
cDNAs were found to be differentially expressed on the cDNA arrays (i.e. >1.5-fold 
difference between PND 60 APO-SUS and -UNSUS hippocampus). However, the 
mRNA expression levels of four of these were not significantly different between 
APO-SUS and -UNSUS rats upon validation of the microarray data by quantitative 
RT-PCR. The differences in expression of two cDNAs (encoding transthyretin and 
prostaglandin D-synthase) were confirmed by the validation analyses but resulted 
from their expression in contaminating choroid plexus (dissection artefact during the 
isolation of the hippocampus). The Aph-1b transcript met the criteria and its ~1.6-
fold reduction in hippocampal mRNA expression in basal and apomorphine-treated 
PND 60 APO-SUS relative to APO-UNSUS rats found on the cDNA microarrays 
was confirmed by quantitative RT-PCR (2.2 ± 0.3- and 3.1 ± 0.8-fold reduction in 
basal and apomorphine-treated PND 60 APO-SUS rats, respectively; n = 9). The 
Aph-1b transcript was not represented on the oligonucleotide microarrays.
Quantitative RT-PCR
For quantitative RT-PCR, first-strand cDNA was prepared from 2 µg of DNase 
I treated total RNA (isolated as described above) using Superscript II reverse 
transcriptase (Invitrogen). PCR samples contained 1X SYBR Green buffer, 3 mM 
MgCl
2
, 0.4 mM dUTP and 0.2 mM each of dATP, dCTP and dGTP, 0.6 U AmpliTaq 
Gold (all from Applied Biosystems), 0.6 µM each oligonucleotide primer (Biolegio) 
and 1/20 synthesized cDNA in a 25-µl volume. Quantitative PCR was performed 
in a PE GeneAmp 5700 apparatus with conditions as follows: 10 min at 94 °C, 
then 40 cycles of 15 s at 94 °C, 30 s at 60 °C and 1 min at 72 °C. ß-Actin was 
amplified from all samples to normalise expression. A control (no template) was 
included for each primer set. Data sets were analysed with Sequence Detection 
System 1.3 software. The following primers were used: Aph-1b-related (448-671): 
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5’-GTGATTCTCCTCAGTTCTTCCTTAATTC and 5’-GCCCATGAGCAC-
CATGATTATAT; Aph-1a related (547-670): 5’-AGAGGAGACGGTACTGGGCTTT 
and 5’-ATGGAAACGGTGACTGCATAGA; presenilin-1 (259-378): 
5’-GTTCCTGTGACCCTCTGCATG and 5’-GCCTACAGTCTCGGTG-
TCTTCTG; presenilin-2 (1093-1218): 5’-GGAGACTTCATCTTCTACAGC-
GTTCT and 5’-GAGCAGCAGGAGGGTGAGAC; nicastrin (504-622): 
5’-TGGCTTGGCTTATGACGACTT and 5’-TCGGTGCAGAGCCATTCTG; Pen-2 
(14-162): 5’-GGGTGTCCAATGAGGAGAAGTT and 5’-TTGATTTGGCTCTGCT-
CTGTGTA; ß-actin (346-435): 5’-CGTGAAAAGATGACCCAGATCA and 
5’-AGAGGCATACAGGGACAACACA; numbers between brackets are nucleotide 
positions from start ATG). All PCR products were generated over intron-exon 
boundaries.
Genomic DNA analysis
APO-SUS and -UNSUS rats were genotyped by extensive Southern blot analysis 
and PCR screening of genomic tail DNA (primers and conditions available on 
request). Comparative analysis of the nucleotide sequences of rat Aph-1b and –1b’ 
was performed with Vector NTI. The nucleotide sequences surrounding exons 5 
and 5’ of Aph-1b and –b’, respectively, and of the junction area within chimaeric 
Aph-1b’/b were determined by PCR analysis of genomic DNA from APO-UNSUS, 
and APO-SUS (II/II) and (I/I) rats using specific primers and subsequent nucleotide 
sequence analysis of the PCR products. 
Northern blotting
Total RNA from hippocampus of PND 9 APO-UNSUS and APO-SUS (II/II), (II/I) 
and (I/I) rats, and from various tissues of PND 9 APO-UNSUS and APO-SUS (I/I) 
rats was isolated as described above, separated on gel (10 µg per lane), blotted and 
hybridised according to standard procedures with a full-length 798-bp rat Aph-1b 
cDNA probe detecting all Aph-1b-related mRNAs (~1,3 kb). 
Western blotting
Protein extractions and immunoblottings were performed as previously described 
(Herreman et al., 2003). To examine Aph-1b protein expression, multiple tissue 
extraction methods and a variety of APO-SUS/-UNSUS and mouse tissues and 
cell lines were used. The polyclonal antibodies against presenilin-1 and nicastrin 
(Herreman et al., 2003), against presenilin-2 (Zymed Laboratories Inc.), and against 
Pen-2 and Aph-1a (Nyabi et al., 2003) were raised in rabbits. The antibodies 
against Aph-1b were directed against the peptides CLVRVITDNRDGPV and 
CVAGGSRRSL, and generated in rabbits (BioGenes GMBH, Germany). To examine 
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γ-secretase substrate cleavage, antibodies were used against the C-terminus of APP 
(C87, polyclonal antibody directed towards the most C-terminal 12 amino acids of 
APP and generated in rabbits), p75NTR (Mahadeo et al., 1994) and ErbB4 (C-18, 
Santa Cruz Biotechnology, Santa Cruz, CA), and against β-tubulin (E7, (Chu and 
Klymkowsky, 1989) on brain tissue samples from three (I/I) rats of different nests 
and three (III/III) rats of different nests. Sample preparations for the analysis of APP, 
p75NTR and ErbB4 were performed as described by (Herreman et al., 2003), (Jung 
et al., 2003), and (Ni et al., 2001), respectively.
Behavioural analysis
For the apomorphine susceptibility test, rats were injected with 1.5 mg/kg apomorphine 
(s.c.) and their gnawing behaviour was tested in an Ungerstedt box (Cools et al., 
1990). In the open field test, rats were placed in the centre of an elevated open field of 
160 x 160 cm without walls. The open field was artificially subdivided into a central 
part (40 x 40 cm) and a peripheral area (16 cm in width). Locomotor behaviour 
was recorded for 30 min with a computerised automated tracking system, and the 
habituation time (defined as the time until the rat stopped locomotor activity for at 
least 90 s) was measured (Cools et al., 1990). The elevated plus maze consisted of a 
plexiglass four-armed maze with two open and two closed arms (10 x 50 cm). Each 
rat was placed in the centre of the plus maze facing a closed arm and the rat was 
allowed to explore the maze for 5 min.
Statistics
Data are presented as mean ± s.e.m. Statistical evaluation was performed using one-
way analysis of variance (ANOVA) followed by a Bonferroni t-test where three 
groups were compared. For the comparison of two groups, the Student’s t test was 
employed. Values of P < 0.05 were considered statistically significant.
Results
Gene expression profiling of APO-SUS and -UNSUS hippocampus
In an attempt to understand the difference between APO-SUS and -UNSUS rats at 
the molecular level, we decided to determine for both lines the mRNA expression 
profiles of the hippocampus of postnatal day 9 (PND 9) and PND 60 rats using 
oligonucleotide and cDNA microarrays. The hippocampus was selected because of 
its well-established physiological role in e.g. behavioural and HPA-axis regulation 
(McEwen, 2002), the neurochemical differences observed in APO-SUS and -UNSUS 
hippocampus (Ellenbroek and Cools, 2002), and the relative ease of its dissection. 
The time point PND 9 was chosen since exposing APO-UNSUS pups to a severe 
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stressor at this stage causes the most dramatic effect on brain information processing 
later on in life (Ellenbroek et al., 1998). At PND 60 the rats are just past their puberty 
and considered to be young adults, and at this age the clear phenotypic differences 
between APO-SUS and -UNSUS rats have been mapped (Ellenbroek et al., 2000; 
Cools and Ellenbroek, 2002; Ellenbroek and Cools, 2002). The mRNA expression 
profiling experiments revealed only one cDNA that met the preset criteria and could be 
confirmed by quantitative reverse transcription-polymerase chain reaction (RT-PCR) 
(see Experimental Procedures for details). This transcript encodes the γ-secretase 
component Aph-1b, a predicted seven-transmembrane protein initially identified 
through genetic screens in worms (Francis et al., 2002; Goutte et al., 2002). 
The Aph-1b gene in APO-SUS and -UNSUS rats
We next considered the possibility that the different Aph-1b mRNA expression levels 
in APO-SUS and -UNSUS were the result of a genomic DNA mutation. Database 
searches revealed that the rat (on chromosome 8q24) and mouse (on chromosome 
9c) contain in tandem two Aph-1b-related copies (designated here Aph-1b and 
Aph-1b’ with -1b downstream of -1b’), each consisting of six exons and spanning 
~20 kb, and separated by ~24 kb. The single human Aph-1b gene (on chromosome 
15q21.3) consists also of six exons, spans ~28 kb and represents the orthologue 
of rat/mouse Aph-1b. Computational approaches to define potential intron-exon 
structure, comparative (rat/mouse) nucleotide sequence analysis and EST database 
searches gave no indications for the presence of a gene in the intergenic region of 
Aph-1b and -1b’. Southern blot and PCR analyses of genomic DNA revealed that all 
APO-UNSUS tested (n = 93) contained three Aph-1b-related copies (here referred to 
as region III; Figure 1A), namely Aph-1b’, chimaeric Aph-1b/b’ (consisting of exons 
1-5 of Aph-1b and exon 6’ of Aph-1b’) and Aph–1b. Of 151 APO-SUS genotyped, 
26% were homozygous for the duplicated genes (II/II), 24% were homozygous for 
chimaeric Aph-1b’/b (consisting of exons 1’-5’ of Aph-1b’ and exon 6 of Aph-1b) 
(I/I), whereas the remaining 50% were heterozygous harbouring both the duplicated 
genes and chimaeric Aph-1b’/b (II/I) (Figure 1A). Interestingly, we found that the 
first-established APO-UNSUS and -SUS lines (Ellenbroek et al., 2000) displayed 
the same genotypes (i.e. all of the original APO-UNSUS tested were III/III, while all 
APO-SUS were II/II, II/I or I/I), indicating that the replication of the original APO-
SUS/-UNSUS lines had resulted in the same Aph-1b genotypical distribution. 
A comparative nucleotide sequence analysis of rat Aph-1b and -1b’ showed a low 
degree of identity, except for the regions surrounding exons 5 and 5’, and exons 6 
and 6’ (Figure 1B). A region of 1106 nucleotides containing exon 5/5’ and identical 
between the two genes was found to represent the junction area of chimaeric Aph-
1b’/b (Figure 1C). These results suggest that an unequal crossing-over (non-allelic 
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homologous recombination) between the identical regions around exons 5 and 5’ 
(direct repeats) resulted in three in-tandem Aph-1b-related copies (region III) and 
chimaeric Aph-1b’/b (region I) (Figure 1D).
Expression of Aph-1b and the other γ-secretase components in APO-SUS and 
-UNSUS rats
Since a longitudinal study on hippocampus of postnatal stages of APO-SUS and 
-UNSUS rats (0, 2, 4, 6, 9, 12, 22, 35, 60 and 100 days of age) showed the largest 
differences in APO-SUS/-UNSUS Aph-1b-related mRNA expression at early post-
natal stages (data not shown), rats of PND 9 were used for subsequent expression 
studies. Quantitative RT-PCR on hippocampus RNA revealed in PND 9 APO-SUS 
rats significantly lower levels of Aph-1b-related mRNAs than in PND 9 APO-
UNSUS rats, namely a 2.3-, 3.2- and 6.2-fold reduction in APO-SUS (II/II), (II/I) 
and (I/I), respectively (Figure 2A). Northern blot analysis confirmed the quantitative 
RT-PCR data for hippocampus (Figure 2B) and furthermore showed, relative to PND 
9 APO-UNSUS rats, clearly reduced levels of Aph-1b-related mRNA expression 
in all other PND 9 APO-SUS (I/I) tissues tested (Figure 2C). We were unable to 
reliably detect the Aph-1b protein, in line with the inability of others to detect this 
seven-transmembrane protein (Gu et al., 2003) and despite the fact that we generated 
two additional antibodies against two computationally selected and previously not 
chosen rat Aph-1b peptide regions.
Besides Aph-1b and its paralogue Aph-1a, the γ-secretase complex is presently 
thought to consist of three other physically interacting components, namely the 
putative enzymatic core multipass transmembrane protein presenilin-1 or -2, the 
type I integral membrane presenilin-associated glycoprotein nicastrin, and the 
small double-membrane-spanning protein Pen-2 (Fortini, 2002; Francis et al., 2002; 
Goutte et al., 2002). Quantitative RT-PCR revealed that in the hippocampus of PND 
9 APO-UNSUS, and APO-SUS (II/II), (II/I) and (I/I) the mRNA levels of Aph-1a, 
presenilin-1 and -2, nicastrin and Pen-2 were not significantly different or only 
slightly affected (Figure 3A). Moreover, no significant differences in the protein 
levels of these γ-secretase components were observed in the hippocampus of PND 9 
APO-UNSUS and -SUS rats (Figure 3B). 
Cleavage activity of the γ-secretase enzyme in APO-SUS and -UNSUS rats
To examine the effect of the differential Aph-1b expression on γ-secretase enzyme 
activity, we performed western blot analysis of the cleavage products of the γ-secretase 
substrates amyloid-β precursor protein APP, p75 neurotrophin receptor (p75NTR) 
and neuregulin receptor ErbB4 in PND 2 APO-SUS (I/I) and APO-UNSUS (III/III) 
rat brain tissues (Figure 4). Since the ratios of the Aph-1b and Aph-1a mRNA levels 
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greatly vary among rat tissues (data not shown), we decided to study tissues with a 
high Aph-1b/-1a mRNA ratio (pons/medulla, ratio ~ 3.8; olfactory bulb, ratio ~ 2.9) 
as well as tissues with a low ratio ([hypo]thalamus, ratio ~ 0.9;  cerebellum, ratio ~ 
0.7). The first substrate examined was the C-terminal fragment of APP (APP-CTF, 
also referred to as C83/C99), a well-defined direct γ-secretase substrate (De Strooper 
et al., 1998). No differences in the levels of APP-CTF were observed in the tissues 
with a low Aph-1b/-1a ratio (cerebellum and [hypo]thalamus), while a significant 
increase was detected in the olfactory bulb and pons/medulla (2.1- and 2.7-fold, 
respectively) of I/I compared to III/III rats. This finding indicates that γ-secretase 
cleavage activity was reduced in the APO-SUS (I/I) rats in tissues that normally 
express relatively high Aph-1b levels (olfactory bulb and pons/medulla). Cleavage 
by γ-secretase of the C-terminal fragment of p75NTR (p75NTR-CTF) yields the 
p75NTR intracellular domain (p75NTR-ICD; (Kanning et al., 2003). No major 
differences in the amounts of p75NTR-ICD were found in the cerebellum, (hypo)
thalamus and pons/medulla, whereas in the I/I rats the levels of this product were 
significantly reduced in the olfactory bulb (1.7-fold). Similarly, the levels of the third 
γ-secretase substrate tested, the C-terminal fragment of ErbB4 (ErbB4-CTF), were 
significantly increased in the olfactory bulb of the I/I compared to the III/III rats (3.0-
fold) and not in the other three tissues. Thus, the reduced expression of Aph-1b in the 
APO-SUS (I/I) rats has decreased γ-secretase cleavage activity in a tissue-dependent 
manner, i.e. only in tissues in which normally a high Aph-1b/-1a ratio occurs (pons/
medulla and olfactory bulb) significant changes in activity could be detected.
Figure 1. Aph-1b in APO-UNSUS and -SUS rats. (A) Schematic of the three Aph-1b-related copies in 
the APO-UNSUS rat (referred to as region III/III) and of the one or two gene copies in the APO-SUS 
rat (region II/II, II/I or I/I); black box, Aph-1b’; white box, Aph-1b; white/black box, chimaeric Aph-
1b/b’; black/white box, chimaeric Aph-1b’/b. The results are based on Southern blot and PCR analyses 
of genomic DNA. (B) Schematic of the degree of nucleotide sequence identity between rat Aph-1b and 
-1b’. The locations of exons 1/1’ to 6/6’ of Aph-1b and -1b’ are indicated by bars below the schematic. 
The loop indicates the absence of 4145 nucleotides in Aph-1b. The region of 1106 nucleotides identical 
between the two genes (surrounding exons 5 and 5’, and representing the site of recombination; see 
under D) is indicated with an arrow above the schematic. (C) Alignment of the nucleotide sequences 
surrounding exon 5 of rat Aph-1b, exon 5/5’ of chimaeric Aph-1b’/b and exon 5’ of Aph-1b’. The 1106-
bp region identical between the genes is indicated with an arrow (as in B and D). The 5’- and 3’-regions 
flanking the 1106-bp region in the chimaeric gene are identical to the corresponding regions in Aph-1b’ 
and -1b, respectively. (D) Schematic of the genomic rearrangement resulting from unequal crossing-
over (interchromosomal, non-allelic homologous recombination) between the in-tandem Aph-1b’ and 
-1b (corresponding to region II in A) and leading to region III (Aph-1b’, chimaeric Aph-1b/b’ and Aph-
1b), and region I (chimaeric Aph-1b’/b). The 1106-bp regions (direct repeat sequences) are depicted as 
arrows, recombination is shown by the X and dots are used for clarity in the presentation.
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Behavioural phenotypes of the I/I, II/II and III/III rats 
We next wondered whether the I/I, II/II and III/III genotypes segregated with specific 
behavioural phenotypes and therefore performed a set of behavioural studies with 
adult rats of the three sublines. We first tested the susceptibility of the three lines 
for apomorphine by scoring their gnawing responses, and found that the III/III rats 
(32 ± 20 gnaws per 45 min) were significantly less susceptible for the drug than 
Figure 2. Aph-1b mRNA expression in the hippocampus and other tissues of PND 9 APO-UNSUS (U) 
and APO-SUS (S) rats. (A) Quantitative RT-PCR on RNA extracted from hippocampus of PND 9 APO-
UNSUS and APO-SUS (II/II), (II/I) and (I/I) rats. The primer sets detected all Aph-1b-related mRNAs. 
Results (n = 6 plus s.e.m.) were normalized towards β-actin and are expressed as arbitrary units (AU). 
Asterisks denote significant differences (P < 0.02). (B) Northern-blot analysis of RNA extracted from 
hippocampus of PND 9 APO-UNSUS and APO-SUS (II/II), (II/I) and (I/I) rats. The blot was hybridised 
with a full-length rat Aph-1b cDNA probe. As a control for RNA loading and integrity, 18S rRNA was 
used. (C) Northern blot analysis of RNA extracted from various tissues of PND 9 APO-UNSUS (III/
III) and APO-SUS (I/I) rats. Tissues used were cerebellum (cer), olfactory bulb (olf), cortex (ctx), 
hippocampus (hip), striatum (str), (hypo)thalamus (thal), pons/medulla (p/m), spinal cord (spin), eye, 
testis (test), stomach (stom), small intestine (s.i.), large intestine (l.i.), lung, liver (liv) and thymus 
(thym). The blot was hybridised with a full-length rat Aph-1b cDNA probe. As a control for RNA loading 
and integrity, 18S rRNA was used. 
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the II/II and I/I rats (1141 ± 189 and 1370 ± 99 gnaws per 45 min, respectively; 
Figure 5A). We then examined the explorative behaviour of the three sublines on 
a large open field. III/III rats habituated significantly faster (605 ± 76 s) than II/
II and I/I rats, which were found to hardly habituate (1548 ± 98 s and 1536 ± 123 
s, respectively; the maximum score was 1800 s) (Figure 5B, upper panel). For the 
III/III, II/II and I/I lines, a gradual increase in locomotor activity in the centre of 
the open field was found, with the I/I rats being significantly more active than the 
III/III rats (Figure 5B, lower panel), indicating a high explorative activity of the 
I/I rats in a cue-less environment. Finally, to assess novelty seeking in a stressful 
environment, the behaviours of the three sublines in the open versus the closed arms 
of the elevated plus maze were compared. The time spent on the open relative to the 
closed arms gradually increased for the III/III, II/II and I/I lines, with a significant 
difference between the III/III rats (8.0 ± 3.5) and the II/II and I/I rat lines (22.6 ± 
5.0 and 30.5 ± 3.9, respectively) (Figure 5C, upper panel). The III/III rats travelled 
significantly shorter distances on the open relative to the closed arms than the II/
II or I/I rats (Figure 5C, middle panel). Furthermore, the number of entries into the 
open versus the closed arms gradually increased for the III/III, II/II and I/I rats, and 
was significantly different between the III/III and I/I rats (Figure 5C, lower panel). 
Figure 3. mRNA and protein expres-
sion of γ-secretase components in the 
hippocampus of PND 9 APO-UNSUS 
(U) and -SUS (S) rats. (A) Quanti-
tative RT-PCR analysis of Aph-1a, 
presenilin-1 (PS1) and -2 (PS2), ni-
castrin (Nct) and Pen-2 mRNAs in the 
hippocampus of PND 9 APO-UNSUS 
and APO-SUS (II/II), (II/I) and (I/I) 
rats. Results (n = 7 plus s.e.m.) were 
normalised towards β-actin and are 
expressed as arbitrary units (AU). 
Asterisks denote significant diffe-
rences (P < 0.02). (B) Western blot 
analysis of the Aph-1a, PS1, PS2, 
Nct and Pen-2 proteins in the hip-
pocampus of PND 9 APO-UNSUS 
and APO-SUS (II/II), (II/I) and (I/I) 
rats. Results (n = 6 plus s.e.m.) were 
normalised towards β-actin and are 
expressed as arbitrary units (AU).
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The results of the elevated plus maze therefore suggest that the I/I and II/II rats 
are less anxious and more active than the III/III rats. Together, the results of the 
apomorphine susceptibility, open field and elevated plus maze tests indicate that a 
number of behavioural phenotypes of the III/III, II/II and I/I rats segregated with the 
genotypes of the three sublines.
Discussion
In this study, we explored the molecular genetic basis of APO-SUS rats that 
have a complex phenotype displaying a number of behavioural, neurochemical, 
endocrinological and immunological disturbances. Microarray analyses revealed the 
differential expression of only one gene (Aph-1b) that was found to be due to a gene-
dosage effect with one or two Aph-1b copies in APO-SUS and three copies in APO-
UNSUS rats. The dosage imbalance was caused by an unequal crossing-over event 
and the site of recombination was established, namely between direct repeats (a 
segmental duplication) within the Aph-1b locus in the rat genome. This recombination 
event is reminiscent of recently described human chromosomal rearrangements that 
involve segmental duplications, cause dosage imbalance of genetic material and 
Figure 4. Western blot analysis of the cleavage products of γ-secretase substrates in PND 2 APO-
UNSUS (U, III/III) and APO-SUS (S, I/I) rat tissues. The cleavages of three direct γ-secretase substrates 
were investigated by analysing the levels of C-terminal fragments of amyloid-β precursor protein 
(APP-CTF), p75 neurotrophin receptor (p75NTR-CTF) and neuregulin receptor ErbB4 (ErbB4-CTF) 
in the olfactory bulb (olf), pons/medulla (p/m), cerebellum (cer), and (hypo)thalamus (thal) of APO-
UNSUS (U,  III/III) and APO-SUS (S, I/I) rats. Included for p75NTR is the analysis of its intracellular 
domain (p75NTR-ICD), a γ-secretase cleavage product. Tubulin was used for normalisation. Levels 
were significantly different between the I/I and III/III rats for APP-CTF, p75NTR-ICD and ErbB4-CTF 
in the olfactory bulb and for APP-CTF in the pons/medulla (P < 0.05; n = 3, with the three rats from 
different nests).
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Figure 5. Behavioural phenotypic analysis of adult rats with I/I, II/II and III/III genotypes. (A) 
Apomorphine susceptibility test for gnawing behaviour. Following 1.5 mg/kg apomorphine (s.c.) 
injection, the gnawing scores of III/III, II/II and I/I rats were recorded for 45 min (n = 12, 10 and 11, 
respectively; plus s.e.m.). (B) Open field test for explorative behaviour. III/III, II/II and I/I rats were 
analysed on a large open field for 30 min. Upper panel: the time period the rats have used to habituate 
(i.e. cease their locomotor activity for 90 s); lower panel: the locomotor activity in the centre of the open 
field (n = 11, 10 and 10, respectively; plus s.e.m.). (C) Elevated plus maze test for novelty seeking in a 
stressful environment. The walking patterns of III/III, II/II and I/I rats in the open and closed arms of 
the elevated plus maze were analysed for 10 min. Upper panel: the time spent in the open relative to the 
closed arms; middle panel: the relative distance travelled in the open relative to the closed arms; lower 
panel: the number of entries into the open relative to the closed arms (n = 11, 16 and 10 respectively; 
plus s.e.m.). Asterisks denote significant differences (*: P < 0.05; **: P < 0.01; ***: P < 0.001).
result in so-called genomic disorders; segmental duplications comprise at least 5% 
of the human genome and duplicon-based genomic rearrangements appear to occur 
de novo at a frequency of 0.7-1 in every 1000 births (Ji et al., 2000). However, in 
contrast to the situation in rodents, the human genome harbours only a single Aph-
1b.
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In addition to the finding of its differential expression, a direct link between Aph-
1b and the observed characteristics of the APO-SUS and -UNSUS rat lines is 
suggested by the fact that the replicated APO-SUS and -UNSUS lines displayed 
similar differences in behaviour and Aph-1b copy numbers as the original lines. 
Furthermore, the results of our behavioural tests indicated that the Aph-1b genotypes 
segregate with a number of behavioural APO-SUS and -UNSUS phenotypes. Aph-1b 
and its paralogue Aph-1a represent components of the γ-secretase enzyme complex 
and, together with Pen-2, are thought to be involved in the regulation of γ-secretase 
activity by modulating the biogenesis of presenilin-nicastrin complexes (De Strooper, 
2003). We have indeed found that in the APO-SUS rats the lower Aph-1b levels 
had changed γ-secretase cleavage activity. The γ-secretase enzymatic machinery 
mediates intramembranous proteolytic cleavage of at least 14 type I transmembrane 
proteins that are thought to be involved in a complicated network of signalling 
pathways affecting many biological processes with a variety of physiological effects, 
especially during early (neuro)development (Fortini, 2002; De Strooper, 2003). 
Taken altogether, the results show that the reduced expression of Aph-1b underlies 
the APO-SUS phenotype. Thus, a subtle imbalance in the expression of a single gene 
product that is involved in a wide variety of developmental signalling pathways may 
well constitute the molecular basis of a complex phenotype that is generally believed 
to have a multifactorial background.
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Abstract
Selectively bred apomorphine susceptible (APO-SUS) rats display a complex 
behavioural phenotype remarkably similar to that of human neurodevelopmental 
disorders, such as schizophrenia. We recently found that the APO-SUS rats have 
only one or two Aph-1b gene copies (I/I and II/II rats, respectively), whereas their 
phenotypic counterpart has three copies (III/III). Aph-1b is a component of the 
γ-secretase enzyme complex that is involved in multiple (neuro)developmental 
signalling pathways. Nevertheless, surprisingly little is known about γ-secretase 
expression during development. Here, we performed a longitudinal quantitative 
PCR study in embryos and the hippocampus of I/I, II/II and III/III rats, and found 
gene-dosage dependent differences in Aph-1b, but not Aph-1a, mRNA expression 
throughout pre- and post-natal development. On the basis of the developmental 
mRNA profiles, we assigned relative activities to the various Aph-1a and -1b gene 
promoters. Furthermore, in the three rat lines we observed both tissue-specific and 
temporal alterations in γ-secretase cleavage activity towards one of its best-known 
substrates, the amyloid-β precursor protein APP. We conclude that the low levels of 
Aph-1b mRNA and γ-secretase activity observed in the I/I and II/II rats during the 
entire developmental period may well underlie their complex phenotype.
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Introduction
Selective breeding of Wistar rats that differ in their susceptibility to the dopamine 
receptor agonist apomorphine has resulted in the generation of two rat lines with 
either a high or a low susceptibility for this drug, the so-called APO-SUS and 
-UNSUS lines, respectively (Cools et al., 1990; Ellenbroek and Cools, 2002). 
Extensive phenotypic analysis of these lines revealed for the APO-SUS rats not 
only a strong, stereotyped gnawing response, but in addition many features that are 
also found in patients suffering from developmental psychiatric illnesses, such as 
schizophrenia. These features include information processing deficits in the brain 
(measured by a reduced prepulse inhibition and latent inhibition), a hyper-reactive 
dopaminergic pathway, an increased stress response, and a variety of behavioural, 
neurochemical, endocrinological and immunological features (Ellenbroek and Cools, 
2002). While many of the differences between the APO-SUS and -UNSUS rat lines 
become apparent later in life, some features have been found at earlier developmental 
stages. For example, APO-SUS rats display a retarded development in comparison 
to APO-UNSUS rats (Degen et al., 2005), such as the development and maturation 
of the thymus and spleen (Cools et al., 1993). Retarded development (e.g. low birth 
weight and slower gestation) is also a hallmark of schizophrenia (Kunugi et al., 
2001; Wahlbeck et al., 2001).
As the molecular basis of the differences between the APO-SUS and -UNSUS 
rats, we recently identified a gene-dosage imbalance of Aph-1b (Coolen et al., 
2005b). APO-SUS rats have only one or two Aph-1b gene copies, whereas APO-
UNSUS rats have three in tandem gene copies, resulting in reduced Aph-1b mRNA 
levels in the APO-SUS rats. The Aph-1b protein is a component of γ-secretase, an 
enzyme complex that regulates the intramembrane proteolysis of a number of type I 
membrane proteins, including Notch, neuregulin and the Alzheimer’s disease-linked 
amyloid-β precursor protein APP (Kopan and Ilagan, 2004). These substrates play 
diverse physiological roles in multiple cell types and tissues, especially during early 
development.(Selkoe and Kopan, 2003) The minimal molecular subunit composition 
of an enzymatically active γ-secretase complex consists of presenilin (either PS-1 
or PS-2), nicastrin (Nct), presenilin enhancer 2 (PEN-2) and the anterior pharynx 
defective 1 protein Aph-1, in mammals Aph-1aS, -1aL or -1b (Kimberly and Wolfe, 
2003). We further established that the three Aph-1b rat genotypes segregated with 
a number of behavioural phenotypes (Coolen et al., 2005b). We now generated by 
crossbreeding, genetic reselection and phenotyping (susceptibility for apomorphine) 
three lines with one, two or three copies of the Aph-1b gene against an otherwise 
highly similar general genetic background (I/I, II/II and III/III lines, respectively). 
In this study, we performed an embryonic to adult longitudinal study on the mRNA 
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expression levels of the three Aph-1 family members in the I/I, II/II and III/III rat 
lines, and analysed the γ-secretase cleavage activity towards APP at a number of 
developmental stages.
Materials and methods
Animals
The generation of the APO-SUS and APO-UNSUS lines from Wistar rats with a high 
or low susceptibility to apomorphine, respectively, has been described previously 
(Cools et al., 1990). When we recently discovered the Aph-1b genotypes in the APO-
SUS and -UNSUS rat lines (Coolen et al., 2005b), we decided to set up a crossbreeding 
scheme. Four male and four female I/I rats of the APO-SUS line were crossed with 
four female and four male III/III rats of the APO-UNSUS line, respectively. The 
offspring (either I/III or III/I) was intercrossed preventing brother-sister pairing and 
the resulting F
2
 generation was genotyped for the Aph-1b locus by PCR analysis of 
genomic DNAs. The rats homozygous for either one or three Aph-1b gene copies 
were used to generate the I/I and III/III lines, respectively; apart from the Aph-1b 
locus, these lines have highly similar general genetic backgrounds. The crossbred 
I/I rats showed a significantly higher apomorphine susceptibility than the crossbred 
III/III rats. For the present studies, we used I/I and III/III rats of the F
3
 generation of 
the crossbred lines. Similarly, the II/II rat line was generated by crossbreeding II/II 
rats of the APO-SUS line and III/III rats of the APO-UNSUS line. The presence of 
a vaginal plug was used to determine embryonic day 0 (ED0). Rats were bred and 
reared in the Central Animal Facility of the Radboud University under approved 
animal protocols and in accordance with institutional guidelines.
Quantitative RT-PCR
Quantitative RT-PCR was performed as described previously 
(Coolen et al., 2005b). The following primers were used: Aph-
1b (448-671): 5’-GTGATTCTCCTCAGTTCTTCC TTAATTC and 
5’-GCCCATGAGCACCATGATTATAT; Aph-1aL (572-779):5’-CCTGGTAGT
TGGGAGTCACCTT and 5’-CGCAGGGCAGAGTACACCAT; Aph-1aS (572-
761): 5’-CCTGGTAGTTGGGAGTCACCTT and 5’-CGGTGCAGTCCAGGTAG 
TCAGT; ß-actin (346-435): 5’-CGTGAAAAGATGACCCAGATCA and 
5’-AGAGGCATACAGGGACAACACA; numbers between brackets are nucleotide 
positions from start ATG. All PCR products were generated over intron-exon 
boundaries. PCR product analysis on a 2% agarose gel revealed a single band for 
each primer pair used. A control (no template) was included for each primer set. Data 
sets were analysed with Sequence Detection System 1.3 software.
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Western blotting
Protein extractions and immunoblottings were performed as described (Herreman 
et al., 2003). The polyclonal antibody C87 directed towards the most C-terminal 
12 amino acids of APP was used at a dilution of 1:3000, and detected both the APP 
full-length protein and the C-terminal fragment of APP (APP-CTF) (Coolen et al., 
2005b). For quantification, the signals were analysed using the Labworks 4.0 program 
(UVP BioImaging systems, Cambridge, United Kingdom). Western blot analysis of 
Aph-1b protein expression was not successful.
Statistics
Statistical evaluation of the quantitative RT-PCR data for the three Aph-1 family 
members was performed by means of a univariate analysis of variance (ANOVA) 
with as dependent variable the normalized transcript levels and as fixed factors the 
genotypes (I/I, II/II and III/III) and the developmental time points (either ED or 
PND). For every time point, data were further analyzed for significant differences 
between the three genotypes using a one-way ANOVA and where appropriate a post 
hoc Bonferroni test. Per genotype, the statistical analysis for differences in transcript 
levels during development was performed by means of an independent samples 
T-test to compare the two embryonic time points, or using a one-way ANOVA and 
a post hoc Bonferroni test for the postnatal time points. A probability of P < 0.05 
was considered statistically significant. For the longitudinal Western blot analyses, 
the data sets were statistically analyzed by means of a univariate ANOVA with as 
dependent variable the APP-CTF/APP-FL levels and as fixed factors the genotypes 
and the developmental time points. Subsequent analysis using an independent samples 
T-test at every time point revealed significant differences between I/I and III/III rat 
tissues. Per rat line, a one-way ANOVA and where appropriate a post hoc Bonferroni 
analysis was used to identify differences between developmental time points. All 
statistical analyses were performed with the SPSS 12.0.1 software program (SPSS 
Inc., Chicago, Illinois, USA).
Results
Aph-1 mRNA levels in developing I/I, II/II and III/III rats
Real-time quantitative RT-PCR analysis of RNA from whole embryos (prenatal) and 
hippocampal tissue (postnatal) revealed similar overall Aph-1b mRNA expression 
profiles for the I/I, II/II and III/III rats with relatively low pre- and early postnatal 
expression that gradually increased over time until at ~PND 22 a plateau was 
reached (Figure 1A). Statistical analysis of the Aph-1b mRNA levels by means of a 
univariate ANOVA revealed significant differences between the genotypes, as well as 
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between the time points analysed (see supplemental tables 1-3 for statistical details). 
Subsequent one-way ANOVA per time point and post hoc Bonferroni analysis showed 
that the Aph-1b mRNA levels were significantly increased in the III/III hippocampal 
samples compared to the II/II or I/I samples at all pre- and postnatal time points 
tested, with the largest differences in the pre- and early postnatal samples (up to 
16-fold reduction in ED13 embryos of I/I compared to III/III rats). Furthermore, 
in the postnatal II/II hippocampal samples the Aph-1b mRNA levels were higher 
than in the I/I samples and reached significant differences from PND 35 onwards 
(up to a two-fold increase). The mRNA expression patterns of Aph-1aL in the three 
rat lines were reminiscent of those of Aph-1b with significant increases from PND 
35 onwards. In contrast, the developmental Aph-1aS mRNA expression levels were 
similar at all stages tested until PND 100, when a significant ~three-fold increase was 
observed (Figure 1C). For Aph-1aL as well as Aph-1aS, statistical analyses revealed 
no significant differences in mRNA expression levels between the three genotypes at 
any pre- or postnatal time point. 
Figure 1. Longitudinal study on Aph-1aL, 
-1aS and -1b mRNA expression levels in 
the I/I, II/II and III/III rats. Quantitative 
RT-PCR analysis of the mRNA levels of 
Aph-1b (A), Aph-1aL (B) and Aph-1aS 
(C) in total ED13 and ED17 embryos 
(left halves of the graphs) and in the 
hippocampus of PND 0, 4, 9, 12, 22, 
35, 60 and 100 rats (right halves of the 
graphs). The Aph-1b primer set detected 
all Aph-1b gene transcripts; the Aph-1aL 
or Aph-1aS primer sets detected the long 
or short transcripts, respectively. Results 
were normalized towards β-actin mRNA 
levels and are expressed as arbitrary 
units (AU) with the level in the PND 0 
III/III hippocampus set to 1 (per time 
point n = 3, plus s.e.m.). (A) Throughout 
development significant differences 
between the III/III and II/II rats as well 
as the III/III and I/I rats were observed 
for the Aph-1b mRNA levels (P < 0.05). 
From PND 35 onwards, Aph-1b mRNA 
levels also differed significantly between 
the II/II and I/I rats (P < 0.05). (B, C) No 
significant differences between the three 
genotypes were observed for the Aph-1aL 
or -1aS mRNA levels.
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γ-Secretase cleavage activity in developing I/I, II/II and III/III rats
Next, we were interested in the effects of the differential expression of Aph-1b mRNA 
in the I/I, II/II and III/III rats on γ-secretase cleavage activity. One of the best-known 
substrates of γ-secretase is the APP protein. The proteolytic processing of APP starts 
with shedding of its extracellular domain by α- or β-secretase, leaving a C-terminal 
fragment (CTF) that is subsequently cleaved by γ-secretase. Western blot analysis 
showed similar amounts of the APP holoprotein (APP-FL) in the olfactory bulb of 
PND 13 I/I, II/II and III/III rats, whereas the levels of the direct γ-secretase substrate 
APP-CTF were relatively high in the I/I, moderate in the II/II, and low in the III/
III rats (Figure 2A). An increased level of APP-CTF implies reduced γ-secretase 
activity. Statistical analysis by means of a one-way ANOVA and post hoc Bonferroni 
revealed between the three genotypes a significant difference in the amounts of APP-
CTF relative to APP-FL  (F[2,8] = 13.5 P < 0.05), namely an ~1.4-fold and an ~1.8-
fold higher ratio in the I/I rats relative to the II/II and III/III rats, respectively. Thus, 
the degree of proteolytic processing of APP by the γ-secretase complex correlated 
with the Aph-1b gene dosage in the I/I, II/II and III/III rats.
Since the Aph-1b mRNA expression levels significantly differed during development 
(Figure 1), we wondered whether the APP cleavage activity of γ-secretase would 
also show ontogenic dynamics. For this purpose, we first determined the γ-secretase 
cleavage activity (i.e. APP-CTF levels) in a number of tissues of I/I and III/III rats 
at PND 13 to identify appropriate tissues for a more detailed longitudinal analysis. 
Western blot analysis revealed variations in APP-CTF levels between the various 
tissues (Figure 2B). An accumulation of the APP-CTF levels was observed in the 
olfactory bulb, testis, spinal cord and lung of I/I compared to III/III rats and the 
latter two tissues were used for the more detailed study. In the spinal cord, the levels 
of APP-FL gradually decreased over time for both I/I and III/III rats from PND 9 
onwards, whereas the APP-CTF levels increased. In contrast, lung tissue showed 
similar expression levels of the holoprotein throughout postnatal development, while 
the APP-CTF levels were markedly increased in both I/I and III/III rats from PND 
13 onwards (Figure 2C and D). Statistical analysis of the APP-CTF/APP-FL ratio 
per time point revealed a significant increase of APP-CTF levels in the spinal cord 
of I/I compared to III/III rats already at PND 2 and also at PND 13 and 35, whereas 
in the lung significant accumulations were found from PND 13 onwards (see also 
supplemental table 4 for statistical details). Thus, during development of the I/I, II/II 
and III/III rats the differential Aph-1b expression levels have spatio-temporal effects 
on γ-secretase cleavage activity towards APP.
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Discussion
The γ-secretase enzyme is involved in a large variety of developmental signalling 
pathways (Artavanis-Tsakonas et al., 1999; Huang et al., 2000; Turner et al., 2003; 
Figure 2. Ontogenic analysis of γ-secretase cleavage activity towards APP in the I/I, II/II and III/III 
rats. (A) APP processing by γ-secretase is dependent on the number of Aph-1b gene copies. Western 
blot analysis of the levels of the APP holoprotein (APP-FL) and C-terminal fragment (APP-CTF) was 
performed in the olfactory bulb of I/I (1), II/II (2) and III/III (3) rats at PND 13. Quantification of the 
APP-CTF relative to the APP-FL levels revealed significant differences between the I/I and II/II, and 
between the I/I and III/III rats (*: P < 0.05; **: P < 0.02; n = 3, with the three rats from different nests, 
plus s.e.m.). (B) Western blot analysis of the APP-CTF levels in a number of tissues of PND 13 I/I (1) 
and III/III (3) rats. Tissues analysed were olfactory bulb (olf), pons/medulla (p/m), hippocampus (hip), 
spinal cord (spc), cortex (ctx), (hypo)thalamus (tha), cerebellum (cer), lung (lng), liver (liv), spleen 
(spl), muscle (msc), testis (tes), pancreas (pan) and tongue (tng). The additional product observed 
in cortex and (hypo)thalamus corresponds to the β-secretase cleavage product CTFβ (C99). (C, D) 
Western blot analysis of the levels of APP-FL and -CTF in the spinal cord (C) and lung (D) of I/I (1) and 
III/III (3) rats at PND 2, 9, 13, 35 and 60. Significantly elevated APP-CTF/-FL ratios in I/I compared to 
III/III rats were found in the spinal cord at PND 2, 13 and 35 and in the lung from PND 13 onwards. (*: 
P < 0.05; **: P < 0.02; n = 3, with the three rats per genotype from different nests, plus s.e.m.).
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Kopan and Ilagan, 2004). It is therefore surprising that little is known about the 
developmental expression patterns of PS, Nct, PEN-2 and Aph-1, the components of 
the γ-secretase complex. In the present study, we examined the mRNA expression 
levels of the three Aph-1 family members (Aph-1b, -1aS and -1aL) and the γ-secretase 
cleavage activity towards APP during the development of rats with one, two or three 
Aph-1b gene copies (I/I, II/II and III/III rats, respectively). Relatively low levels 
of Aph-1b mRNA were detected during the pre- and early postnatal developmental 
stages, whereas from PND 35 onwards we found increased levels that remained high 
during further development. This developmental Aph-1b mRNA expression profile 
thus suggests that in the rat the demand for Aph-1b is higher postnatally than during 
early development. The availability of the three Aph-1b mRNA expression profiles 
together with the knowledge of the genetic make-up of the Aph-1b loci in the I/I, 
II/II and III/III rat lines allows us to speculate about the developmental activity of 
the various Aph-1b gene promoters; the different sets of Aph-1b genes and gene 
promoters in the three rat lines are schematically depicted in Figure 3. Despite 
the extra gene copy in the II/II rats, the Aph-1b mRNA expression levels were not 
different during early development of the I/I and II/II rats, indicating that prenatally 
either the Aph-1b gene promoter displays a relatively low activity or the Aph-1b’/b 
hybrid gene promoter has a relative high activity. Conversely, in the III/III rats we 
found higher Aph-1b mRNA expression levels than one would expect on the basis 
of three gene copies and the promoter of the Aph-1b/-1b’ hybrid gene thus appears 
to display a relatively high activity throughout development. The observed Aph-1b 
mRNA expression levels are therefore not always in full accordance with the number 
of Aph-1b gene copies. 
Neither pre- nor postnatally the levels of Aph-1aS and -1aL mRNA differed between 
the three rat lines, indicating that these paralogues did not compensate for the altered 
Aph-1b mRNA levels. This is in line with the results of recent RNA interference 
and knockout studies on the Aph-1 family members in the mouse showing that the 
expression levels of the other γ-secretase components were affected only when Aph-
1a expression was silenced and not with abolished Aph-1b expression (Shirotani 
et al., 2004; Saito and Araki, 2005; Serneels et al., 2005). Similar to the results 
obtained with reduced Aph-1a expression, knock down or knock out of either of the 
γ-secretase components PS1, Nct or PEN-2 in the mouse led to affected levels of 
most of the nonsilenced γ-secretase subunits (Chen et al., 2003; Gu et al., 2003; Li 
et al., 2003a; Li et al., 2003b; Takasugi et al., 2003; Hasegawa et al., 2004; Zhang 
et al., 2005). In contrast, ablation of mouse PS2 expression had little effect on the 
expression levels of the other γ-secretase components (Herreman et al., 1999; Chen 
et al., 2003; Zhang et al., 2005), comparable to what we have observed in the I/I, II/
II and III/III rat lines concerning the effect of reduced Aph-1b expression (Coolen et 
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al., 2005b). These findings suggest that PS2 and Aph-1b are somehow related.
The reduced ontogenic Aph-1b mRNA levels observed in the hippocampus may well 
underlie the large differences in stress susceptibility of the rats with one, two or three 
Aph-1b gene copies (Coolen et al., 2005a), as the hippocampus is known to modulate 
the stress axis (Knigge, 1961; Jacobson and Sapolsky, 1991). In addition, the marked 
hippocampal differences may be related to the dopaminergic hyperreactivity of 
the rats, since one of the most important projections of the hippocampus runs to 
the ventral striatum (Groenewegen et al., 1999). In psychiatric disorders, such as 
schizophrenia, stress susceptibility and dopaminergic hyperreactivity have also 
been observed (Lammers et al., 1995; Muller-Spahn et al., 1998). According to 
the developmental hypothesis of schizophrenia, the pathophysiology and aetiology 
of the disorder are related to an affected development or maturation of the brain. 
Epidemiological studies have provided a solid basis for this hypothesis, e.g. during 
early life schizophrenic individuals have shown a retarded motor and cognitive 
development (Jones, 1997; Isohanni et al., 2000; Cannon et al., 2002). Furthermore, 
disturbances in the cytoarchitecture of the hippocampal formation (Kovelman and 
Scheibel, 1984) and entorhinal cortex (Bernstein et al., 1998) can only be adequately 
explained by aberrant brain development. Unfortunately, schizophrenia has an adult 
onset and it has turned out to be difficult to elucidate its molecular basis (Andreasen, 
2000). Perhaps the results of our longitudinal developmental study on the I/I, II/II 
and III/III rat lines may help in the understanding of the molecular background of 
such neurodevelopmental disorders.
Figure 3. Schematic representation of the Aph-1b genes in the I/I, II/II and III/III rat lines. The I/I rats 
have only one Aph-1b gene (the Aph-1b’/-1b hybrid gene consisting of exons 1-5 of Aph-1b’ and exons 
5-6 of Aph-1b), the II/II rats contain the Aph-1b’ and Aph-1b genes, and the III/III rats harbor, besides 
the Aph-1b’ and Aph-1b genes, an additional Aph-1b/-1b’ hybrid gene . The activities of the various 
promoters, as deduced from the developmental mRNA expression profiles (Figure 1), are indicated by 
the black arrows with their thickness corresponding to the level of activity (lower arrows: prenatal 
activity; upper arrows: postnatal activity). Open arrows indicate the promoters of the various genes.
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We have found that in the three rat lines the Aph-1b mRNA expression levels 
correlated with the degree of APP processing by γ-secretase. Similarly, complete 
silencing of the expression of PS1, Nct, PEN-2 or Aph-1a in the mouse resulted in 
reduced γ-secretase activity (also indicated by elevated APP-CTF levels) (Rozmahel 
et al., 2002; Li et al., 2003a; Hasegawa et al., 2004; Ma et al., 2005; Serneels et al., 
2005; Zhang et al., 2005). Conversely, preventing mouse PS2 or Aph-1b expression 
did not affect or only slightly decreased γ-secretase activity, respectively, and gave 
only a mild phenotype, whereas removal of PS1, Nct or Aph-1a is lethal (Herreman 
et al., 1999; Serneels et al., 2005). We therefore hypothesize that the functioning of 
the PS2- and Aph-1b-containing γ-secretase complex is different from that of the 
complexes with other subunit compositions.
The reduction in APP processing that we observed may be related to the hyperactive 
behaviour displayed by rats with one or two Aph-1b gene copies (Coolen et al., 
2005b). Interestingly, in mice the reverse situation, namely overexpressed APP (or 
APP-CTF), results in general hypoactive behaviour (D’Hooge et al., 1996; Lalonde 
et al., 2002). We further found that the effects on γ-secretase activity were tissue 
specific. In general, in a tissue with a high level of Aph-1b mRNA compared to the 
Aph-1a mRNA level (a high Aph-1b/-1a mRNA ratio) relatively large differences in 
the APP-CTF levels were found between the I/I and III/III rats. In the hippocampus, 
a tissue with a relatively low Aph-1b/-1a ratio (Coolen et al., 2005a), we did not 
observe significant differences in γ-secretase cleavage activity between the three rat 
lines, while large alterations in hippocampal Aph-1b mRNA levels were detected 
(~8-fold at PND 13). It thus appears that a reduced Aph-1b expression causes a more 
severe effect on γ-secretase activity in tissues with a high Aph-1b/-1a ratio than in 
tissues with a low ratio. Furthermore, sufficient amounts of the direct γ-secretase 
substrate APP-CTF had to be present in a tissue to allow detection of any significant 
difference in γ-secretase cleavage activity. For instance, the lung has a high Aph-
1b/-1a ratio, but we did not observe an affected γ-secretase activity in early postnatal 
lung, presumably due to the low levels of APP-CTF in this tissue.
The γ-secretase complex is able to cleave an ever-growing list of now at least 15 
substrates and it is likely that in the I/I rats the effect of the reduced Aph-1b mRNA 
expression was not restricted to the decreases in APP cleavage, but that the cleavages 
of other (developmentally important) γ-secretase substrates, like Notch, neuregulin, 
ErbB4 and N-cadherin, were also affected. Such a broad ontogenic effect presumably 
resulted in not only retarded development (Cools et al., 1993; Degen et al., 2005), 
but also in the complex phenotype of the SUS rats in adulthood (Ellenbroek and 
Cools, 2002; Coolen et al., 2005b).
In conclusion, a subtle ontogenic imbalance in the expression of a single γ-secretase 
component causes spatio-temporal differences in γ-secretase enzymatic activity. 
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Because γ-secretase complexes with different subunit compositions are not 
functionally redundant and each complex is involved in the preferential cleavage of 
a subset of γ-secretase substrates (Hebert et al., 2004; Shirotani et al., 2004; Coolen 
et al., 2005b), a complex (neuro)developmental phenotype may arise in an organism 
with altered expression of a γ-secretase component. Thus, affecting the ontogenic 
expression of a single developmentally important protein may ultimately result in a 
complex phenotype later in life.
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Supplemental tables
Supplemental table 1. Statistical support for Figure 1 by means of a univariate ANOVA on longitudinal 
mRNA expression levels of Aph-1 family members in the hippocampus of I/I, II/II and III/III rats 
(significant if P < 0.05; NS: no significant differences).
Aph-1b Aph-1aS Aph-1aL
ED
geno: F(2,19) = 57.6
ED: F(1,19) = 9.8
geno*ED: F(2,19) = 4.5
geno: NS
ED: F(1,21) = 12.6
geno*ED: NS
geno: NS
ED: F(1,22) = 18.9
geno*ED: NS
PND
geno: F(2,81) = 242.3
PND: F(1,81) = 26.8
geno*PND F(1,81) = 3.2
geno: NS
PND: F(1,86) = 64.1
geno*PND: NS
geno: NS
PND: F(1,86) = 20.0
geno*PND: NS
Supplemental table 2. Since the univariate ANOVA for Figure 1 yielded statistical significance, we 
performed for the I/I, II/II and III/III rats over the embryonic time points an independent samples T-test 
and over the postnatal time points a one-way ANOVA and where appropriate a post hoc Bonferroni 
analysis. Significant differences between time frames are indicated (significant if P < 0.05; NS: no 
significant differences).
ED                                PND                                    
independent 
samples T-test
one-way ANOVA Bonferroni
I/I NS PND: F(7,27) = 17.7
PND(0-4)<PND(22-100) PND(9-
12) < PND(35-60)
Aph-1b II/II NS PND: F(7,25) = 5.5 PND(0) < PND(22)
III/III ED13 < ED17 PND: F(7,26) = 17.2
PND(0-4)<PND(22-100) PND(0-
4) < PND(9) 
PND(12) < PND(22-35)
I/I NS PND: F(7,27) = 19.1 PND0-60) < PND(100)
Aph-1aS II/II NS PND: F(7,27) = 17.9 PND(0-60) < PND(100)
III/III NS PND: F(7,29) = 29.8 PND(0-60) < PND(100)
I/I NS PND: F(7,27) = 11.6 PND(0-9) < PND(35-60)
Aph-1aL II/II NS PND: F(7,27) = 3.2 NS
III/III NS PND: F(7,29) = 11.4 PND(0-12) < PND(35-100)
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Supplemental table 3. Since the univariate ANOVA for Figure 1 yielded statistical significance, we 
performed for every developmental time point a comparison of the transcript levels of the I/I, II/II 
and III/III rats by means of a one-way ANOVA and where appropriate a post hoc Bonferroni analysis. 
Significant differences between genotypes are indicated (significant if P < 0.05; NS: no significant 
differences).
Aph-1b Aph-1aS Aph-1aL
ED 13 one-way ANOVA geno: F(2,8) = 34.1 NS NS
Bonferroni (I/I or II/II) < III/III - -
17 one-way ANOVA geno: F(2,9) = 34.0 NS NS
Bonferroni (I/I or II/II) < III/III - -
PND 0 one-way ANOVA geno: F(2,8) = 129.5 NS NS
Bonferroni (I/I or II/II) < III/III - -
4 one-way ANOVA geno: F(2,8) = 52.0 NS NS
Bonferroni (I/I or II/II) < III/III - -
9 one-way ANOVA geno: F(2,8) = 148.2 NS NS
Bonferroni (I/I or II/II) < III/III - -
12 one-way ANOVA geno: F(2,8) = 90.9 NS NS
Bonferroni (I/I or II/II) < III/III - -
22 one-way ANOVA geno: F(2,10) = 10.7 NS NS
Bonferroni (I/I or II/II) < III/III - -
35 one-way ANOVA geno: F(2,8) = 135.5 NS NS
Bonferroni I/I < II/II < III/III - -
60 one-way ANOVA geno: F(2,15) = 51.9 NS NS
Bonferroni I/I < II/II < III/III - -
100 one-way ANOVA geno: F(2,8) = 295.3 NS geno: F(2,8) = 5.2
Bonferroni I/I < II/II < III/III - NS
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Supplemental table 4. Statistical support for Figure 2 by means of a univariate ANOVA on longitudinal 
APP-CTF levels in the spinal cord and lung of I/I and III/III rats. Since the univariate ANOVA yielded 
statistical significance, we performed an independent samples T-test over the APP-CTF levels for every 
developmental time point, and for both I/I and III/III rats a one-way ANOVA and post hoc a Bonferroni 
analysis. Significant differences between genotypes or time frames are indicated (significant if P < 0.05; 
NS: no significant differences).
spinal cord 
univariate ANOVA PND independent samples T-test 
geno: NS 2 NS
PND: F(4,30) = 15.6 9 NS
geno*PND: NS 13 I/I > III/III 
35 I/I > III/III 
60 NS
geno one-way ANOVA Bonferroni 
I/I F(4,14) = 4.4 PND(2) < PND(35) 
III/III F(4,14) = 46.2 PND(2-13) < PND35-60) 
lung
univariate ANOVA PND independent samples T-test 
geno: F(1,30) = 13.1 2 NS
PND: F(4,30) = 22.7 9 NS
geno*PND: F(4,30) = 3.4 13 NS
35 I/I > III/III 
60 I/I > III/III 
geno one-way ANOVA Bonferroni 
I/I F(4,14) = 21.3 PND(2-9) < PND(13-60) 
III/III F(4,14) = 4.4 NS
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Abstract
The γ-secretase enzyme complex displays intramembrane catalytic activity towards 
many type I transmembrane proteins, including the Alzheimer-linked amyloid 
β-protein precursor (APP) and the neuregulin receptor ErbB4. Active γ-secretase 
is a tetrameric protein complex consisting of presenilin-1 (or -2), nicastrin, PEN-2, 
and Aph-1a (or -1b). We have recently discovered that pharmacogenetically bred 
apomorphine-susceptible Wistar rats (APO-SUS) have only one or two copies of 
the Aph-1b gene (termed I/I and II/II rats, respectively), whereas their phenotypic 
counterparts (APO-UNSUS) have three copies (III/III). As a result, APO-SUS 
rats display reduced Aph-1b expression and a complex phenotype reminiscent of 
neurodevelopmental disorders. Here we determined in the I/I and III/III rats the 
γ-secretase cleavage activity towards the three APP superfamily members, p75 
neurotrophin receptor, ErbB4 and neuregulin-2, and found that the cleavage of only 
a subset of the substrates was changed. Furthermore, the observed differences were 
restricted to tissues that normally express relatively high Aph-1b compared to Aph-
1a levels. Thus, we provide in vivo evidence that subtle alterations in γ-secretase 
subunit composition may lead to a variety of affected (neuro)developmental 
signalling pathways and, consequently, a complex phenotype.
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Introduction
The γ-secretase complex belongs to the family of aspartyl proteases and cleaves 
many type I transmembrane proteins within their membrane domain, after removal 
of the ectodomain (Kopan and Ilagan, 2004). The complex is notoriously known 
because of its role in the pathological production of amyloid-β in Alzheimer’s disease 
(reviewed in Fortini, 2002; Sisodia and St George-Hyslop, 2002; Tanzi and Bertram, 
2005). Under normal physiological conditions, γ-secretase causes the release of 
the intracellular domain (ICD) of a growing list of proteins, such as the amyloid 
β-precursor protein (APP), its relatives the APP-like proteins APLP1 and APLP2, 
Notch, neuregulin, the neuregulin receptor ErbB4, p75 neurotrophin receptor, 
N-cadherin and ApoER2. These type I transmembrane proteins are part of multiple 
(neuro)developmental signalling pathways (reviewed in Koo and Kopan, 2004; 
Kopan and Ilagan, 2004). Recently, the minimal molecular subunit composition of 
the γ-secretase complex has been solved, namely presenilin (either PS-1 or PS-2), 
nicastrin (Nct), presenilin enhancer 2 (PEN-2) and the anterior pharynx defective 
1 protein Aph-1, in mammals Aph-1aS, -1aL or -1b (De Strooper et al., 1998; Yu 
et al., 2000; Francis et al., 2002; Edbauer et al., 2003). In total six complexes with 
different subunit compositions can be formed because of the two presenilin proteins 
and the three Aph-1 proteins (Shirotani et al., 2004). It has been widely accepted that 
PS is the catalytic core protein of the complex, but the specific functions of the other 
γ-secretase components are less clear. Nct may have a role in stabilizing the complex 
or create a substrate docking site of the complex (Berezovska et al., 2003; Zhang et 
al., 2005), while Aph-1 has been suggested to stabilize both the maturing and final 
γ-secretase complex (Lee et al., 2004), and PEN-2 may assist in the endoproteolysis 
of the presenilin holoprotein during final maturation of the complex (reviewed in 
Periz and Fortini, 2004).
In a previous gene expression profiling study, we discovered a reduced expression 
of Aph-1b mRNA as the only difference between a pharmacogenetically selected 
apomorphine-susceptible (APO-SUS) rat line displaying many features of a complex 
neurodevelopmental disorder and its phenotypic counterpart, the apomorphine-
unsusceptible (APO-UNSUS) line (Coolen et al., 2005). The APO-SUS and -UNSUS 
rats differ not only in information processing deficits in the brain (measured by pre-
pulse inhibition and latent inhibition), but also show hyperactivity in an open field 
and in the elevated-plus maze, a hyper-reactive dopaminergic pathway, an increased 
stress response, and a variety of behavioural, neurochemical, endocrinological and 
immunological features (Ellenbroek and Cools, 2002). A detailed genomic analysis 
of the rat lines revealed an imbalance in Aph-1b gene copy numbers; APO-SUS 
rats have only one or two copies of the gene, whereas the APO-UNSUS genome 
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contains three in-tandem gene copies (Coolen et al., 2005). We now generated via 
cross-breeding and genetic re-selection two new rat lines; one homozygous for the 
allele with a single Aph-1b gene (the I/I rat line) and one homozygous for the allele 
with three gene copies (the III/III rat line). Here, we analysed in various tissues of the 
I/I and III/III rats the γ-secretase cleavage activity by determining the endogenous 
levels of protein fragments derived from a number of γ-secretase substrates, namely 
the three APP superfamily members, p75, ErbB4 and neuregulin-2 (NRG2).
Materials and methods
Animals
Initially, systemic administration of apomorphine (1.5 mg/kg s.c.) was used to select 
Wistar rats with a high or low susceptibility to this drug (APO-SUS and APO-
UNSUS rats, respectively). The evoked stereotyped gnawing behaviour (APO-
SUS: >500 gnaws in 45 min; APO-UNSUS: <10 gnaws in 45 min) was used to 
select female and male rats for breeding the two distinct lines (Cools et al., 1990). 
Phenotyping of the rat lines was reviewed elsewhere (Ellenbroek and Cools, 2002). 
When we recently discovered the different Aph-1b genotypes in the rat lines (Coolen 
et al., 2005), we decided to use rats of the 21st generation to set up a crossbreeding 
scheme. Four male and four female I/I rats of the APO-SUS line were crossed with 
four female and four male III/III rats of the APO-UNSUS line, respectively. The 
offspring (either I/III or III/I) was inter-crossed preventing brother-sister pairing and 
the resulting F
2
 generation was genotyped for the Aph-1b locus by PCR analysis of 
genomic DNAs. The rats homozygous for either one or three Aph-1b gene copies 
were used to generate I/I and III/III lines, respectively; apart from the Aph-1b locus, 
these lines have highly similar general genetic backgrounds. The crossbred I/I rats 
showed a significantly higher apomorphine susceptibility than the crossbred III/III 
rats. For the present γ-secretase cleavage activity studies, we used I/I and III/III rats 
of the F
3
 generation of the crossbred lines. Rats were bred and reared in the Central 
Animal Facility of the Radboud University under approved animal protocols and in 
accordance with institutional guidelines.
Northern blot analysis
Total RNA from various tissues of PND 9 I/I and III/III rats was isolated with the 
Trizol reagent (Gibco BRL Life Technologies), separated on gel (10 µg per lane), 
blotted and hybridised according to standard procedures with a full-length 798-bp 
rat Aph-1b cDNA probe detecting one product of ~1.3 kb. After stripping, the blot 
was rehybridised with a full-length 741-bp rat Aph-1aS cDNA probe detecting both 
the short and long isoform of Aph-1a (Aph-1aS of ~2.2 kb and Aph-1aL of ~1.8 
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kb, respectively). For quantification, hybridisation signals were analysed using the 
Labworks 4.0 program (UVP BioImaging systems, Cambridge, United Kingdom).
Quantitative RT-PCR
For quantitative RT-PCR, first-strand cDNA was prepared from 2 µg of DNase I treated 
total RNA (isolated as described above) using Superscript II reverse transcriptase 
(Invitrogen). PCR samples contained 1X SYBR Green buffer, 3 mM MgCl
2
, 0.4 mM 
dUTP and 0.2 mM each of dATP, dCTP and dGTP, 0.6 U AmpliTaq Gold (all from Applied 
Biosystems), 0.6 µM each oligonucleotide primer (Biolegio) and 1/20 synthesised 
cDNA in a 25-µl volume. Quantitative PCR was performed in a PE GeneAmp 5700 
apparatus with conditions as follows: 10 min at 94 °C, then 40 cycles of 15 s at 94 °C, 
30 s at 60 °C and 1 min at 72 °C. ß-Actin was amplified from all samples to normalize 
expression. A control (no template) was included for each primer set. Data sets were 
analysed with Sequence Detection System 1.3 software. The following primers 
were used: Aph-1b (448-671): 5’-GTGATTCTCCTCAGTTCTTCCTTAATTC and 
5’-GCCCATGAGCACCATGATTATAT; Aph-1a (547-670): 5’-AGAGGAGACGG-
TACTGGGCTTT and 5’-ATGGAAACGGTGACTGCATAGA; ß-actin (346-435): 
5’-CGTGAAAAGATGACCCAGATCA and 5’-AGAGGCATACAGGGACAAC-
ACA; numbers between brackets are nucleotide positions from start ATG). The Aph-
1b primers detected all transcripts from the Aph-1b genes and the Aph-1a primers 
detected both Aph-1aS and -1aL mRNA. All PCR products were generated over 
intron-exon boundaries.
Western blot analysis
Protein extractions and immunoblottings were performed as previously described 
(Herreman et al., 2003). Briefly, selected brain regions and tissues were dissected 
from pups at PND 13 and homogenised in 50 mM Tris (pH8.0), 150 mM NaCl and 
0.5% NP-40 and postnuclear fractions were isolated by centrifugation at 10,000 x 
g for one hour at 4°C. Proteins in the supernatant were quantified using a standard 
Bradford assay (Pierce) and 20 µg protein was loaded per lane on Tris-Tricine SDS-
PAGE gels (in case of APP, APLP1 and APLP2) or on Tris-Glycine SDS-PAGE 
gels (for NRG2, ErbB4, p75 and tubulin) and transferred to nitrocellulose or PVDF 
membranes for Western blot detection. This Western blotting procedure allowed 
the detection of the C-terminal fragments (CTFs) of APP (using the C-terminally 
directed antibody C87, 1:3000) (Coolen et al., 2005), APLP1 (antibody CT-11, 
1:2000) (Thinakaran et al., 1995) , APLP2 (antibody AP-tail, 1:2000) (Sester et al., 
2000) and NRG2 (anti-proNRG, 1:2000) (Montero et al., 2002), the intracellular 
domain (ICD) of ErbB4 (antibody C-18, 1:3000; Santa Cruz Biotechnology, Santa 
Cruz, CA) and both the CTF and ICD of p75 (anti-p75-ICD, 1:3000) (Mahadeo et al., 
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1994). The antibody against β-tubulin (antibody E7, 1:3000) (Chu and Klymkowsky, 
1989) was used as an internal loading control. All antibodies were tested on tissue 
samples from five I/I rats of different nests and five III/III rats of different nests. 
Identical tissue lysates were used to test the different γ-secretase substrate levels. For 
quantification, hybridisation signals were analysed using the Labworks 4.0 program 
(UVP BioImaging systems, Cambridge, United Kingdom).
Statistics
Data obtained by quantitative RT-PCR were analysed per tissue by means of an 
independent samples T-test. Data from the Western blot analyses were analysed per 
substrate by means of a univariate analysis of variance (ANOVA) with the dependent 
variable density (values normalised against tubulin) and the fixed factors genotype (I/I 
and III/III) and tissue (e.g. olfactory bulb, spinal cord, or cortex). Where appropriate, 
data were further analysed per tissue by means of a one-way ANOVA on genotype. A 
probability of P < 0.05 was considered statistically significant. All statistical analyses 
were performed with the SPSS 12.0.1 software program (SPSS Inc., Chicago, Illinois).
Results
Aph-1a and Aph-1b mRNA levels in I/I and III/III rat tissues
Northern blot analysis revealed high levels of Aph-1b mRNA in most III/III rat 
tissues analysed, whereas in the same tissues of I/I rats the levels were not or hardly 
above background (Figure 1A). In contrast, the mRNA levels of Aph-1aS and -1aL 
did not differ between I/I and III/III rat tissues, also not in the tissues with large 
differences in Aph-1b expression. Furthermore, the ratios between the Aph-1b and 
Aph-1a mRNA levels greatly varied among the III/III rat tissues. Tissues such as 
the olfactory bulb, pons/medulla, testis and lung showed high Aph-1b/-1a ratios, 
while the cortex, hippocampus, spinal cord, stomach, large intestine and thymus had 
moderate ratios, and the cerebellum, striatum, (hypo)thalamus, eye, heart, muscle, 
small intestine, spleen, liver and pancreas showed low ratios (Figure 1A). Real-time 
quantitative RT-PCR analysis of Aph-1b mRNA expression in cerebellum, olfactory 
bulb, cortex and lung revealed significant reductions in these tissues of I/I compared 
to III/III rats (P < 0.05), with the largest difference observed in the olfactory bulb 
(~8-fold reduction) (Figure 1B). The four tissues did not differ in Aph-1a mRNA 
levels between the two rat lines; the cerebellum showed the highest Aph-1a mRNA 
expression levels (one-way ANOVA followed by a post-hoc Bonferroni test: P < 
0.05). The quantitative RT-PCR data confirmed the Aph-1b/-1a ratios obtained 
through Northern blot analysis (olfactory bulb and lung displayed high ratios, cortex 
showed moderate ratios, and cerebellum had low ratios) (Figure 1B).
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Figure 1. Analysis of Aph-1a and -1b mRNA expression in various tissues of I/I and III/III rats. (A) 
Northern blot analysis of total RNA from the respective tissues of I/I and III/III rats. The blot was 
hybridised with a full-length rat Aph-1b cDNA probe and subsequently, following stripping, rehybridised 
with a full-length rat Aph-1a cDNA probe; the Aph-1a probe detected both the short and long isoform 
(Aph-1aS and -1aL, respectively). The 18S rRNA signal was used as a control for RNA loading and 
integrity. The Aph-1b/-1a intensity ratio was determined for every III/III rat tissue and categorised as 
high (Aph-1b/-1a > 2.0; +++), moderate (1.0 < Aph-1b/-1a ≤ 2.0; ++) or low (Aph-1b/-1a ≤ 1.0; +). 
Tissues used were cerebellum (cer), olfactory bulb (olf), cortex (ctx), hippocampus (hip), striatum (str), 
(hypo)thalamus (tha), pons/medulla (p/m), spinal cord (spc), eye, testis (tes), heart, (hrt), muscle (msc), 
stomach (sto), small intestine (s.i.), large intestine (l.i.), lung (lng), spleen (spl), liver (liv), thymus (thy) 
and pancreas (pan) of PND 9 III/III (3) or I/I (1) rats. (B) Real-time quantitative RT-PCR on total RNA 
from a number of I/I and III/III rat tissues. Tissues examined were cerebellum (cer), olfactory bulb (olf), 
cortex (ctx) and lung (lng). The Aph-1b mRNA levels of I/I compared to III/III rats were significantly 
reduced in the four tissues analysed (P < 0.05), whereas Aph-1a mRNA levels did not differ between the 
rat lines. The Aph-1b/-1a ratios calculated from the quantitative RT-PCR data were categorised as high 
(Aph-1b/-1a > 2.0; +++), moderate (1.0 < Aph-1b/-1a ≤ 2.0; ++) or low (Aph-1b/-1a ≤ 1.0; +). The 
Aph-1a primer set detected both Aph-1aS and -1aL mRNA. Results (n = 3; plus s.e.m.) were normalised 
towards β-actin and are expressed as arbitrary units (AU).
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γ-Secretase cleavage activity towards the APP superfamily members in I/I and III/
III rat tissues
Since the Aph-1 protein is an essential component of the γ-secretase complex, we 
were interested in the effect of the differential mRNA expression of Aph-1b on the 
proteolytic cleavage activity of the complex in I/I and III/III rat tissues. To this end, 
the levels of cleavage products of various γ-secretase substrates were examined by 
Western blot analysis using antibodies directed against the C-terminal regions of 
the substrates. In general, the proteolytic processing of a γ-secretase substrate starts 
with shedding of its extracellular domain, leaving a C-terminal fragment (CTF) that 
is subsequently cleaved by γ-secretase to its ICD. One of the best-known substrates 
of γ-secretase is the Alzheimer’s disease-linked APP protein. APP is part of the APP 
superfamily that in mammals includes the two APP-like proteins APLP1 and APLP2. 
We compared the γ-secretase cleavage activities towards the APP superfamily 
members in tissues of III/III rats having different Aph-1b/-1a ratios (high: olfactory 
bulb and lung; moderate: spinal cord and cortex; low: [hypo]thalamus, cerebellum 
and spleen) with the activities in the corresponding I/I rat tissues. Statistical analysis 
of the levels of direct γ-secretase substrates (CTFs) using a univariate analysis of 
variance (ANOVA) revealed a genotype effect for all three APP superfamily members 
(APP-CTF: F(1,62) = 15.9 P < 0.05; APLP1-CTF: F(1,13) = 22.4 P < 0.05; APLP2-
CTF: F(1,46) = 17.6 P < 0.05). Subsequent one-way ANOVA analysis showed that 
the CTF levels were significantly increased in the olfactory bulb (APP: 1.6-fold [P 
< 0.01]; APLP1: 2.0-fold [P < 0.05]; APLP2: 2.1-fold [P < 0.05]), the lung (APP: 
2.2-fold [P < 0.05]; APLP2: 1.3-fold [P < 0.05]), the spinal cord (APP: 1.6-fold [P 
< 0.02]; APLP1: 1.6-fold [P < 0.05]; APLP2: 1.8-fold [P < 0.05]) and the cortex 
(APP: 1.3-fold [P < 0.05]; APLP2: 2.2-fold [P < 0.02]) of I/I compared to III/III rats. 
No significant differences in the CTF levels were observed in the (hypo)thalamus, 
cerebellum and spleen of I/I and III/III rats, that is in tissues with a low Aph-1b/-1a 
ratio (Figure 2).
Figure 2. Western blot analysis of the γ-secretase cleavage products derived from the APP, APLP1 
and APLP2 proteins in various tissues of I/I and III/III rats. (A) The levels of the C-terminal fragments 
(CTFs) of amyloid-β precursor protein (APP), and the APP-like proteins APLP1 and APLP2 (sizes 
of all three CTFs ~10 kDa) were analysed in neuronal tissues of PND 13 I/I (1) and III/III (3) rats 
using specific antibodies. Tissues used were the olfactory bulb (high Aph-1b/-1a ratio), spinal cord and 
cortex (moderate ratio), and (hypo)thalamus and cerebellum (low ratio). (B) Levels of APP-, APLP1- 
and APLP2-CTF were analysed in the lung (high Aph-1b/-1a ratio) and spleen (low ratio) of PND 
13 I/I and III/III rats. In each case, tubulin (~55-kDa) was used for normalisation. Bars represent 
quantifications in arbitrary units of normalised CTF signals of five tissue samples with the average 
level in III/III rat tissues set to 1. The levels of the APP, APLP1 and APLP2 holoproteins were similar 
in the I/I and III/III rat tissues. Significant differences in CTF levels between the I/I and III/III rats for 
the three APP superfamily members were found in the olfactory bulb and spinal cord, and for APP and 
APLP2 in the cortex, (hypo)thalamus and lung. *:P < 0.05; **:P < 0.02; ***: P < 0.01; n = 5, with the 
five rats per genotype from different nests; plus s.e.m.; BD: below detection.
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Figure 3. Western blot analysis of the γ-secretase cleavage products derived from p75, ErbB4 and 
NRG2 in various tissues of I/I and III/III rats. (A) The levels of the C-terminal fragments (CTFs) 
of p75 neurotrophin receptor (~30-kDa, p75-CTF) and neuregulin-2 (~20/25-kDa, NRG2-CTF) were 
analysed in neuronal tissues of PND 13 I/I (1) and III/III (3) rats. For p75 and neuregulin receptor 
ErbB4, levels of a γ-secretase cleavage end product, namely the intracellular domains (~25-kDa, p75-
ICD and ~80-kDa, ErbB4-ICD, respectively), are included. Tissues used were the olfactory bulb (high 
Aph-1b/-1a ratio), spinal cord and cortex (moderate ratio), and (hypo)thalamus and cerebellum (low 
ratio). (B) Levels of p75-CTF, p75-ICD, ErbB4-ICD and NRG2-CTF were analysed in lung (high Aph-
1b/-1a ratio) and spleen (low ratio) of PND 13 I/I and III/III rats. Tubulin (~ 55-kDa) was used for 
normalisation. Bars represent quantifications in arbitrary units of normalised signals of five tissue 
samples with the average level in III/III rat tissues set to 1. While the levels of the holoproteins of 
p75 and ErbB4 were similar in all I/I and III/III rat tissues tested, the levels of intact NRG2 were 
significantly increased in the (hypo)thalamus and spleen of the I/I rats (2.7-fold [P < 0.01], and 2.3-
fold [P < 0.05], respectively. The levels of p75-ICD and ErbB4-ICD were significantly different only 
in the olfactory bulb of I/I and III/III rats (1.8-fold [P < 0.05], and 1.3-fold [P < 0.05], respectively). 
Although the NRG2-CTF levels were different in the spleen of the I/I and III/III rats, dividing the CTF 
levels by the NRG2 holoprotein levels showed no affected γ-secretase cleavage activity. *: P < 0.05; 
**: P < 0.02; ***: P < 0.01; n = 5, whereby the five rats per genotype were taken from different nests; 
plus s.e.m.; ♦: non specific product; BD: below detection.
γ-Secretase cleavage activity towards p75, ErbB4 and NRG2 in I/I and III/III rat 
tissues
To examine whether substrates other than the APP superfamily members showed 
affected levels of their γ-secretase cleavage products in I/I compared to III/III rats, 
we next analysed the cleavages of p75, ErbB4 and NRG2. Although no significant 
differences were found in the univariate ANOVA for the cleavage products of p75, 
ErbB4, or NRG2, visual inspection of the data prompted us to perform a one-way 
ANOVA per tissue. The levels of p75-CTF were similar in all I/I and III/III rat tissues 
tested, whereas p75-ICD showed significantly reduced levels only in the olfactory 
bulb of the I/I rats (1.8-fold [P < 0.05]). The olfactory bulb was also the only tissue 
with significantly reduced ErbB4-ICD levels when comparing I/I and III/III rat 
tissues (1.3-fold [P < 0.05]). The CTF levels of NRG2 were similar in all tissues 
examined (Figure 3).
Discussion
Over- and under-expression studies with transfected cells as well as analyses of 
knockout mice have shown that the γ-secretase complex requires at least four protein 
components to display cleavage activity, namely presenilin (PS-1 or -2), nicastrin, 
PEN-2 and Aph-1 (Aph-1aS, -1aL or -1b) (De Strooper et al., 1998; Yu et al., 2000; 
Francis et al., 2002; Edbauer et al., 2003; Kim et al., 2003; Lai et al., 2003; Serneels 
et al., 2005). In the present study, we examined the mRNA expression levels of 
Aph-1aS, -1aL and Aph-1b, and the effects of the differential Aph-1b expression on 
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the cleavage activity of the γ-secretase complex in rats with one or three Aph-1b 
gene copies (I/I and III/III rats, respectively). Since a clear reduction of the Aph-
1b mRNA levels in I/I compared to III/III rats was found, while the Aph-1aS and 
-1aL mRNA levels were similar between the two rat lines, the Aph-1a paralogues 
do not compensate for the reduced expression of Aph-1b. The ratios between the 
Aph-1b and -1a mRNA levels greatly varied among the III/III rat tissues. Tissues 
that normally have a high Aph-1b/-1a ratio displayed clear differences in γ-secretase 
cleavage activity when comparing I/I and III/III rats, whereas the activity in tissues 
with a low ratio was not or hardly affected. Furthermore, within a particular tissue 
the processing of the various substrates tested was not affected to the same extent. 
This suggests that in vivo Aph-1a and -1b are not functionally redundant but are each 
involved in the preferential cleavage of a subset of γ-secretase substrates (Figure 
4).
We have previously found that the Aph-1b rat genotypes segregated with a number of 
behavioural phenotypes (Coolen et al., 2005), and that rats with the natural Aph-1b 
knockdown (APO-SUS) display alterations in brain information processing (prepulse 
inhibition and latent inhibition), locomotor activity in response to novelty, fleeing 
and problem-solving behaviour, and hypothalamus-pituitary-adrenal axis response 
to stress (Cools et al., 1990; Coenders et al., 1992; Ellenbroek et al., 1995; Rots et 
al., 1995). It would have been of great interest to compare this complex behavioural 
phenotype with the phenotype of mice generated by partial gene inactivation and 
thus reduced expression of the other γ-secretase components (heterozygous knockout 
mice), but behavioural studies on such models have not yet been performed. 
Unfortunately, complete knockouts of PS1, nicastrin and Aph-1a are lethal (Shen et 
al., 1997; Li et al., 2003; Ma et al., 2005; Serneels et al., 2005), and although PS2 as 
well as Aph-1b null mutations are viable and healthy, they have not been analysed for 
the features observed in APO-SUS rats (Donoviel et al., 1999; Herreman et al., 1999; 
Serneels et al., 2005) and a PEN-2 knockout mouse has not yet been generated. 
However, the behavioural phenotypes of a number of mice with altered expression of 
a substrate of γ-secretase have been examined and some of these show an interesting 
overlap with the APO-SUS phenotype. For example, heterozygous ErbB4 or NRG1 
knockout mice (with an overall ~50% reduction of mRNA expression) are also 
hyperactive in an open field test and show an impaired prepulse inhibition (Gerlai 
et al., 2000; Stefansson et al., 2002), whereas reduced expression of Notch had no 
effect on the open field behaviour (Costa et al., 2003). Conversely, overexpression of 
human APP751 or APP-CTF caused a general hypoactivity in mice (D’Hooge et al., 
1996; Lalonde et al., 2002). Behavioural studies on APLP1, APLP2, p75 or NRG2 
heterozygous knockout or transgenic mice have not yet been described.
In our studies, we further found that of the brain tissues examined, the olfactory 
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Figure 4. Schematic representation of the tissue- and substrate-specific changes in γ-secretase activity 
upon reduced expression of Aph-1b, affecting a great variety of signalling pathways and resulting in 
a complex phenotype. Reduction of Aph-1b levels (in I/I compared to III/III rats) causes changes in 
γ-secretase complex compositions; complexes containing Aph-1b (termed 1b) become less available 
(smaller hexagonal sizes), whereas Aph-1a containing complexes remain unaffected (1a; same hexagonal 
sizes). These changes affect γ-secretase cleavage activity (indicated by changes in arrow thickness), but 
only towards a limited number of substrates and only in certain tissues. The sizes of the circles reflect 
the different substrate levels in the various tissues and the thickness of the arrows corresponds to the 
activity towards a specific substrate. For clarity, only two types of γ-secretase complexes (1a and 1b) 
and six substrates (A through F) are shown; in mammals, six γ-secretase complexes with different 
subunit compositions can be formed and over 15 substrates are known thus far. Since the various 
substrates are part of diverse (neuro-)developmental signalling pathways, the reduced expression of a 
single gene (Aph-1b) eventually results in a complex phenotype, which is generally thought to have a 
multigenic origin.
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bulb of the I/I rats displayed the most severely affected γ-secretase cleavage activity. 
This tissue showed significantly changed levels of the γ-secretase cleavage products 
of the three APP superfamily members, as well as of ErbB4 and p75. The olfactory 
bulb not only contains relatively high expression levels of PS1 and PS2, and of 
the γ-secretase substrates APP, APLP2 and p75 (Thinakaran et al., 1995; Lee et al., 
1996; Page et al., 1996; Tisay et al., 2000), but also shows high binding affinity for 
γ-secretase ligands (Yan et al., 2004). Removal of the olfactory bulb from normal 
rats has been accepted as a model for agitated depression (reviewed in Kelly et al., 
1997; Harkin et al., 2003). These so-called OBX rats show a number of behavioural 
changes, such as hyperactivity in an open field test, increased open arm entries in the 
elevated plus-maze, impairment in passive-avoidance learning as well as impaired 
acquisition in aversive learning, which can be reversed by chronic treatment with 
antidepressant drugs. Furthermore, OBX rats display alterations in the functioning of 
the HPA-axis, the immune system, thymus and spleen weight, and self-administration 
of drugs. Intriguingly, all of these phenotypic features are also observed in APO-
SUS rats (Ellenbroek and Cools, 2002; Coolen et al., 2005). Of further interest is 
that human neurological disorders, such as Alzheimer’s disease and schizophrenia, 
are characterised by olfactory dysfunction (reviewed in Hawkes, 2003; Moberg 
and Turetsky, 2003). Still, at present it is not clear to what extent the differences in 
γ-secretase cleavage activity found in tissues other than the olfactory bulb, such as 
the cortex, spinal cord and lung, have also contributed to the complex phenotype of 
the APO-SUS rats. 
In conclusion, the differential expression of Aph-1b in the I/I and III/III rats caused 
substrate-specific alterations in γ-secretase cleavage activity, particularly in tissues 
with relatively high Aph-1b levels. We conclude from our studies on a natural Aph-
1b knock-down in the rat that a subtle imbalance in the expression of a γ-secretase 
component gives rise to subtle changes in the proteolytic processing of a number 
of γ-secretase substrates that occur in multiple tissues (Figure 4). Thus, a single 
gene defect may affect a great variety of (neuro)developmental signalling pathways, 
resulting in a complex phenotype that is generally thought to have a multigenic 
origin. Furthermore, the γ-secretase complex, generally known because it is linked 
to Alzheimer’s disease (a neurodegenerative and ageing disorder), may also be 
associated with (neuro)developmental disorders that become apparent much earlier 
in life.
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Abstract    
A combination of genetic variations, epimutations and environmental factors may be 
involved in the etiology of complex neurodevelopmental disorders like schizophrenia. 
To study such disorders, we use apomorphine-unsusceptible (APO-UNSUS) Wistar 
rats and their phenotypic counterpart apomorphine-susceptible (APO-SUS) rats that 
display a complex phenotype remarkably similar to that of schizophrenic patients. 
As the molecular basis of the APO-SUS/UNSUS rat model, we recently identified 
a genomic rearrangement of the Aph-1b gene. Here, we discovered between the 
two rat lines differences other than the Aph-1b gene defect, including a remarkable 
cluster of genetic variations, two variants corresponding to topoisomerase II-
based recombination hot spots and an epigenetic (DNA methylation) difference in 
cerebellum and (hypo)thalamic but not hippocampal genomic DNA. Furthermore, 
genetic variations were found to correlate with the degree of apomorphine 
susceptibility in unselected Wistar rats. Together, the results show that a number 
of genetic and epigenetic differences exist between the APO-SUS and -UNSUS rat 
genomes, raising the possibility that in addition to the Aph-1b gene defect the newly 
identified variations may also contribute to the complex APO-SUS phenotype.
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Introduction   
Schizophrenia is a neurodevelopmental disorder affecting nearly 1% of the world’s 
population (Jablensky et al., 1987), and is characterized by positive and negative 
symptoms (Kay and Opler, 1987). The aetiology of schizophrenia and other related 
disorders, such as schizoaffective and bipolar disorder, is still unclear. Twin, family 
and adoption studies have suggested that complex interactions at the genetic and 
environmental level underlie the aetiology of schizophrenia (Gottesman, 1991). It 
is thought that gene variations by themselves do not result in schizophrenia, but 
they can establish a predisposition status that, when combined with environmental 
stressors, may lead to schizophrenia pathogenesis. Numerous environmental factors, 
such as viral infections (Mednick et al., 1988), insufficient folate and methionine 
levels (Regland, 2005), or repeated psychological stress (Goldstein, 1987), can 
influence brain development of prenatal or early postnatal individuals with a genetic 
predisposition for neuropsychiatric disorders. Due to the heterogeneity in genetic 
and environmental interactions, most of the genes and pathways for schizophrenia 
and for other complex disorders are still unknown. 
To get insight into the gene (or genes) that may be involved in schizophrenia 
pathogenesis, a rat model was developed with schizophrenia-like features. This 
model was based on the behavioural response of Wistar rats to the dopamine agonist 
apomorphine (Cools et al., 1990). The apomorphine-susceptible (APO-SUS) rat 
line displayed many features of psychopathology, with similar disturbances at the 
behavioural, physiological, endocrinological and pharmacological level as seen in 
schizophrenics (Ellenbroek and Cools, 2002). For example, APO-SUS rats have a 
reduced prepulse inhibition and latent inhibition (Ellenbroek et al., 1995), display a 
higher plasma release of adrenocorticotropin (ACTH) and corticosteroids in response 
to novelty (Rots et al., 1995), are more sensitive to dopamimetic drugs (Ellenbroek 
et al., 2000), and have a higher susceptibility to inflammatory and infectious diseases 
when compared to apomorphine-unsusceptible (APO-UNSUS) rats (Kavelaars et al., 
1997). We therefore wondered about the molecular-genetic basis underlying the APO-
SUS/-UNSUS rat model and recently identified a genetic difference between the two 
rat lines (Coolen et al., 2005). Whereas APO-UNSUS rats harbour three gene copies 
of the γ-secretase component Aph-1b, APO-SUS rats have only one or two copies. 
This gene-dosage imbalance was due to an unequal crossing over event (nonallelic 
homologous recombination) between two direct repeats (a segmental duplication) 
within the Aph-1b locus. In addition, we observed a direct link between the Aph-
1b genotypes and a number of phenotypic APO-SUS and –UNSUS characteristics 
(Coolen et al., 2005). Approximately 10 years after developing the APO-SUS and 
–UNSUS lines a second, independent breeding procedure was started that resulted in 
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rats with features similar to those displayed by the original APO-SUS and -UNSUS 
rat lines (Ellenbroek and Cools, 2002). Interestingly, the replicated rat lines also 
resulted in APO-UNSUS rats with three Aph-1b gene copy numbers and APO-SUS 
rats with only one or two gene copies (Coolen et al., 2005). 
In the present study, we wondered whether genetic variations other than the Aph-
1b gene-dosage imbalance may be present between the APO-SUS and -UNSUS 
rats, and whether epigenetic factors may be involved as well. Epigenetics has been 
defined as heritable changes in gene expression that do not occur by changes in the 
DNA sequence, but by modifications in DNA methylation and chromatin remodeling 
(Wolffe and Matzke, 1999), or, in its widest sense, as any change in an organism that 
is not due to genetic factors (Van de Vijver et al., 2002). Increasing evidence suggests 
that epigenetic modifications play a role in disease susceptibility (reviewed by Jirtle 
and Skinner, 2007). We used the arbitrarily primed-polymerase chain reaction 
(AP-PCR) fingerprinting technique (Welsh and McClelland, 1990) to analyse the 
genomes and epigenomes (DNA methylation) of the APO-SUS and –UNSUS rats. 
Comparison of the AP-PCR fingerprints generated from the genomic DNAs of the 
two rat lines revealed genetic as well as epigenetic alterations and we conclude that, 
besides in the Aph-1b locus, a number of other variations are present in the APO-
SUS and –UNSUS genomes and epigenomes.
Materials and Methods  
Experimental animals
The generation of the APO-SUS and -UNSUS rat lines with a high or low susceptibility 
for apomorphine, respectively, has been described previously (Cools et al., 1990). 
The present experiments were performed with male APO-SUS and –UNSUS rats 
belonging to the 32nd (original lines) and 18th (replicate lines) generation. At post-natal 
day 60 (PND60), APO-SUS and -UNSUS rats were sacrificed and the hippocampus, 
cerebellum and the combined thalamus/hypothalamus (further denoted as (hypo)
thalamus) were isolated. To establish their apomorphine susceptibility, unselected 
male Wistar rats of the Nijmegen outbred population (PND60) were injected with 
apomorphine (1.5 mg/kg s.c.) and gnawing scores were measured in a gnawing box 
for 45 minutes, as described previously (Cools et al., 1990). Immediately following 
the measurements, the rats were sacrificed and the same tissues (hippocampus, 
cerebellum and (hypo)thalamus) were removed. All rats were bred and reared in 
the Central Animal Facility of the Radboud University Nijmegen under approved 
animal protocols and in accordance with institutional guidelines.
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Arbitrarily primed-PCR
Genomic DNAs were isolated from hippocampus, cerebellum and (hypo)thalamus 
using standard procedures involving the use of proteinase K and phenol extraction. 
Two micrograms of genomic DNA were digested with 20 units of RsaI, 20 units 
RsaI in combination with the methylation-sensitive enzyme HpaII, or 20 units 
RsaI and MspI (MBI Fermentas) in a total volume of 40 µl at 37°C for 16h. HpaII 
does not cut DNA if the internal cytosine (CCGG) is methylated, whereas MspI is 
insensitive to DNA methylation. Using such combinations of methylation-sensitive 
and -insensitive enzymes allows genome-wide screening for differences at the 
genetic level (single-nucleotide polymorphisms – SNPs, duplications, insertions, 
deletions and recombinations) as well as the epigenetic (DNA methylation) level. 
Restriction enzymes were heat inactivated by incubating the reactions at 65°C 
for 20 min. Digested DNA (100 ng) was amplified using AP-PCR (Welsh and 
McClelland, 1990) with a single primer. PCRs were performed in a total volume 
of 25 µl containing 10 mM Tris-HCl (pH 8.3), 2.5 mM MgCl
2
, 50 mM KCl, 
0.001% gelatin, 0.25% Nonidet P-40, 0.25% Tween-20, 200 µM each of the four 
deoxynucleotide triphosphates, ~1 µCi of [α-32P]dCTP (3000 Ci/mmol, Amersham 
Corp.), 25 pmol of primer (AP-1: 5’-AACCCTCACCCTAACCCCGG-3’, 
AP-7: 5’-AACCCTCACCCTAAGGCGCG-3’, AP-777: 5’-CACTCCTCTAC-
AAGGTGCCG-3’ or Topo: 5’-GCCTCCTTGCAGGTCTTT-3’), and 0.8 units of 
Taq polymerase (MBI Fermentas). Reactions were carried out in a thermal cycler 
(PerkinElmer) with five cycles of low stringency (94°C for 30 sec, 40°C for 60 sec, 
72°C for 1.5 min), followed by 30 cycles of high stringency (94°C for 15 sec, 55°C 
for 15 sec, 72°C for 1 min). Two microliters of the PCR products were analysed 
on high-resolution 5% polyacrylamide gels under denaturing conditions (7 M urea) 
for 4-4.5 h at 70 W. Gels were dried and radiolabelled DNA was visualized by 
autoradiography at -70°C (CEA AB, Sweden). 
Cloning and sequencing of AP-PCR fragments
AP-PCR fragments generated from APO-SUS and –UNSUS rat genomic DNAs 
were excised from the dried gels and incubated in 50 µl MilliQ at 80°C for 10 min. 
The eluted DNA (two microliters) was reamplified with the same primer as used for 
the AP-PCR to generate sufficient amounts of template for subsequent cloning. The 
reactions were carried out for 40 cycles of 94°C for 1 min, 55°C for 30 sec, 72°C 
for 1 min, under the same conditions as described in the AP-PCR protocol (except 
that [α-32P]dCTP was not included). The PCR products were purified, cloned into the 
pGEM-T easy vector (Promega) and sequenced with a T7 or Sp6 primer according to 
the manufacturer’s instructions using the ABI310 machine (Applied Biosystems).
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Sequencing and genotyping of chromosomal region 9q22 
A 1948-bp fragment that harbours the nucleotide sequence corresponding to product 3 
was obtained by PCR on genomic DNA derived from (hypo)thalamic tissue of an APO-
UNSUS rat using forward primer 5’-GGGAAGCAACGCATCCTG-3’ and reverse 
primer 5’-CATATCAAAGCACCAAGTCCACAG-3’. The DNA was subsequently 
purified and directly sequenced using the ABI310 machine (Applied Biosystems). 
Genotyping of chromosomal region 9q22 was performed with PCR using primers 
specific for either the APO-SUS or APO-UNSUS genomic sequence. Briefly, PCRs 
were performed in a total volume of 20 µl containing 50 ng genomic DNA, 10 mM 
Tris-HCl (pH 8.3), 2.5 mM MgCl
2
, 50 mM KCl, 0.001% gelatin, 0.25% Nonidet 
P-40, 0.25% Tween-20, 200 µM each of the four deoxynucleotide triphosphates, 
0.6 µM of each primer (FW: 5’- AACACTTGGACTCATTCTCACTGG-[G (SUS) 
or T (UNSUS)]-3 ’ and RV: 5’- CCTGGATGGAATGTTGACAC-[C (SUS) or T 
(UNSUS)]-3’), and 0.8 units of Taq polymerase (MBI Fermentas). Reactions were 
carried out at 94°C for 60 sec, 58°C for 60 sec and 72°C for 60 sec for 35 cycles. 
Products were analysed on a 1% agarose gel. 
Quantification and statistics
Quantification of AP-PCR products was performed using the Labworks 4.0 program 
(UVP BioImaging Systems, Cambridge, UK) and statistical evaluation was performed 
by means of an unpaired Student’s t-test.
Results   
AP-PCR DNA fingerprint patterns of the APO-SUS and APO-UNSUS rat genomes 
and epigenomes
In order to identify differences between the genomes and epigenomes of APO-SUS 
and -UNSUS rats, we performed a comparative analysis of fingerprints of AP-PCR 
products generated from genomic DNAs of the two rat lines. Initially, genomic 
DNAs isolated from APO-SUS and APO-UNSUS (hypo)thalamic tissue and digested 
with RsaI in combination with the methylation-sensitive restriction enzyme HpaII 
(CCGG) was analysed using arbitrary primers AP-1, AP-7 or AP-777. These primers 
were selected from a total set of ten primers because they gave fingerprints with 
reproducible and discrete products (data not shown). Typical AP-PCR fingerprints 
obtained with the three selected arbitrary primers are shown in figure 1. With each 
arbitrary primer ~30 chromosomal fragments were reproducibly amplified. DNAs 
digested with RsaI and the methylation-insensitive enzyme MspI served as controls 
to determine whether the observed differences were due to a differential methylation 
of the CCGG sequence or a genetic polymorphism in this sequence. AP-PCR analysis 
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with primer AP-1 revealed 16 products corresponding to fragments without an HpaII 
site (“genetic fragments”) and 23 products corresponding to fragments containing 
an HpaII site (“epigenetic fragments”). Analysis with AP-PCR primer AP-7 showed 
17 genetic and 11 epigenetic fragments, and with AP-777 primer 22 genetic and 6 
epigenetic fragments.
Figure 1. AP-PCR analysis of genomic DNAs from APO-UNSUS (U) and APO-SUS (S) (hypo)thalamus. 
AP-PCR was performed with primers AP-1, AP-7 and AP-777 using genomic DNAs digested with RsaI 
and HpaII (H) or RsaI and MspI (M) as templates. Epigenetic products (methylation-sensitive and thus 
absent in the MspI lanes) are indicated by closed arrows and genetic products (methylation-insensitive 
and thus present in the MspI lanes) by open arrows. 
108
Genetic and epigenetic variations
Genetic variations between the APO-SUS and APO-UNSUS rat genomes  
Comparison of the genetic fingerprints generated with primers AP-1, -7 and -777 
revealed three reproducible variations between the genomic DNAs from the original 
(F32) APO-SUS and –UNSUS rats, designated products 1, 2 and 3 (figure 2a). Product 
1 was less prominent in the APO-SUS than in the APO-UNSUS rats, product 2 was 
found only in APO-SUS, while the level of product 3 was higher in the APO-SUS 
than -UNSUS rats. Interestingly, the three products were also present in the replicate 
(F18) lines and at the same levels, indicating that the replication of the APO-SUS 
and -UNSUS lines had resulted in a similar genotypic distribution. Next, digestions 
using RsaI in combination with MspI were used to examine whether the observed 
differences were due to a genetic or an epigenetic alteration. Following digestion 
with RsaI and MspI, products 1, 2 and 3 were still found, indicating that the presence 
of the three AP-PCR products was due to genetic differences (figure 2b). 
We previously discovered that the Aph-1b gene-dosage imbalance between the APO-
SUS and –UNSUS rats is the result of a DNA recombination event between the two 
Aph-1b genes. Furthermore, we identified the region in which the recombination 
occurred, namely in a region of 1106 nucleotides that is identical between the 
two genes and encompasses exon 5 (Coolen et al., 2005). In the present study, we 
decided to examine in detail the site of recombination and found a topoisomerase II 
binding site (5’-ACCCACCTGCTGGTGTCC-3’) in the DNA region harbouring the 
recombination site. Topoisomerase II binding sites (with the vertebrate consensus 
sequence 5’-RNYNNCNNGYNGKTNYNY-3’) (Spitzner and Muller, 1988) are 
known to be hotspots where DNA recombination events occur easily (Craig and 
Nash, 1983). We therefore wondered whether other topoisomerase II binding sites 
could have led to additional differences between the APO-SUS and –UNSUS rat 
genomes. Interestingly, using a primer based on the topoisomerase II binding site 
consensus for PCR analysis of genomic DNAs digested with EcoRI or MboI revealed 
two differences between the APO-SUS (n=3) and –UNSUS (n=2) rat genomes of the 
original (F32) lines, designated products 4 and 5 (figure 2c). Product 4 was present 
in APO-SUS but not in APO-UNSUS rat genomic DNA. In the replicate –SUS and 
-UNSUS lines (F18), the genomes of two APO-UNSUS rats did also not contain 
product 4, whereas it was present in two of the four APO-SUS rats tested. Product 5 
was present in three of the four APO-UNSUS rats examined (in both the original and 
the replicate lines), whereas it was not observed in the seven APO-SUS rats tested 
(figure 2c). 
Epigenetic variations between the APO-SUS and APO-UNSUS rat genomes  
We then wondered whether, besides the five genetic variations, also epigenetic 
variations would be present between the APO-SUS and –UNSUS rat lines. AP-PCR 
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analysis using primer AP-1 on RsaI- and HpaII-digested genomic DNAs from APO-
SUS and –UNSUS (hypo)thalamus revealed one epigenetic variation, designated the 
E1-product (figure 3a). The difference was observed in both the original APO-SUS 
and -UNSUS rats as well as the replicated lines. An ~1.4-fold reduced amount of the 
E1-product was observed in APO-SUS when compared with APO-UNSUS genomic 
DNAs (n=12, p<0.05). Since DNA methylation may be tissue specific, we decided to 
examine the E1-product in two other brain tissues. The level of the E1-product was 
~2-fold reduced in genomic DNAs from the cerebellum of APO-SUS compared to 
APO-UNSUS rats (n=4, p<0.01), while no difference in the E1-levels was found in 
the hippocampus of the APO-SUS and -UNSUS rats (n=4). 
Figure 2. Genetic variations in genomic DNAs from APO-SUS (S) and APO-UNSUS (U) (hypo)thalamus. 
Rats were from the original (F32) or the replicate (F18) rat lines. (A) Products generated by AP-PCR 
using primers AP-1 (product 1), AP-7 (product 2) or AP-777 (product 3) on genomic DNAs digested 
with the methylation-insensitive enzyme RsaI and the methylation-sensitive enzyme HpaII. ND = not 
determined. (B) Products 1, 2 and 3 generated by AP-PCR on genomic DNAs digested with RsaI and 
HpaII (H) or with the two methylation-insensitive enzymes RsaI and MspI (M). MspI products served as 
controls to determine whether products 1, 2 and 3 were due to differential methylation or to a genetic 
polymorphism. The fact that products 1, 2 and 3 were still present following MspI digestion indicates 
that they represent products without an HpaII site (“genetic fragments”). (C) Products generated by AP-
PCR using a topoisomerase II binding site consensus sequence (5’-GCCTCCTTGCAGGTCTTT-3’) on 
genomic DNAs digested with the methylation-insensitive enzymes EcoRI (product 4) or MboI (product 
5). Arrows indicate increased amounts of the AP-PCR products. 
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Chromosomal localizations of the genetic and epigenetic variations between the 
APO-SUS and –UNSUS rat genomes
To identify the locations of the genetic and epigenetic variations within the APO-
SUS and -UNSUS rat genomes, AP-PCR fragments 1, 2, 3 and E1 were excised 
from the gel and each fragment was reamplified with the primer used for the original 
AP-PCR reaction. DNA sequence analysis of the amplified PCR fragments and 
database searches with the obtained nucleotide sequences revealed the chromosomal 
localisations of the four fragments; product 1 was located on chromosome 19q11, 
~3.3 kb upstream of the first exon of the GAIP-interacting protein, C terminus (GIPC) 
gene; product 2 was part of a repeat sequence located on chromosome 2q34; product 
3 was located in the first intron of the myosin 1b gene on chromosome 9q22; the 
epigenetic variation E1 was located on chromosome 6q31, downstream of the Jun 
dimerization protein 2 (NP_446346.1) and upstream of the ATF-like basic leucine 
Figure 3.  Epigenetic variation in genomic DNAs from APO-SUS (S) and APO-UNSUS (U) (hypo)
thalamus. Rats were from the original (F32) or the replicate (F18) rat lines. (A) Product E1 generated 
by AP-PCR using primer AP-1 on genomic DNAs digested with RsaI and HpaII. Arrow indicates a 
representative example of an AP-PCR product that did not show variable amounts using primer AP-1 
(randomly chosen out of 38 products) and was used for normalization. (B) The AP-PCR E1-product 
generated from genomic DNAs from cerebellum, hippocampus and (hypo)thalamus. All rats were from 
different nests. The products indicated by the arrow were used for normalisation. Amounts for the 
epigenetic E1-product were significantly different between the APO-SUS and APO-UNSUS rats in the 
cerebellum (** p < 0.01; n=4, plus s.e.m.) and (hypo)thalamus  (* p < 0.05; n=12, plus s.e.m.), but not 
in the hippocampus (n=4, plus s.e.m.). 
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zipper transcriptional factor B-ATF (SF-HT-activated gene 2; XP_216745.2). Since 
product 3 was localized within a gene, we decided to analyse this chromosomal 
region in more detail. Sequence analysis of the DNA region corresponding to AP-PCR 
fragment 3 and its surrounding region revealed a remarkably high number of genetic 
variations: 10 of the 1948 base pairs analysed were different between the APO-SUS 
and –UNSUS genomes (figure 4). Comparison of the nucleotide sequences of the 
APO-SUS and –UNSUS DNA regions with the corresponding database sequence 
(geneID: 117057) revealed a 100% identity between the database and the APO-
UNSUS sequences, indicating that the APO-SUS genome has diverged from the 
database sequence. Next, more APO-SUS and -UNSUS rats were genotyped for this 
region. All APO-UNSUS rats tested (n=5) indeed showed the database sequence, 
whereas the APO-SUS rats tested (n=5) all contained the relatively high number of 
variations in this chromosomal region. 
The newly identified genetic and epigenetic variations, and apomorphine 
susceptibility in Wistar rats
We wondered whether the molecular-genetic difference between the APO-SUS 
and –UNSUS rats (the Aph-1b gene-dosage imbalance) would also be present in 
the Nijmegen outbred population of Wistar rats, or if the imbalance was generated 
during the breeding of the rat lines. PCR analysis of the Aph-1b locus in the 50 
Figure 4. Nucleotide sequence of chromosomal region 9q22, corresponding to product 3, in APO-SUS 
and APO-UNSUS rats. APO-SUS/-UNSUS genomic variations are indicated between brackets; the 
first nucleotide represents the APO-UNSUS sequence, the second nucleotide the APO-SUS sequence. 
The nucleotide sequences corresponding to the annealing sites of arbitrary primer AP-777 are 
underlined. 
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Wistar rats examined revealed in all cases the presence of three copies of the Aph-1b 
gene, suggesting that the reduction of Aph-1b copies in the APO-SUS rats had been 
induced during the breeding of the rats. 
We next wondered whether the newly identified genetic and epigenetic variations in 
the APO-SUS and -UNSUS genomes were also induced during the breeding of the 
two rat lines, or if these variants are already present in Wistar rats. For this purpose, 
we performed AP-PCR analysis of (hypo)thalamic genomic DNAs from Wistar rats 
using primers AP-1, -7 and –777. The fingerprints revealed the presence of the APO-
SUS as well as the APO-UNSUS variants of the genetic products 1, 2 and 3 (n=8) 
and the epigenetic E1-product (n=4) in Wistar rats (figure 5), indicating that the 
newly identified variations were not induced during breeding of the APO-SUS and 
-UNSUS lines, but were already present in the original Wistar population. 
To study whether the presence or absence of the genetic AP-PCR products observed in 
the APO-SUS and –UNSUS rats (products 1, 2 and 3) was linked to the apomorphine 
susceptibility of Wistar rats, we examined a group of five rats with low susceptibility 
to apomorphine (<10 gnaws per 45 min) and a highly susceptible group of three rats 
(>500 gnaws per 45 min). Product 1, which was less abundant in APO-SUS than 
-UNSUS rats, was not present in the three Wistar rats with high gnawing scores, but 
was also not found in two of the five Wistar rats with low gnawing scores. Of the eight 
rats examined, the APO-SUS-specific product 2 was found in two Wistar rats with 
a high and only one rat with a low degree of apomorphine susceptibility. The DNA 
region corresponding to product 3 was found twice as the APO-UNSUS sequence in 
the group consisting of the low-apomorphine-susceptible Wistar rats and once in the 
group of the high-apomorphine-susceptible rats (figure 5a). These results indicate 
that none of the three products was directly linked to the apomorphine susceptibility 
of the Wistar rats. However, apomorphine susceptibility may not be the result of only 
a single genetic variation, but rather of multiple genetic and epigenetic alterations. 
Interestingly, 67% of the three genetic products present in the Wistar rats with low 
apomorphine susceptibility were also found in the APO-UNSUS genome, and 78% 
of the three products in Wistar rats with high apomorphine susceptibility were APO-
SUS-specific variants (figure 5a), indicating that a combination of the three genetic 
products may well be linked to apomorphine susceptibility. To study the link between 
the epigenetic E1-product and apomorphine susceptibility, two Wistar rats with low 
gnawing scores and two with high gnawing scores were examined for the amount 
of the E1-product in the cerebellum. Similar amounts of the E1-product as detected 
in APO-UNSUS rats were found in one Wistar rat with a low and in one Wistar rat 
with a high gnawing score. The amount of the E1-product detected in APO-SUS rats 
was found in one Wistar rat with low and in one Wistar rat with high apomorphine 
susceptibility, indicating that no direct link exists between the E1-product and 
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apomorphine susceptibility. As observed in the APO-SUS and –UNSUS rats, no 
variation was detected in the level of the E1-product in hippocampal genomic DNAs 
from the four Wistar rats tested (figure 5b).
Discussion   
In this study, we investigated the genetic and epigenetic background of the 
phenotypically well-characterized APO-SUS and APO-UNSUS rats. Unravelling the 
Figure 5. AP-PCR analysis (products 1, 2 and E1) and specific PCR (product 3) analysis of genomic DNAs 
from Wistar rats with low or high apomorphine susceptibility. (A) The presence or absence of products 1, 
2 and 3 (genetic differences) was analysed in genomic DNAs from the (hypo)thalamus of Wistar rats with 
low (<10 gnaws in 45 min) or high (>500 gnaws in 45 min) apomorphine susceptibility. U: APO-UNSUS, 
S: APO-SUS. Lower panel: the amounts of the three products present in the Wistar rats were compared 
with the amounts found in the APO-SUS and –UNSUS rats. : the genotype of the genetic products 1, 2 
or 3 in the Wistar rats with low apomorphine susceptibility is similar to the products 1, 2 and 3 genotype 
of the APO-UNSUS rats; : the genotype in the Wistar rats with low apomorphine susceptibility 
deviates from the APO-UNSUS genotype; : the genotype in the Wistar rats with high apomorphine 
susceptibility is comparable with the genotype in the APO-SUS rat; : the genotype in the Wistar rats 
with high apomorphine susceptibility deviates from the genotype in the APO-SUS rats. (B) AP-PCR 
analysis of the epigenetic E1-product (E1) on genomic DNAs from cerebellum and hippocampus of four 
Wistar rats. The product indicated by the arrow is an example of a product that did not show variable 
amounts and was used for normalisation of the E1-product. The amounts of the E1-products generated 
from the cerebellum or hippocampus were not different between the two Wistar rats with low gnawing 
scores (<10 gnaws in 45 min) and the two Wistar rats with high gnawing scores (>500 gnaws in 45 min).
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molecular basis of this rat model may help in our understanding of complex human 
neurodevelopmental disorders, since many of the characteristics of the APO-SUS rat 
line are also observed in schizophrenic patients (Ellenbroek and Cools, 2002). We 
recently identified a gene-dosage imbalance in the Aph-1b locus of the APO-SUS 
and –UNSUS rats, leading to a reduced expression of the Aph-1b gene in APO-SUS 
rats and a segregation with a number of behavioural parameters (Coolen et al., 2005). 
Here, we used AP-PCR analysis as an approach to explore the presence of any other 
alterations in the two genomes and epigenomes. We indeed identified additional 
genetic and epigenetic variations, indicating that the Aph-1b locus might not be 
solely responsible for the observed phenotypes of the two rat lines and suggesting a 
multi-genetic and -epigenetic origin of the differences observed between the APO-
SUS and –UNSUS rats. Importantly, we found similar AP-PCR patterns in both the 
original and replicate APO-SUS and –UNSUS lines. It is therefore highly unlikely 
that the observed variations between the APO-SUS and -UNSUS rat genomes were 
simply due to coincidence. 
Detailed analysis of one of the newly identified genetic alterations (in the DNA region 
corresponding to product 3) revealed in APO-SUS rats a cluster of variations in the 
myosin 1b gene. Hence, this cluster appears to be a hotspot for genetic instability. 
Product 1 was located upstream of the GIPC gene encoding a protein interacting 
with membrane-associated and transmembrane proteins, including the dopamine 
receptors D2 and D3 (Jeanneteau et al., 2004). The genetic variation in this locus 
may therefore contribute to the differences in apomorphine susceptibility between 
the APO-SUS and -UNSUS rat lines. We also identified genetic alterations using a 
primer corresponding to a topoisomerase II binding site consensus. The rationale 
for this study was based on our present finding that a topoisomerase II binding site 
was located at the recombination site in the Aph-1b locus. The two newly identified, 
topoisomerase II-based genetic variations might point to a more general role for 
topoisomerase II binding sites in psychopathological mechanisms. We hypothesize 
that at these sites environmental factors, such as stress during early development, 
may cause an increase in the incidence of recombination and other mutagenic events, 
leading to brain dysfunction and affected behavior. Besides the genetic differences, 
one tissue-specific epigenetic variation was found between the APO-SUS and 
–UNSUS epigenomes. At present it is not clear what, if any, functional consequence 
should be attributed to the decrease in the methylation status of this CpG in the 
(hypo)thalamus and cerebellum, but not in the hippocampus, of APO-SUS relative 
to APO-UNSUS rats. 
Earlier microarray analysis of mRNA expression in the hippocampus of the APO-
SUS and -UNSUS rats (~7000 full-length sequences and ~1000 EST clusters) 
revealed that only Aph-1b was differentially expressed (Coolen et al., 2005). The 
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newly identified variations open the possibility that for an explanation of the 
background of the rat model one has to consider more genes that operate together in 
a multi-genetic and -epigenetic setting with several susceptibility loci. Thus, based 
on our present findings, more than one locus may be responsible for the complex 
phenotype of APO-SUS rats. Recently, it has been established that the contribution 
of genetic modifiers is also of importance for the outcome of a phenotype, since 
they can modulate the severity of the affected phenotype and the phenotypic 
characteristics without having a clear effect on the normal situation (Nadeau, 2001; 
Nadeau and Topol, 2006). Hence, as part of the genetic and epigenetic background 
of the APO-SUS and -UNSUS rat lines, our newly identified variants can be genetic 
and epigenetic modifiers influencing the phenotypic expression of the model. Insight 
into the genetic and epigenetic background may provide diagnostic tools, and clues 
for mechanisms and pathways to explain complex disorders.
Besides the multiple variations in the APO-SUS and –UNSUS rat genomes and 
epigenomes, Aph-1b will presumably be a major player in the development of the 
complex APO-SUS phenotype, since it has a broad cellular effect via tissue-specific 
cleavage of many different substrates (Coolen et al., 2006b) and is functional already 
during early development (Coolen et al., 2006a). Remarkably, however, the number 
of Aph-1b gene copies was not linked to apomorphine susceptibility in Wistar rats. 
Whereas their apomorphine susceptibility varied, all unselected Wistar rats tested 
harboured three copies of the Aph-1b gene. Therefore, genetic and epigenetic factors 
other than Aph-1b will likely contribute to the susceptibility for apomorphine. We 
now indeed found a correlation between the newly identified genetic variations and 
the apomorphine susceptibility in the Wistar population, confirming our hypothesis 
that apomorphine susceptibility is caused by a number of genetic and epigenetic 
factors. A combination of the newly identified variations may have thus initially 
contributed to the degree of apomorphine susceptibility in the original Wistar rat 
population. Subsequent apomorphine injections to determine the susceptibility for 
the drug during the breeding of the APO-SUS and –UNSUS lines may have acted 
as an environmental stressor, triggering the Aph-1b recombination event at the 
topoisomerase II binding site only in rats with a high susceptibility for apomorphine. 
The induced gene-dosage imbalance of the Aph-1b gene, probably in combination 
with other genetic or epigenetic factors, could then have led to the complex phenotype 
observed in the APO-SUS rats.    
In conclusion, the present findings suggest that psychopathological disturbances may 
be the result of multiple genetic as well as epigenetic factors. We infer that our newly 
identified variations are susceptibility loci for schizophrenia-like features in the rat 
and may give new insights into the genetic and epigenetic background of complex 
neurodevelopmental disorders. 
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Abstract
Complex phenotypes are thought to have a multifactorial origin with multiple 
genetic variations that act in concert with environmental factors. Besides single-
nucleotide polymorphisms and mutations, copy number variations (CNVs) may play 
a substantial role in the pathogenesis of complex disorders. Here, we performed 
comparative genomic hybridization (CGH) to explore genome-wide CNVs in Wistar 
rats with a high susceptibility for the dopamine receptor agonist apomorphine (the 
so-called APO-SUS rats) and in their phenotypic counterparts (the so-called APO-
UNSUS rats). APO-SUS rats show features as seen in patients with a complex 
aetiology and may thus be used to study (aspects of) complex disorder pathogenesis. 
Candidate genomic variations located in intragenic regions were validated and nine 
CNVs were found to segregate with both the original and the replicate APO-SUS/-
UNSUS rat lines. The findings suggest a contribution of these CNVs to the complex 
APO-SUS phenotype. 
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Introduction
Twin, family and adoption studies have suggested that complex interactions at the 
genetic and environmental level underlie the aetiology of complex disorders, such 
as schizophrenia and bipolar disorder (Gottesman, 1991). Due to these interactions 
and the expected subtle influence of susceptibility genes, the genes and pathways for 
most complex disorders are however still unknown (van Loo and Martens, 2007). 
One approach to identify susceptibility genes and pathways for complex disorders 
is through the use of an animal model. In this study, we used the so-called APO-
SUS/-UNSUS rat model, a model based on the differential response of the rats to 
the dopamine receptor agonist apomorphine (Cools et al., 1990). Apomorphine-
susceptible (APO-SUS) and apomorphine-unsusceptible (APO-UNSUS) rat lines 
have been generated twice with a time interval of a decade (original lines in 1985 
and replicate lines in 1995 (Cools et al., 1990; Ellenbroek et al., 2000)). Since the 
APO-SUS rats showed many features of psychopathology, with disturbances at the 
behavioural, physiological, endocrinological and pharmacological level similar to 
those seen in patients with a complex disorder (Ellenbroek and Cools, 2002), the 
APO-SUS/-UNSUS rat lines may represent an interesting model to study (aspects 
of) complex disorders. 
Copy number variations (CNVs) may play a considerable role in the pathogenesis 
of complex disorders (Lee and Lupski, 2006). Estimates suggest that ~12% of the 
human genome consists of CNVs, ranging from kilobases to megabases in size 
(Redon et al., 2006). In the present study, we searched for CNVs in the genomes of 
the original as well as the replicate APO-SUS and –UNSUS rat lines, and wondered 
whether they are functionally linked to the complex APO-SUS phenotype. Since 
many human CNVs have been found to overlap with CNV regions in the rat (Guryev 
et al., 2008), findings in the rat may well be of significance for the human situation. 
To identify CNVs in the APO-SUS and –UNSUS rat genomes, we here used 
comparative genomic hybridisation (CGH), a technology that allows a genome-wide 
screening for CNVs with a relatively high resolution.
Materials and Methods
Experimental animals
The generation of the APO-SUS and -UNSUS rat lines with a high and a low 
susceptibility for apomorphine, respectively, has been described previously (Cools 
et al., 1990; Ellenbroek et al., 2000). The present experiments were performed 
with male APO-SUS and –UNSUS rats belonging to the 41st (original lines) and 
26th (replicate lines) generation, and unselected male Wistar rats from the Nijmegen 
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outbred population. On post-natal day 60, the rats were injected with apomorphine 
(1.5 mg/kg s.c.) and gnawing scores were measured in a gnawing box for 45 minutes, 
as described previously (Cools et al., 1990). Following the measurements, the rats 
were sacrificed and the brains were isolated. All rats were bred and reared in the 
Central Animal Facility of the Radboud University (Nijmegen, The Netherlands) 
under approved animal protocols and in accordance with institutional guidelines.
CGH analysis
Genomic DNAs (gDNAs) from the replicate APO-SUS and –UNSUS rats were 
extracted from cortex tissue (DNeasy Blood and Tissue Kit, QIAGEN), randomly 
primed with Cyanine 3 or 5 and applied to the rat Agilent 244A arrays. Assays were 
performed in duplicate with dye swap. The arrays consisted of 235,000 probes (each 
~60 nucleotides long), providing a mean resolution of one probe every 6 kb. Intensity 
ratios from the duplicate scans were averaged and normalized ratios were analysed 
with Agilent CGH analytics software (v3.4) to identify significant CNVs.
Genomic PCR and genomic quantitative PCR analysis
CNVs identified with the CGH technology were validated using genomic 
quantitative PCR analysis (qPCR) or standard PCR analysis (with an internal control 
to test for PCR efficiency). PCR assays were developed based on sequences from 
the UCSC Genome Browser database (UCSC Rn4; assembly Nov2004) with the 
PCR products spanning the CGH probe region. PCRs were performed in a total 
volume of 20 µl containing 10 ng gDNA, 10 mM Tris-HCl (pH 8.3), 2.5 mM 
MgCl
2
, 50 mM KCl, 0.001% gelatin, 0.25% Nonidet P-40, 0.25% Tween-20, 250 
µM each of the four deoxynucleotide triphosphates, 1 U Taq polymerase and 0.3 
µM each of the four primers (one primer set specific for the chromosomal region 
in which the CNV was located (see Supplementary table for primer details) and a 
second primer set to test for PCR efficiency: 5’-CGTCTCCATCACGGGTTTG-3’ 
and 5’-AAGTTTTCCCAGGAGCAGTCAA-3’). Reactions were carried out at 
94°C for 60 sec, 60°C for 30 sec and 72°C for 45 sec for 35 cycles in a Peltier 
Thermal Cycler. Products were analysed on a 2% agarose gel. qPCR samples 
contained 10 ng gDNA, 1 x Power SYBR green PCR master mix (Applied 
Biosystems) and 0.3 µM of each primer (Biolegio; see Supplementary table for 
primer details) in a 10 µl volume. Reactions were carried out in a Rotor-Gene 
6000 apparatus (Corbett Life Sciences) under the following conditions: 10 min at 
95°C, then 40 cycles of 15 s at 95°C and 1 min at 60°C. Two genomic regions 
(complexin 1 on chromosome 14p22: 5’-AAGAGCAAACGTGGTGGGTAGA-3’ 
and 5’-GCCTGGGCCACTCTCTTCA-3’ and mineralocorticoid receptor on 
chromosome 19q11: 5’-GAAGTCTGCGTGGCGGG-3’ and 5’-AAAAGAGGGTT
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GTGAGGTCAATTTC-3’) were amplified from all samples and used to validate 
the differences in copy number between the rats. qPCR data were analyzed with the 
Rotor-Gene 6000 software (v1.7). 
Results
CNVs in the APO-SUS and –UNSUS rat genomes
To determine the number of CNVs in the APO-SUS/-UNSUS rat genomes and 
to identify their corresponding genomic regions, high resolution oligonucleotide 
CGH analysis on gDNAs from the replicate APO-SUS and –UNSUS rat lines was 
performed. Initially, 367 CGH probes (~0.16% of the Agilent CGH probes) were 
identified that represented differences in copy number between the APO-SUS and 
–UNSUS gDNAs. 201 Probes showed an increase in copy number and 166 a decrease 
in the APO-SUS genome compared to the APO-UNSUS genome. The CNVs were not 
equally distributed over the chromosomes, i.e. most of the 367 probes were located 
on chromosomes 4 and 20 (43 and 53 probes, respectively), whereas no probes were 
found on chromosome 19, only two on chromosome 18, three on chromosome 9, and 
four on chromosomes 6 and 15 (figure 1). 
Figure 1. Chromosomal distributions of CNVs within the APO-SUS and -UNSUS rat genomes. (A) 
CNVs were not equally distributed over the 20 autosomal chromosomes (the X and Y chromosomes 
were not included in the CGH analysis); no CNV was found on chromosome 19 and only two were 
present on chromosome 18. The largest number of CNVs was found on chromosomes 4 and 20. (B) 
Intrachromosomal distributions of the CNVs. Per chromosome two bars are shown: The first bars 
represent a schematic overview of the chromosomes, with the light-colored bands representing 
euchromatin and the dark-colored bands representing heterochromatin regions. The second bars 
illustrate the locations of the APO-SUS/-UNSUS CNVs.
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In our attempt to identify CNVs with a functional relevance, we decided to focus 
mainly on CNVs located within a gene(s). To validate the intragenic candidate regions 
(132 probes covering 47 CNVs; table 1), PCR or qPCR analysis was performed with 
gDNAs from eight APO-SUS rats with high gnawing scores (>500 counts/45 min) 
and eight APO-UNSUS rats with low gnawing scores (<10 counts/45 min). This 
analysis revealed 25 regions that contained a CNV that segregated with the APO-
SUS/-UNSUS lines. Of these regions, 16 showed an increase in copy number and 
9 a decrease in the APO-SUS compared to the APO–UNSUS genomes (table 2). 
Interestingly, all APO-UNSUS rat genomes examined showed similar CNV patterns, 
with only four of the 25 CNVs displaying individual differences within the group (n 
= 8). In contrast, the APO-SUS rat genomes showed more variations in their patterns 
with nine CNVs exhibiting individual differences (n = 8) (table 2).
Sa Region Probe localisationb Gene
+ 1q12 48844408-48844467 afadin (Af6)
+ 1q21 81322251-81346296 cytochrome P-450b type e 
+ 1q21 81355452-81355509 cytochrome P450e-L (Cyp450IIB2)
+ 1q31 132513907-132513966 LRRGT00049 
+ 1q54 252177147-252177206 cyclin M2 (Cnnm2)
- 2q14 40418324-40418383 cAMP-specific phosphodiesterase PDE4D7 (Pde4d)
- 2q16 58321364-58321423 solute carrier family 1 (glial high affinity glutamate transpor-
ter), member 3 (Slc1a3)
- 2q16 58945286-58962650 prolactin receptor 
+ 3q12 34109106-34109165 rattus norvegicus cDNA sequence, complete 5' and 3' 
UTR's.
- 3q21 52825116-52825175 glutamic acid decarboxylase 1 (Gad1)
+ 3q24 62659492-62659551 phosphodiesterase 1A, calmodulin-dependent (Pde1a)
- 3q42 146565477-146586794 RNA-binding region (RNP1, RRM) containing 2 (Rnpc2)
- 4q42 156513753-156513812 Ninjurin 2 (Ninj2)
+ 4q42 167373472-167597397 LINE-1 retrotransposon nucleic acid binding protein mRNA
+ 4q42 167610209-167713739 Ly49 inhibitory receptor 9 (Ly49i9)
+ 4q42 167722626-167769236 LINE-1 retrotransposon nucleic acid binding protein mRNA
+ 5q21 40864501-40864560 fucosyltransferase 9 (Fut9)
+ 5q34 125542582-125542641 disabled homolog 1 (Drosophila) (Dab1)
+ 5q36 135556739-135571102 cytochrome P450, 4a12 (Cyp4a12)
- 5q36 135620211-135646248 cytochrome P450, subfamily 4A, polypeptide 11 (Cyp4a11)
+ 5q36 158440757-158440816 Ba1-651 mRNA
continued on next page 
Table 1. Intragenic CNVs found by APO-SUS and –UNSUS CGH analysis
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Since the APO-SUS and –UNSUS lines have been made twice via separate and 
independent selection and breeding procedures (original lines started in 1985 and 
replicate lines in 1995), similar representations of a particular CNV in the original 
and replicate APO-SUS and –UNSUS lines would point to a link between this CNV 
and the APO-SUS/-UNSUS phenotype. We therefore examined the original APO-
Sa Region Probe localisationb Gene
+ 7q35 133872643-133886266 nel-like 2 homolog (chicken) (Nell2)
+ 8q21 37240112-37240171 urinary protein 2 (Rup2)
- 8q24 71093969-71129268 anterior pharynx defective 1b homolog (C. elegans) 
(Aph1b)
+ 8q24 80216254-80216313 Mitogen-activated protein kinase 6 (Mapk6)
- 8q24 81962445-81974483 tubulointerstitial nephritis antigen (Tinag)
+ 8q31 90466184-90466243 LRRGT00008 mRNA
- 10q24 63190604-63206723 Rabphilin 3A-like (without C2 domains) (Rph3al)
+ 10q26 72239224-72239283 DEAD (Asp-Glu-Ala-Asp) box polypeptide 52 (Ddx52)
+ 10q32.2 105202914-105202973 CD300 antigen like family member F (Cd300lf)
- 10q32.3 107465582-107465641 septin 9 (Sept9), transcript variant 2
+ 10q32.3 109397560-109397619 brain-specific angiogenesis inhibitor 1-associated protein 
2 (Baiap2)
- 11q11 20602835-20602894 neural cell adhesion molecule 2 (Ncam2)
- 11q23 78379058-78415151 similar to LIM domain containing preferred translocation 
partner in lipoma (LOC288010)
- 11q23 84075431-84192014 clone LuMo47.3 immunoglobulin lambda light chain mRNA
- 13q21 66504082-66504141 niban protein (Niban)
+ 13q24 90017140-90017199 Spectrin alpha 1 (Spna1)
- 14p21 21949892-21965334 sulfotransferase, estrogen preferring (Ste)
+ 14p21 22155706-22170876 UDP glycosyltransferase 2 family, polypeptide B (Ugt2b)
- 17q12.1 72111961-72112005 GTP binding protein 4 (Gtpbp4)
+ 20p12 2783283-2796035 MHC class I RT1.Aw3 protein, haplotype l.
+ 20p12 3433631-3472185 clone:bC9, differentially expressed in pylorus.
+ 20p12 3497512-3497571 dimethylarginine dimethylaminohydrolase 2 (Ddah2)
+ 20p12 3499460-3612973 Chloride intracellular channel 1 (Clic1)
- 20p12 4700166-4700225 RT1 class II, locus Ba (RT1-Ba)
- 20p12 4733170-4733229 RT1 class II, locus Bb (RT1-Bb)
+ 20p12 5810464-5810523 nudix (nucleotide diphosphate linked moiety X)-type motif 
3 (Nudt3)
continued 
aS: CGH results of the APO-SUS (S) and -UNSUS (U) comparison. + : more copies in APO-SUS 
compared to -UNSUS, - : less copies in APO-SUS compared to -UNSUS. bProbe localisation is based 
on UCSC genome browser rat November 2004.
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SUS and –UNSUS genomes for the 25 CNVs found to be different in the replicate 
lines. Interestingly, nine of the CNVs (CNVs located in afadin6 [AF6 on chromosome 
1q12], cytochrome P-450b type e [Cyp450b type e; 1q21], cytochrome P450e-L 
[Cyp450IIB2; 1q21], cyclin M2 [Cnnm2; 1q54], disabled homolog 1 [Dab1; 5q34], 
anterior pharynx defective 1b [Aph-1b; 8q24], brain-specific angiogenesis inhibitor 
1-associated protein 2 [Baiap2; 10q32.3], neural cell adhesion molecule 2 [Ncam2; 
11q11] and GTP binding protein 4 [Gtpbp4; 17q12.1]) showed a similar distribution 
in the original and replicate lines (table 2). 
Intragenic CNVs in the APO-SUS/-UNSUS rat genomes and apomorphine 
susceptibility
Next, we wondered whether any of the nine SUS/-UNSUS CNVs that were similarly 
distributed among the original and replicate lines would correlate with apomorphine 
susceptibility, the criterion originally used to create the APO-SUS and –UNSUS rat 
lines. For this purpose, we decided to crossbreed rats from the replicate APO-SUS 
line with rats from the replicate APO-UNSUS line. Following intercrossing of the 
offspring, males from the resulting F
6
 generation were tested for their apomorphine 
susceptibility and eight rats with a low apomorphine susceptibility (<10 counts/45 
min) and eight rats with a high apomorphine susceptibility (>500 counts/45 min) 
were selected for CNV analysis. None of the nine CNVs showed a correlation with 
apomorphine susceptibility, indicating that none of the CNVs was solely responsible 
for the susceptibility to the drug (table 3). 
In addition, we analysed the nature of the nine SUS/-UNSUS CNVs in gDNAs from 
normal (unselected) Wistar rats from the Nijmegen outbred population. gDNAs from 
Gene L L L L L L L L H H H H H H H H U S
Af6 + + + + + + + + + + + + + + + + - +
Cyp450b type e + + - + - - - - + - - + - - - - - +
Cyp450IIB2 + + - + - - - - + - - + - - - - - +
Cnnm2 + + + + + + - + + + - + + - + + - +
Dab1 - + - + - + - - - + - - + - - - - +
Aph-1b - - - - + + + + - - - - + + + + + -
Baiap2 - + + - + + + + + + + + + - + + - +
Ncam2 + + + + + - + + + + + + + + + + + -
Gtpbp4 - - - - + + + + - - + + + + + + + -
Table 3. Intragenic CNVs in crossbred APO-SUS/-UNSUS rats with a low and high apomorphine 
susceptibility
L: APO-SUS/-UNSUS crossbred with a low apomorphine susceptibility; H: APO-SUS/-UNSUS 
crossbred with a high apomorphine susceptibility; U: APO-UNSUS; S: APO-SUS; +: relatively high 
PCR signal; -: relatively low PCR signal; ±: intermediate PCR signal. 
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eight Wistar rats with a low apomorphine susceptibility and from eight Wistar rats 
with a high apomorphine susceptibility were analysed. PCR and qPCR analyses of 
these 16 Wistar genomes revealed that again none of the nine CNVs was linked to 
apomorphine susceptibility (table 4). 
Gene L L L L L L L L H H H H H H H H U S
Af6 + - - - - + - + - - + + + + - - - +
Cyp450b type e + - - + + + - + - + - + + + + + - +
Cyp450IIB2 + + - + + + - + - + - + + + + + - +
Cnnm2 - - + + + - + + + - - + - + - + - +
Dab1 - - + - - + - + - - - - - - + - - +
Aph-1b + + + + + + + + + + + + + + + + + -
Baiap2 + + + + + - + + - + + + - + + + - +
Ncam2 + + + + + + + + + + + + + + + + + -
Gtpbp4 - + - + - - - - - - + - - - - + + -
Table 4. Intragenic CNVs in Wistar rats with a low and high apomorphine susceptibility
L: Wistar rat with a low apomorphine susceptibility; H: Wistar rat with a high apomorphine 
susceptibility; U: APO-UNSUS; S: APO-SUS; +: relatively high PCR signal; -: relatively low PCR 
signal; ±: intermediate PCR signal. 
Discussion
In this study, we identified 25 CNVs that segregated with the phenotypically well-
characterized replicate APO-SUS and –UNSUS rat lines. Interestingly, nine of the 
25 CNVs were found in a similar distribution in both the original and replicate APO-
SUS and –UNSUS lines, indicating that these CNVs may well be functionally linked 
to aspects of the complex APO-SUS phenotype. One of the CNVs, namely the CNV 
located within the Aph-1b locus, has been described previously as a gene-dosage 
imbalance correlating with (aspects of) the complex APO-SUS phenotype. Whereas 
APO-UNSUS rats harbour three gene copies of the g-secretase component Aph-1b, 
APO-SUS rats have only one or two copies. This gene-dosage imbalance was due 
to an unequal crossing over event (nonallelic homologous recombination) between 
two direct repeats (a segmental duplication) within the Aph-1b locus (Coolen et al., 
2005).
We now thus identified eight new CNV loci that may contribute to the complex 
APO-SUS phenotype, namely AF6, Cyp450b type e, Cyp450IIB2, Cnnm2, Dab1, 
Baiap2, Ncam2 and Gtpbp4. AF6, also known as myeloid/lymphoid or mixed-
lineage leukemia translocated to 4 (MLLT4), is an actin filament-binding protein that 
regulates cell-cell adhesions. Since AF6 knock-out mice show severe developmental 
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defects (e.g. disorganisation of the ectoderm, impaired mesoderm migration and loss 
of somites), AF6 is thought to be essential for proper morphogenesis (Ikeda et al., 
1999). Two cytochrome P450 family genes contained a CNV. The many cytochrome 
P450 family members are involved in the metabolism of thousands of endogenous 
and exogenous compounds (Brown et al., 2008), and may thus influence multiple 
cellular processes. Cnnm2 is a protein with a still unknown function. Interestingly, 
Cnnm2 is located within a quantitative trait locus (QTL) for behavioural stress 
responses (Ahmadiyeh et al., 2005), a feature found to be different between the 
APO-SUS and -UNSUS rats (Rots et al., 1995). Dab1 is an adaptor protein that 
plays a key role in brain development. Dab1 mediates reelin signalling and regulates 
migration of cortical neurons in early brain development. In mice, reduced expression 
of Dab1 resulted in widespread misplacement of neurons and ataxia (Sheldon et al., 
1997). In addition, within the genomic Dab1 region, a QTL for spike wave discharge 
intensities (Swd2; T2swd/wag) has been identified (Gauguier et al., 2004), a feature 
also affected in APO-SUS rats (de Bruin et al., 2000). Baiap2 functions as an insulin 
receptor tyrosine kinase substrate and may be involved in neurodegenerative diseases 
(Mackie and Aitken, 2005). Ncam2 belongs to the immunoglobulin superfamily 
and plays a role in olfactory sensory information projections (Alenius and Bohm, 
1997). Finally, Gtpbp4 belongs to the family of GTPases involved in the regulation 
of a wide variety of processes during neuronal development, including neurite 
branching, axonal navigation and synapse formation. Thus, the eight newly identified 
chromosomal loci containing a CNV may well contribute to the complex APO-SUS 
phenotype. However, the functional consequence, if any, of these new CNVs for the 
APO-SUS and –UNSUS rat phenotypes is at present unclear. 
Guryev et al. (2008) have reported that in CNV-harbouring regions within the 
genomes of the Brown Norway-Lx and SHR/OlaIpcv rat strains up to 44% of the 
genes were differentially expressed, indicating a functional effect for a substantial 
number of CNV-containing regions. Extensive spatio-temporal mRNA and protein 
expression profiling will reveal whether a CNV leads to aberrant expression levels of 
the respective genes in the APO-SUS/-UNSUS rat model. Whether any of such CNVs 
is indeed linked to the complex APO-SUS phenotype has to await time-consuming 
experiments based on crossing, backcrossing, genetic re-selection and subsequent 
phenotypical analyses of the selected APO-SUS/-UNSUS rat lines. 
Since human and rat CNVs appear to be overlapping (Guryev et al., 2008), our 
findings may well be of significance for understanding complex human disorders. 
Interestingly, for six of the nine genes with a CNV in the replicate and original 
APO-SUS/–UNSUS rat genomes (AF6, Cyp450b type 2, Cyp450IIb2, Dab1, Baiap2 
and Ncam2), CNVs have been reported in the corresponding human genes as well 
(based on Database of Genomic Variants; build 36, update 26 June 2008 (Iafrate et 
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al., 2004)). It would therefore be of interest to examine whether any of these human 
CNVs is associated with a complex disorder in human.
None of the CNVs in the nine APO-SUS/–UNSUS chromosomal regions was 
directly linked to apomorphine susceptibility in crossbred APO-SUS/-UNSUS or 
unselected Wistar rats. The lack of a direct link with any of the CNVs likely indicates 
that, in addition to environmental factors, genetic variations other than the CNVs 
identified here may contribute to the susceptibility for apomorphine. Furthermore, 
apomorphine susceptibility may not be influenced by only a single CNV (or another 
genetic variation), but rather by multiple genetic variations. Besides, in our quest 
to identify a correlation between a particular genomic region and apomorphine-
susceptibility we focused on CNVs located within or nearby a gene. A CNV located 
in an intergenic region may however also have a functional effect, e.g. through 
regulatory elements present within a CNV region.
Most likely our study did not reveal all CNVs that occur in the APO-SUS and –UNSUS 
rat genomes. The Brown Norway genome has been sequenced and represents the 
rat genome deposited in genomic assemblies and databases, and has been chosen 
for constructing the CGH array. Yet, the Brown Norway genome is known to be 
genetically different from the genome of the Wistar rat (Saar et al., 2008), the strain 
used to create the APO-SUS and –UNSUS lines. Wistar-specific genomic segments 
are therefore not represented on the genomic arrays and thus additional CNVs may 
exist in this species. Nevertheless, our results show that at least nine CNVs are 
present in the APO-SUS/-UNSUS genomes and may play a role in the complex 
APO-SUS phenotype. 
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Gene 5’-sequence-3’ amplicon size (bp)
PCR or 
qPCR 
validation
Af6 5’-TCGTAGTGCCTACGATTGAAATAGC-3’5’-GTCATTGGTTCACTTAAAAAAAAAAAAA-3 130 qPCR
Cyp450b type e 5’-CCTTTTTGTGTTGTCAGTAGCCC-3’5’-AAATCAGGTGTCAAGCCCAGTC-3’ 187 PCR
Cyp450IIB2 5’-TCTTAACTAATGGAGCATCCTGGTC-3’5’-TGGCATGAATATCATCTTACCCC-3’ 104 qPCR
Cnnm2 5’-GTTGCTGGATACTAATCAAACTGTTTG-3’5’-CATTAGTGACAGGGCATTGGTC-3’ 101 PCR
Pde4d 5’-CAGATGGGAGAAGAGTTAAAGAGTCTTT-3’5’-CCTTCTCTATCAGGAAATTTACTACCAAA-3’ 110 PCR
prolactin receptor 5’-TATTCTAGTTTTACAAGTTGAAAGTTTATCCAC-3’5’-CATCAAGAACTCCATTTGTTACTAAGTCTG-3’ 100 PCR
Pde1a 5’-CACAATGTTACTATCATAAGGAACCATTT-3’5’-GCTGTAGATAATTAATAAGGTGACAGATGTTA-3’ 112 PCR
Dab1 5’-AGAAATGCAAAAGTTAAAAAGGATACATC-3’5’-CAAAACTACCCCCAAGACAACC-3’ 101 PCR
Cyp4a12 5’-ATTTAAAAAATTACAACTCTTCTCCTGGTT-3’5’-GGTTAAAATAGATCTGAGTTCAAACGTATC-3’ 115 qPCR
Cyp4a11 5’-ATGATATGTAGGCTTCAAGTGTTAGCG-3’5’-TTTTTTACCCTTTCAACCCTCAAA-3’ 151 qPCR
Ba1-651 5’-CTCTGCAGGTCCTAGCCTCCTA-3’5’-AATACACACTGGACCTACTTACAATGGTA-3’ 102 PCR
Nell2 5’-AGCCTTAGTAATTCACGCACCATT-3”5’-GGAGAGAGAAAAGCTGAAGAGTAGTCA-3’ 100 PCR
Rup2 5’-AATCGATTCTAGAGGAATTTGTCGG-3’5’-GAGTGGTTGCTACAACCCAGG-3’ 91 PCR
Aph-1b 5’-GAGTGGGAATGAACTAGCCCT-3’5’-GTCCTCTAAACTGTATTCCTGCTGG-3’ 109 qPCR
Cd300lf 5’-TGTGTGATGTGTGGGTGGAAT-3’5’-AGTATGAGGCAGAATAGAACAGGGTAAA-3’ 107 PCR
Baiap2 5’-AAGGTGTTGGTTACTAGAGAGCCTT-3’5’-TGGCAACCCTCACTGAGTAGGT-3’ 109 PCR
Ncam2 5’-TCATTCATTTATAAGCGATGCCA-3’5’-TTAACACAAAATGAATGCTAGATATCAAAAA-3’ 112 qPCR
LOC288010 5’-CCGCAATTCTGCACAATCAT-3’5’-AGCGGCTTGTACATGCGAG-3’ 101 qPCR
LuMo47.3 5’-AATTATTGAGGATTGTTGATTTTGAAGTT-3’5’-GACTCACATTGTGCACTTTGAAAAC-3’ 143 PCR
Niban 5’-AATTAGGGATGTTTGGTCTTTATGGTTA-3’5’-ATCCGCTGAAAAGTAAAAGCTGA-3’ 117 PCR
Spna1 5’-TACTTACTACTAAATCTTGTGTGTCCCCTT-3’5’-ATTTCCAGAACTATGAGTTTACTTAATAGTGAA-3’ 101 PCR
Gtpbp4 5’-GCCCTTCTTTGCAGGCTTC-3’5’-AAAGTGAAACCCGCGTGTG-3’ 103 qPCR
RT1.Aw3 5’-ACGACCCGTTCAATCTGTCC-3’5’-TTGCAAATCCTATTTAGCTGTGAGA-3’ 101 qPCR
Clic1 5’-GTCTTGACCTTCGACCCTGG-3’5’-CAAGGGACACGAATGGAGTTTC-3’ 99 PCR
Nudt3 5’-CGACACTCGTGGCTTACAGAGATA-3’5’-TGGTCTTAGGGTTACTGTTTCTTGTAGTTAT-3’ 140 PCR
Supplemental table. Primer sequences used for PCR and qPCR validation of CGH results
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Abstract
Atherosclerosis is a common multifactorial disease resulting from an interaction 
between susceptibility genes and environmental factors. The causative genes 
that contribute to atherosclerosis are elusive. Based on recent findings with a 
Wistar rat model, we speculated that the g-secretase pathway may be associated 
with atherosclerosis. We have tested for association of premature coronary 
atherosclerosis with a non-synonymous single-nucleotide polymorphism (SNP) 
in the g-secretase component APH1B (Phe217Leu; rs1047552), a SNP previously 
linked to Alzheimer’s disease. Analysis of a Dutch Caucasian cohort (780 cases; 
1414 controls) showed a higher prevalence of the risk allele in the patients (odds 
ratio (OR) = 1.35), albeit not statistically different from the control population. 
Intriguingly, after gender stratification, the difference was significant in males (OR = 
1.63; p = 0.033), but not in females (OR=0.50; p=0.20). Since Phe217Leu-mutated 
APH1B showed reduced g-secretase activity in mouse embryonic fibroblasts, the 
genetic variation is likely functional. We conclude that, in a male-specific manner, 
disturbed g-secretase signalling may play a role in the susceptibility for premature 
coronary atherosclerosis. 
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Introduction
Atherosclerosis is the basis of coronary artery disease and thought to be a multifactorial 
disease caused by susceptibility genes that act in concert with environmental factors. 
A number of susceptibility genes have been identified (e.g. apolipoprotein E (APOE) 
(Horejsi and Ceska, 2000), low density lipoprotein receptor (Salazar et al., 2000) 
and methylenetetrahydrofolate reductase (Morita et al., 1997)), but the signalling 
pathways responsible for vascular cell pathology are elusive. Interestingly, Wistar rats 
that display a high susceptibility for the dopamine receptor agonist apomorphine, the 
so-called apomorphine-susceptible (APO-SUS) rats (Cools et al., 1990; Ellenbroek 
et al., 2000), show an impaired vasorelaxation to adrenergic stimuli when compared 
with their phenotypic counterparts APO-UNSUS rats (Smits et al., 2002; Riksen 
et al., 2003). Impaired vasorelaxation is associated with an increased risk for the 
development of hypertension and vascular diseases such as atherosclerosis (Hadi et al., 
2005). We recently identified a gene-dosage imbalance of the g-secretase component 
Aph-1b as the molecular-genetic basis of the difference between the APO-SUS and 
-UNSUS rats (Coolen et al., 2005). The g-secretase enzyme complex cleaves many 
type I transmembrane proteins, including the amyloid-β (Aβ) precursor protein APP 
(known to be involved in neuronal amyloid plaque formation in Alzheimer’s disease 
[AD]), NOTCH1-4, neuregulin, low-density lipoprotein receptor related protein 
(LRP1, 2 and 8) and N-cadherin (Koo and Kopan, 2004; Kopan and Ilagan, 2004). 
In view of the above findings, we hypothesize that the g-secretase pathway may be 
linked to atherosclerosis. Increasing evidence suggests a link between altered vascular 
homeostasis, as seen in atherosclerosis, and the neurodegenerative disease AD. Apart 
from a partially overlapping epidemiology and an altered cholesterol homeostasis, 
atherosclerosis and AD have also been found to share genetic risk factors, including 
APOE and LRP1 (Kang et al., 1997; Rubinsztein and Easton, 1999; Horejsi and 
Ceska, 2000; Schulz et al., 2002). Since the rare non-synonymous single-nucleotide 
polymorphism (SNP) Phe217Leu (rs1047552; T>G) in the human APH1B gene has 
recently been found to be associated with AD (Poli et al., 2008), we have now tested 
whether this SNP is also associated with premature coronary atherosclerosis.
Materials and Methods
Subjects
We selected consecutive Dutch premature coronary atherosclerosis patients (n=780, 
age 43.3 ± 5.3; 582 males, age 43.6 ± 5.3 and 198 females, age 42.5 ± 5.5) who 
qualified for inclusion after a myocardial infarction, surgical or percutaneous 
coronary revascularization, or a coronary angiogram with evidence of at least a 
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70% stenosis in a major epicardial artery (Atherosclerosis Outpatient Clinic of the 
Academic Medical Center of the University of Amsterdam). The study was approved 
by the Medical Ethical Committee of the Academic Medical Center (Amsterdam, The 
Netherlands) and all patients gave written informed consent. The control subjects 
(n=1414, age 51.8 ± 11.9; 938 males, age 53.7 ± 10.9 and 476 females, age 48.2 ± 
12.9) were from the Sanquin Blood Bank. Volunteers were recruited at their blood 
donation session at one of the collection sites of the Sanquin Blood Bank covering 
the north west of the Netherlands. Therefore more than >95% of these donors lived 
in the Dutch postal code area 1000-4000. This area was chosen while the Amsterdam 
patient cohort geographically overlaps the region of the blood donor cohort serving 
as control donors.
Biochemical analysis
In the atherosclerosis patients, plasma cholesterol and triglycerides were determined 
with commercially available enzymatic methods (Boehringer Mannheim, FRG, 
No. 237574, and Sera-PAK, No. 6639, respectively). To determine high-density 
lipoprotein cholesterol, the polyethylene glycol 6000 precipitation method was used. 
Low-density lipoprotein cholesterol was calculated by the Friedewald formula. 
APH1B genotyping
Following the isolation of genomic DNA, APH1B (MIM# 607630) 
Phe217Leu genotyping was performed via allele-specific PCR 
using primers specific for SNP rs1047552 (outer/general primers: 
forward: 5’-TGCCTTCTAGGGTTACCATCTGA-3’ and reverse: 
5’-AGTCGGCTTTACACTGTCCCA-3’. Inner/specific primers: forward specific 
for the “T-allele”: 5’-AATAAACCTGGCGTCAGCATTT-3’ and reverse specific for 
the “G-allele”: 5’-GCCCATGAGCACCAGGATTATC-3’).
Generation of Aph-1abc-/- mouse embryonic fibroblast (MEF) lines 
Conditionally targeted (Aph-1a and Aph-1c) or classically targeted (Aph-1b) 
mice were described before (Serneels et al., 2005). Animals carrying a null allele 
were obtained after breeding with transgenic mice expressing a Pgk driven Cre-
recombinase. Mouse embryos were dissected at E8.5 from Aph-1abc+/- crosses 
and genotype was determined by PCR analysis on yolk sacs. Mouse embryonic 
fibroblast (MEF) cultures were derived from dissociated Aph-1abc-/- mouse embryos 
(Herreman et al., 2003).
Generation of stable cell lines
The Phe217 to Leu217 mutation was made using the QuikChange II site-directed 
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mutagenesis kit (Stratagene), using human wild-type APH1B cloned into pcDNA3.1 
Zeo+ (Invitrogen) as template. The primers used to introduce the mutation were: 5’
-CCTGGCGTCAGCATTGATAATCCTGGTGCTC-3’ (forward); 5’-GAGCACCA
GGATTATCAATGCTGACGCCAGG-3’ (reverse). Phe217 and Leu217 hAPH1B 
were recloned into pMSCVpuro* and cotransfected into HEK293 cells with helper 
plasmid pIK Ecopac for packaging into retroviruses. Retroviruses were harvested 
and snap frozen aliquots were stored at –80°C until use. MEF Aph-1abc-/- cells were 
transduced with retrovirus for 24 hrs followed by puromycin selection in DMEM/
F12 supplemented with 10% FCS until stable lines were obtained.
Measurement of gamma-secretase activity towards different substrates
Stably transfected MEFs were seeded and grown to confluency. Cells were rinsed 
twice with ice-cold PBS and lysed in 1% Triton, and postnuclear fractions were 
isolated by centrifugation at 10,000g for 15 min at 4°C. Proteins were quantified 
using a standard Bradford assay (Pierce) and 10-15 µg protein/lane was loaded on 
Bis-Tris SDS-PAGE gels (Invitrogen) and transferred to nitrocellulose membranes 
for Western blot detection for the indicated proteins. Gamma-secretase activity 
towards each substrate was expressed as the level of substrate C-terminal fragment 
(the direct gamma-secretase substrate) relative to levels of full-length protein. 
For densitometric quantification, the films were scanned using an Image Scanner 
(Amersham Pharmacia) and analyzed using ImageMaster.
 
Antibodies
APP was detected with C-terminal pAb B63.1 and syndecan 3 with C-terminal mAb 
2E9. An antibody against the N-cadherin C-terminus (clone 32, BD Bioscience) was 
purchased.
Statistical analysis
Genotype frequencies were tested for the Hardy-Weinberg equilibrium. Differences 
between cases and controls were analysed by standard contingency table analysis 
using two-tailed χ2 test probabilities. Odds ratios (95% confidence intervals (CI)) 
were calculated as an index of the association of the APH1B genotypes with premature 
atherosclerosis. Continuous and categorical biochemical and clinical variables were 
determined with the Student’s t-test and χ2-analysis, respectively. A p-value < 0.05 
was considered statistically significant (GraphPad Software Inc, San Diego, CA, 
USA). Though being conservative, Bonferonni correction was used to determine 
the significance of the biochemical and clinical variables. Power calculations were 
estimated using Quanto v1.2 (Gauderman, 2002).
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Results
Male-specific association of APH1B Phe217Leu with premature coronary 
atherosclerosis
Since a gene-dosage imbalance of the Aph-1b gene was the molecular-genetic 
basis of the APO-SUS/-UNSUS rat model (Coolen et al., 2005) and the model was 
characterized by a disturbed endothelium-dependent vascular reactivity (Smits et al., 
2002; Riksen et al., 2003), we tested the hypothesis that a genetic variation in the 
APH1B gene may contribute to atherosclerosis susceptibility in humans. In a Dutch 
case-control cohort consisting of 780 patients with premature coronary atherosclerosis 
and 1414 controls, we found a higher prevalence of the risk allele (G-allele) in the 
patients, albeit not statistically different (χ2 = 2.09, df = 1, p =0.15; OR = 1.35; CI = 
0.90-2.01). Intriguingly, after gender stratification, the difference was significant in 
the male population (χ2 = 4.52, df = 1, p =0.033; OR = 1.63; CI = 1.04-2.58), whereas 
females were not significantly different (χ2 = 1.62, df = 1, p = 0.20; OR = 0.50; CI 
= 0.17-1.48) (table 1). Power analysis showed that for the detection in the female 
subpopulation of a risk effect similar to that observed in the male subpopulation, the 
power was insufficient (92% power for the total population; 81% power for the male 
subpopulation and 38% power for the female subpopulation, assuming a relative 
risk of 1.63, a disease allele frequency of 3.3% and a disease prevalence of 5%). 
All genotype distributions tested (cases and controls) fulfilled the Hardy-Weinberg 
criteria (data not shown). 
Genotype 
Frequencies (%)
Allele 
Frequencies (%)
n TT TG GG  T G p OR
total
   controls 1414 96.0 4.0 0 98.0 2.0
   patients 780 94.6 5.4 0 97.3 2.7 0.15 1.35
males
   controls 938 95.9 4.1 0 98.0 2.0
   patients 582 93.5 6.5 0 96.7 3.3 0.033* 1.63
females
   controls 476 96.0 4.0 0 98.0 2.0
   patients 198 98.0 2.0 0 99.0 1.0 0.20 0.50
Table 1. Genotype and allele frequencies for the APH1B Phe217Leu variation in a Dutch case-control 
study on premature coronary atherosclerosis 
Standard Chi-square tests were applied to evaluate the association with premature coronary 
atherosclerosis. OR = odds ratio; *p<0.05.
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Association of APH1B 217Leu with fibrinogen levels in premature coronary 
atherosclerosis
We then compared the association of the APH1B 217Leu allele with clinical parameters 
in the atherosclerosis patients, including the presence of risk factors (e.g. smoking 
behavior and occurrence of hypertension and diabetes mellitus), and the blood 
levels of lipid compounds (e.g. cholesterol, triglycerides, and low- and high-density 
lipoprotein cholesterol) (for a detailed overview of the parameters tested, see table 
2). These parameters were not related to the APH1B Phe217Leu variation (table 2), 
except for a significant association (p = 0.028) with the fibrinogen levels in patients 
containing or lacking the APH1B Leu217 allele. Patients without the Leu217 allele 
displayed fibrinogen levels of 322.8 ± 80.55 gr/l (n = 327, plus SD), whereas patients 
with the Leu217 allele had levels of 375.0 ± 82.08 gr/l (n = 12, plus SD) (table 2); 
due to low female patient numbers, gender stratification for fibrinogen levels was 
not possible. After Bonferroni adjustment for multiple comparisons, however, no 
statistically significant association of the fibrinogen levels with the Leu217 allele 
was detected (Bonferroni's adjustment requires a significance level of p ≤ 0.00156). 
Evolutionary conservation of amino acid residue Phe217 within the APH1 family
The degree of conservation of an amino acid within a protein family is usually 
indicative of its importance for protein functioning. A multiple sequence alignment 
of members of the APH1 family (figure 1) showed that the Phe217 residue is 
conserved from plant, invertebrates, lower vertebrates, rodents and primates to man. 
The various APH1 proteins all contain at residue 217 either a phenylalanine (F) 
or the conservative change to tyrosine (Y). The Support Vector Machine (SVM) 
score (http://www.SNPs3D.org) (Yue et al., 2006) of –1.12 for Phe217Leu indicates 
a likely impact of this substitution on APH1B protein function.
Functional analysis of the APH1B Phe217Leu polymorphism
We wondered whether the presence of a leucine instead of the conserved residue 
Phe217 of the APH1B protein would be of functional importance. Aph-1abc-/- mouse 
embryonic fibroblasts were stably transfected with human APH1B Phe217 or Leu217. 
g-Secretase activity was measured by quantifying the levels of different g-secretase 
substrates in cell culture extracts. We observed a 1.6-fold reduction (p<0.05, n=8) of 
g-secretase activity towards one of its substrates, syndecan-3 (Schulz et al., 2003), 
indicating a subtle influence on g-secretase cleavage activity. The cleavages of two 
other substrates, N-cadherin and APP, were slightly but not significantly changed 
(figure 2). Thus, in a substrate-dependent manner the Phe217Leu substitution affected 
g-secretase cleavage activity.
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without APH1B 
217Leu
with APH1B 
217Leu
values ± SD n values ± SD n p
Age (years) 43.3 ± 5.3 739 42.9 ± 5.3 42 0.60
BMI (kg/m2) 26.9 ± 4.2 739 26.8 ± 3.1 42 0.88
Age first manisfestation vascular event (yrs) 41.6 ± 5.9 739 40.9 ± 6.1 42 0.47
Systolic blood pressure (mmHg) 129.1 ± 17.2 739 127.0 ± 18.5 42 0.45
Diastolic blood pressure (mmHg) 79.5 ± 10.5 739 81.2 ± 12.6 42 0.32
Total cholesterol prior to medication (mmol/l) 6.3 ± 1.9 286 6.6 ± 1.4 20 0.50
LDL-cholesterol prior to medication (mmol/l) 3.9 ± 1.3 220 4.4 ± 1.3 14 0.20
HDL-cholesterol prior to medication (mmol/l) 1.1 ± 0.4 231 1.0 ± 0.2 15 0.43
Triglycerids prior to medication (mmol/l) 1.8 ± 1.2 229 1.9 ± 0.7 15 0.77
Total cholesterol with medication (mmol/l) 5.0 ± 1.5 738 4.9 ± 1.7 42 0.88
LDL-cholesterol with medication (mmol/l) 3.0 ± 1.2 730 3.1 ± 1.8 41 0.78
HDL-cholesterol with medication (mmol/l) 1.1 ± 0.3 737 1.1 ± 0.4 42 0.41
Triglycerids with medication (mmol/l) 2.1 ± 4.0 738 1.8 ± 1.6 42 0.68
Apo A1 lipoprotein (mmol/l) 1.3 ± 0.3 495 1.2 ± 0.2 29 0.12
Apo B100 lipoprotein (mmol/l) 1.1 ± 0.6 494 1.0 ± 0.4 29 0.40
Lipoprotein (a) (mg/l) 215.2 ± 309.4 496 240.7 ± 377.1 30 0.66
Blood sedimentation rate (BSE) (mm/h) 10.4 ± 11.3 345 9.4 ± 5.2 16 0.74
Fibrinogen (gr/l) 322.8 ± 80.5 327 375.0 ± 82.1 12 0.028 *
% n % n p
Acute myocardial infarction 73.34 739 69.05 42 0.54
Coronary angiography abnormal 98.23 621 97.14 35 0.64
Percutaneous transluminal coronary angioplasty 66.98 739 80.95 42 0.06
Coronary artery bypass grafting 7.98 739 4.76 42 0.45
Complaints claudication (<500 m walking distance) 11.77 739 7.14 42 0.36
Percutaneous transluminal angioplasty 7.58 739 7.14 42 0.92
Peripheral artery bypass grafting 2.84 739 0 42 0.27
Cerebro vascular accident 2.98 739 4.88 41 0.50
Smoking before the first event date 75.24 739 66.67 42 0.21
Treated for hypertension 25.44 735 33.33 42 0.26
Treated for diabetes mellitus 7.44 739 4.76 42 0.52
Hypercholesterolemia 1st degree relative 48.37 552 48.57 35 0.98
Hypertension treatment first degree relative 45.71 617 47.37 38 0.84
Diabetes treatment first degree relative 27.42 660 23.08 39 0.55
Table 2. Clinical and biochemical characteristics of the premature coronary atherosclerosis patients 
with and without the APH1B 217Leu allele 
Values are given as mean levels ± SD or as percentages. N, number of individuals tested; BMI, body mass 
index; LDL, low density lipoprotein; HDL, high density lipoprotein; Apo, apolipoprotein. *p<0.05.
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Discussion
In this study we show that the non-synonymous Phe217Leu polymorphism 
in the human APH1B gene is a male-specific risk factor for premature coronary 
atherosclerosis. The reduced g-secretase cleavage activity of Leu217 APH1B, albeit 
in a substrate-specific manner, suggests a functional relevance of this polymorphism. 
Functional consequences of reduced gene dosage of Aph-1b were also observed in the 
APO-SUS/-UNSUS rat model (Coolen et al., 2005), an animal model with complex 
features, including an impaired vasorelaxation response to adrenergic stimuli (Smits 
et al., 2002; Riksen et al., 2003), which increases the risk for the development of 
hypertension and vascular diseases. The gene-dosage imbalance of the Aph-1b gene 
(three gene copies in APO-UNSUS rats and one or two gene copies in APO-SUS 
rats) segregated with differences in g-secretase cleavage activity and a number of 
other phenotypic characteristics (Coolen et al., 2005). We therefore speculate that 
a subtle effect on APH1B expression or function (copy number variation in rat or 
Phe217Leu variation in human, respectively) may affect g-secretase activity and 
signalling downstream of gamma-secretase cleavage and, consequently, give rise 
to vascular complications. Interestingly, the APH1B Phe217Leu polymorphism was 
recently found to be also associated with AD (Poli et al., 2008). AD pathogenesis 
is frequently characterized by a peripheral vascular disturbance and is often linked 
to other cholesterol/lipoprotein diseases, including atherosclerosis (Casserly and 
Topol, 2004). In addition, cerebral atherosclerosis has been found to be a strong 
contributory factor to sporadic AD pathogenesis (Roher et al., 2003). The APH1B 
Figure 1. Alignment of vertebrate and invertebrate amino acid sequences of the region within APH1 
surrounding residue 217. A black background indicates identical amino acid residues; a grey background 
indicates a conservative amino acid change. Abbreviations: Hs, Homo sapiens; Pt, Pan troglodytes; 
Rn, Rattus norvegicus; Mm, Mus musculus; Xt, Xenopus tropicalis; Dr, Danio rerio; Dm, Drosophila 
melanogaster; Ce, Caenorhabditis elegans; At, Arabidopsis thaliana. Sequences were aligned using 
Vector NTI (9.0) with default parameters.
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Phe217Leu variation may thus play a dual role by affecting atherosclerosis as 
well as AD pathogenesis, suggesting  that the two diseases have converged and 
that the g-secretase signalling pathway is a susceptibility pathway for vascular 
complications.
In line with the above supposition, a number of the g-secretase substrates have been 
implicated in vascular pathogenesis. LRP, which belongs to a gene family involved 
in mediating cellular uptake of cholesterol-rich lipoproteins (the low-density 
lipoprotein receptor (LDLR) gene family), is highly expressed in atherosclerotic 
lesions (Luoma et al., 1994; Hiltunen et al., 1998) and has been shown to represent 
a susceptibility gene for atherosclerosis (Schulz et al., 2002). The AD-associated 
g-secretase substrate APP may be involved in vascular pathogenesis as well, since it 
metabolises cholesterol (Nelson and Alkon, 2005), physically interacts with LRP1 
(Rebeck et al., 2001), and gives rise to the amyloid plaque constituents Aβ-40 and -42. 
Besides these well-studied substrates, the g-secretase substrates NOTCH3, colony-
stimulating factor 1 (CSF1), CD44, neuregulin and ERBB4 may also be involved 
in the vascular complications in patients with the APH1B Phe217Leu variation. 
Mutations in NOTCH3 may cause cerebral autosomal dominant arteriopathy with 
subcortical infarcts and leukoecephelopathy (CADASIL), a syndrome characterized 
Figure 2. γ-Secretase cleavage activity of human wild-type APH1B (Phe217) and human mutant 
APH1B (Leu217) stably transfected into Aph-1abc-/- mouse embryonic fibroblast cells. The levels of 
the C-terminal fragments (CTFs) of N-cadherin, APP and syndecan-3 were analysed in cells stably 
transfected with human APH1B Phe217 (WT) or human APH1B Leu217 (MUT). In the MUT cells, the 
CTF levels of N-cadherin and APP were slightly increased (1.1-fold and 1.2-fold, respectively), but 
the difference failed to reach significance. The levels of syndecan-3-CTF were significantly increased 
(1.6-fold; p=0.044), indicating a reduced γ-secretase cleavage activity. Bars represent quantifications 
of CTF signals normalized to full-length protein levels in eight stably transfected cell lines with the 
average level in WT cell lines set to 100%.*: p<0.05.
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by systemic vascular smooth muscle cell (VSMC) degeneration (Wang et al., 2008). 
CSF1 can contribute to atherosclerosis development via fatty streak formation 
and progression to complex fibrous lesions (Rajavashisth et al., 1998), and CD44 
may enhance atherosclerosis pathogenesis via reactive oxygen species (Vendrov et 
al., 2006), whereas neuregulin and ERBB4 are necessary for vascular growth and 
development (Gassmann et al., 1995; Meyer and Birchmeier, 1995; Kramer et al., 
1996). 
Our results show that, remarkably, only male individuals with atherosclerosis seem 
to be associated with the APH1B Phe217Leu variation. This might indicate a role for 
hormones or the involvement of a Y-chromosome-linked modulation. Such a gender-
specific association has been observed for other SNPs as well, like a male-specific 
association of the APOE2 and APOE4 alleles with cardiovascular disease (Lahoz et 
al., 2001). Thus, susceptibility to many common diseases may well be the result of 
complex interactions involving gender, genes and environmental factors. Following 
Bonferroni correction for multiple testing, no significant associations between the 
APH1B polymorphism and plasma lipoprotein parameters or other risk factors were 
observed in the atherosclerosis patients. More detailed studies will be necessary to 
establish the biochemical mechanisms underlying atherosclerosis in patients carrying 
the Phe217Leu polymorphism. 
In the present study, association was only tested for premature coronary 
atherosclerosis, a disease with a substantial heritability (Rissanen, 1979). To 
investigate whether the Phe217Leu SNP constitutes a susceptibility factor for other 
vascular complications, it would be of interest to also test for association in elderly 
atherosclerotic patients and in patients with other vascular defects (e.g. myocardial 
infarction). No significant association of the APH1B chromosomal region with 
coronary artery disease, myocardial infarction or other related diseases has been 
found in recent genome-wide association studies (GWAS) (Helgadottir et al., 2007; 
McPherson et al., 2007; O’Donnell et al., 2007; Samani et al., 2007). Thus, apart from 
the functional Phe217Leu polymorphism, the contribution of any additional genetic 
variant in the APH1B gene to the phenotype is expected to be small. Unfortunately, 
no results for the APH1B Phe217Leu polymorphism are available from the GWAS 
since this polymorphism was not represented on the arrays used in these studies. In 
addition, based on the data from the International HapMap-CEU project none of 
the SNPs tested in the GWAS is in near perfect proxy (r2 ≥ 0.8) to the Phe217Leu 
polymorphism.  Therefore, the GWAS data do not provide any additional information 
concerning the functional APH1B Phe217Leu SNP.
In conclusion, our results suggest that the g-secretase pathway is a candidate pathway 
for premature coronary atherosclerosis and warrant further studies on genetic 
variations in this pathway in various diseases with vascular complications.  
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Abstract 
Epilepsy is a heterogeneous disorder with susceptibility genes and environmental 
factors that can act together to produce the phenotype. Based on our recent findings 
with a Wistar rat model, we hypothesized that the g-secretase pathway may be involved 
in epileptic seizures. Here, we examined in Caucasian epilepsy-control cohorts 
the functional single-nucleotide polymorphism (SNP) Phe217Leu (rs1047552) 
in the human gene encoding the g-secretase component APH1B. We find that the 
polymorphism was significantly associated (χ2 = 3.90, df = 1, p = 0.048; OR = 2.42; 
CI = 0.98-5.99) in a Dutch cohort of idiopathic generalized epilepsy (IGE), with a 
higher prevalence of the risk allele in the cases. Analysis of the polymorphism in 
an independent second IGE cohort from the United Kingdom (Kent) also showed 
a higher prevalence of the risk allele in the cases, albeit not statistically different 
from the control population (χ2 = 0.21, df = 1, p = 0.65; OR = 1.19; CI = 0.56-2.53). 
Furthermore, analysis in yet another independent group of epilepsy patients from 
the United Kingdom (Glasgow) showed a higher prevalence of the risk allele in the 
IGE than the non-IGE patients. Thus, the g-secretase pathway may constitute a novel 
susceptibility pathway for IGE.
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Introduction
Epilepsy is characterized by abnormal electrical brain activity and has a genetically 
determined aetiology. Numerous linkage and association studies have been 
performed to identify epilepsy susceptibility chromosomal regions and genes. 
Although a number of genes have been found to be linked to the familial monogenic 
epilepsies, consistent identification of the predisposing genetic variants in the more 
common epilepsies (e.g. idiopathic generalized epilepsies (IGEs)) has mostly not 
been achieved (reviewed by Dibbens et al., 2007). The expected subtle influence of 
susceptibility genes and the complex interactions with environmental factors increase 
the difficulty to unravel the aetiology of the common or complex epilepsies. 
The findings reported here have their roots in our recent studies on the molecular 
genetic basis of a Wistar rat model with a high susceptibility to the dopamine receptor 
agonist apomorphine (so-called APO-SUS rats) (Cools et al., 1990). These rats display 
features resembling those of epilepsy, including abnormalities in brain information 
processing and increased bursts of bilateral synchronous spike wave discharges 
recorded with electroencephalography (Cools and Peeters, 1992; Ellenbroek et al., 
1995; de Bruin et al., 2000). RNA expression studies and genetic analyses have 
revealed that the difference underlying the APO-SUS and its counterpart the APO-
UNSUS rats concerns a gene-dosage imbalance of Aph-1b (Coolen et al., 2005), a 
component of the g-secretase complex. The g-secretase enzyme complex consists of 
four different integral membrane proteins, namely presenilin (either PS1 or PS2), 
nicastrin, presenilin-enhancer 2 (PEN2) and APH1 (Fortini, 2002; Francis et al., 
2002; Goutte et al., 2002; Kimberly and Wolfe, 2003). The enzyme is responsible 
for the proteolytic processing of a wide variety of type I transmembrane proteins, 
including amyloid-β precursor protein (APP) and its relatives the APP-like proteins 
APLP1 and APLP2, Notch1-4, glutamate receptor 3 (GluR3), human leucocyte 
antigen-A2 (HLA-A2) and the voltage-gated sodium channel beta 2 subunit (Scn2b) 
(reviewed by Parks and Curtis, 2007). The reduction of Aph-1b gene copies in 
the APO-SUS rats segregated with a reduced tissue-specific and spatio-temporal 
g-secretase cleavage activity (Coolen et al., 2006a; Coolen et al., 2006b). 
On the basis of the results obtained with the APO-SUS and -UNSUS rat model, 
we speculated that a genetic variation in the APH1B gene may contribute to the 
susceptibility for epilepsy in humans. Interestingly, we recently discovered a single-
nucleotide polymorphism (SNP), namely the Phe217Leu variation (rs1047552) located 
in exon 6 of the human APH1B gene, that in transfection studies affected g-secretase 
cleavage activity, suggesting a functional relevance for this SNP (van Loo et al., 
2008). In the present study, we therefore tested in Caucasian case-control cohorts for 
association of the functional Phe217Leu genetic variation in APH1B with epilepsy.
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Materials and Methods
Subjects
The Dutch cohort consisted of 175 Caucasian IGE patients and 277 Caucasian 
blood bank controls from the same geographic region. The study was approved 
by the Medical Ethical Committee of the University Medical Center Utrecht and 
all participating patients provided informed consent. The patient group from the 
United Kingdom (Kent) consisted of 226 Caucasian patients with a broad IGE 
phenotype. Patients with a diagnosis of IGE and generalized spike/wave on EEG 
were recruited through East Kent Hospitals. Control DNA was obtained from 309 
unrelated individuals with the same ethnic background and recruited from the same 
region, group-matched for age and sex, and no history of epilepsy or blackouts. 
Ethical approval was obtained. The second patient group from the United Kingdom 
(Glasgow) consisted of 595 Caucasian patients recruited from out-patient clinics at 
the Epilepsy Unit, Western Infirmary, Glasgow, Scotland. DNA sample collection 
and analysis was approved by the West Research Ethics Committee, North Glasgow 
University Hospitals NHS Trust and all participants provided written, informed 
consent. The epilepsy was classified as localization-related in 422 (71%) patients, 
idiopathic generalised in 157 (26%), and was unclassified in the remaining 16 (3%) 
individuals. 
APH1B genotyping
Following DNA isolation according to standard procedures, APH1B Phe217Leu 
genotyping was performed using the invader assay (Prevention Genetics) or via 
allele-specific PCR using primers specific for single-nucleotide polymorphism (SNP) 
rs1047552. For the latter approach, the PCR mixture contained ~20 ng genomic DNA, 
10 mM Tris-HCl (pH 8.3), 2.5 mM MgCl
2
, 50 mM KCl, 0.001% gelatin, 0.25% Nonidet 
P-40, 0.25% Tween-20, 200 µM each of the four deoxynucleotide triphosphates, 0.8 
units of Taq polymerase (MBI Fermentas) and 0.6 µM of each of four oligonucleotide 
primers (outer/general primers: forward: 5’-TGCCTTCTAGGGTTACCATCTGA-3’ 
and reverse: 5’-AGTCGGCTTTACACTGTCCCA-3’. Inner/specific primers: 
forward specific for the “T-allele”: 5’-AATAAACCTGGCGTCAGCATTT-3’ and 
reverse specific for the “G-allele”: 5’-GCCCATGAGCACCAGGATTATC-3’) in a 
total volume of 20 µl. Reactions were amplified for 30 cycles at 94°C for 1 min, 
68°C for 30 sec and 72°C for 1 min, followed by a final extension step at 72°C for 10 
minutes. PCR products were analysed on 1% agarose gels. The homozygous TT- and 
GG-genotypes gave two bands, (621 / 370 and 621 / 294 base pairs, respectively), 
whereas the heterozygous TG-genotype resulted in three bands (621, 370 and 294 
base pairs).
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Statistical analysis
Differences between cases and controls were analysed by standard contingency table 
analysis using two-tailed χ2 test probabilities. Genotype frequencies were tested for 
deviation from Hardy-Weinberg equilibrium (HWE). The strength of association 
was summarized by using the odds ratio (OR with 95% confidence intervals (CI)), in 
which an OR greater than 1.0 indicated a positive association (GraphPad Software 
Inc, San Diego, CA, USA).
Results
In search for potential association of the functional APH1B Phe217Leu genetic 
variation with epilepsy, we first tested a Dutch cohort consisting of 175 IGE patients 
and 277 controls from the same geographic region. Interestingly, allele frequencies 
were significantly different between the Dutch epilepsy patients and the control 
population (χ2 = 3.90, df = 1, p = 0.048; OR = 2.42; CI = 0.98-5.99), with a higher 
prevalence of the risk allele (G-allele) in the patients (table 1). 
For association studies of disorders with a high level of heterogeneity and in particular 
when a low minor allele frequency (MAF) of the susceptibility polymorphism is 
involved (as holds for the Phe217Leu polymorphism), reliable association data are 
difficult to obtain. Consequently, additional populations are necessary to increase the 
power in order to allow a statistically significant disorder/genotype relationship. We 
therefore decided to screen a second cohort, consisting of 226 Caucasian patients with 
IGE and 309 Caucasian controls (cohort from Kent). This second cohort also showed 
a higher prevalence of the risk allele in the cases, albeit not statistically different 
from the control population (χ2 = 0.21, df = 1, p = 0.65; OR = 1.19; CI = 0.56-2.53) 
(table 1). A third group consisted of 595 Caucasian epilepsy patients from Glasgow 
(including 157 patients with the IGE subtype). Analysis of these patients showed a 
higher prevalence of the risk allele in the IGE subtype (MAF of 4.5%) compared 
to the non-IGE subtype (MAF of 2.9%) (table 1), indicating an enrichment of the 
APH1B Phe217Leu risk allele in the IGE subtype. All genotype distributions tested 
(cases and controls) did not significantly deviate from HWE (data not shown).
Discussion
In the present study on three independent Caucasian groups, we show that the APH1B 
Phe217Leu polymorphism may be a risk factor for epilepsy, more specifically for 
the IGE subtype. Although the cohort from the United Kingdom failed to reach 
significant levels, a higher prevalence of the risk allele was found among IGE 
patients from both the Dutch and the United Kingdom cohort when compared with 
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healthy controls. Furthermore, analysis of a third group of epilepsy patients (United 
Kingdom, Glasgow), showed a higher prevalence of the risk allele in the IGE 
patients compared to the non-IGE patients. Thus, our data suggest that the APH1B 
Phe217Leu polymorphism may be a risk factor for IGE. Nevertheless, replication 
of our results in other IGE cohorts and extrapolation to other epilepsy subtypes will 
be essential to reveal whether the APH1B Phe217Leu SNP constitutes a risk factor 
solely for IGE or for a wide variety of epilepsy subtypes.
A functional defect in the APH1B gene was also observed in the APO-SUS/-UNSUS 
rat model (Coolen et al., 2005), an animal model with neurodevelopmental alterations 
(Ellenbroek et al., 1995; Ellenbroek and Cools, 2002), including increased bursts of 
spike wave discharges (de Bruin et al., 2000). The gene-dosage imbalance of the Aph-
1b gene (three gene copies in APO-UNSUS rats and one or two gene copies in APO-
SUS rats) segregated with differences in g-secretase cleavage activity and a number 
of phenotypic characteristics (Coolen et al., 2005). Furthermore, we recently found 
a reduced g-secretase cleavage activity in Aph-1abc-/- mouse embryonic fibroblasts 
(MEFs) transfected with the APH1B Leu217 variant when compared with Aph-1abc-/- 
MEFs transfected with the Phe217 variant, indicating that the APH1B Phe217Leu 
polymorphism represents a functional polymorphism (van Loo et al., 2008). We 
therefore speculate that a subtle effect on APH1B expression or function (copy 
number variation in rat or Phe217Leu variation in human, respectively) may affect 
g-secretase signalling and consequently influence neuronal functioning, including 
Genotype 
Frequencies (%)
Allele 
Frequencies (%)
n TT TG GG  T G p OR
The Netherlands
   Patients (IGE) 175 93.1 6.9 0 96.6 3.4 0.048* 2.42
   Controls 277 97.1 2.9 0 98.6 1.4
United Kingdom (Kent)
  Patients (IGE) 226 94.2 5.8 0 97.1 2.9 0.65 1.19
   Controls 309 95.1 4.9 0 97.6 2.4
United Kingdom (Glasgow)
   Patients (IGE) 157 91.1 8.9 0 95.5 4.5 0.17 1.59
   Patients (Non-IGE) 438 94.5 5.3 0.2 97.1 2.9
Table 1. Genotype and allele frequencies for the APH1B Phe217Leu variation in epilepsy case-control 
studies
Standard Chi-square tests were applied to evaluate the association of the APH1B Phe217Leu variation 
with epilepsy. OR = odds ratio; *p<0.05.
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the interplay of excitatory and inhibitory neurons that can generate the abnormal 
oscillations as seen in people with epilepsy.
Although the APH1B Phe217Leu polymorphism has been previously associated 
with Alzheimer’s disease and premature coronary atherosclerosis (Poli et al., 2008; 
van Loo et al., 2008), it has not been considered before in the context of epilepsy. 
Interestingly, a number of g-secretase substrates, namely Scnb2, GluR3 and HLA-A2, 
have been found to be involved in the development of epileptic seizures. Scnb2 
homozygous knock-out mice (Scn2b-/-) showed a deficient regulation of electrical 
excitability in the brain, resulting in an increased susceptibility to epileptic seizures 
(Chen et al., 2002). Immunization of rabbits with the GluR3 protein induced epileptic 
seizures in the animals and serum samples of people with epilepsy contained more 
often antibodies to GluR3 compared to healthy controls (Rogers et al., 1994; Wiendl 
et al., 2001; Mantegazza et al., 2002), indicating a link between GluR3 and the 
development of epileptic seizures. For the g-secretase substrate HLA-A2, a higher 
percentage of antigen was found in the sera of epilepsy patients compared to controls 
(Fontana et al., 1978). Since we now find that the human g-secretase polymorphism 
Phe217Leu may be associated with epilepsy and rats with a reduced number of 
Aph1b gene copies display an increased incidence of bursts of bilateral synchronous 
spike wave discharges (de Bruin et al., 2000), we hypothesize that in a subset of 
individuals a disturbed g-secretase signalling may lead to epileptic alterations. 
Altogether, our results suggest that g-secretase signalling may be a critical process 
for the generation of normal brain rhythms and may represent a candidate pathway 
for IGE.
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APH1B SNP and susceptibility for HIV-1 infection
Abstract 
Susceptibility for human immunodeficiency virus type 1 (HIV-1) infection is 
individual specific and may be influenced by host genetics. Based on recent findings 
with a rat model, we speculated that the γ-secretase pathway may be associated with 
an individuals’ infection susceptibility. We here find that in a Xhosa indigenous 
South African cohort a functional single-nucleotide polymorphism in the γ-secretase 
component APH1B shows a tendency for association with HIV-1 infection (p=0.087). 
Interestingly, the polymorphism was significantly associated in a second, Caucasian 
cohort for HIV-1 infection (p=0.049). Together, our results suggest a role for the 
γ-secretase pathway in susceptibility for HIV-1 infection.
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Introduction
Human immunodeficiency virus type 1 (HIV-1) infection is the causative factor 
of acquired immunodeficiency syndrome (AIDS) and has a strikingly increasing 
prevalence rate, especially in developing countries (McCutchan, 2006). The 
susceptibility to HIV-1 infection is remarkably dependent on the individual; whereas 
some HIV-1 infected individuals show a rapid progression to AIDS, others exhibit an 
asymptomatic survival despite their HIV-1 infection (Klein and Miedema, 1995). In 
addition, some individuals have remained HIV-1 negative despite reported exposure 
to HIV-1 during high-risk sexual behaviour. Host factors, such as genetic mutations 
and single-nucleotide polymorphisms (SNPs), may therefore contribute to HIV-
1 infection susceptibility and disease progression. A number of genetic variants, 
including variations within the chemokine receptor 5 (CCR5) gene, have been found 
to be associated with the acquisition of HIV-1 infection and its clinical course (Reiche 
et al., 2007). However, the key genes and pathways involved in HIV-1 infection 
susceptibility are not clear. 
Apomorphine-susceptible (APO-SUS) and apomorphine-unsusceptible (APO-
UNSUS) Wistar rats have been shown to differ in immunological parameters 
(Ellenbroek and Cools, 2002). For instance, APO-SUS rats displayed a stronger T 
helper 2 (Th2)-dependent IgE response upon worm infection, a lower Th1-mediated 
autoimmune encephalomyelitis response and a disturbed Th1/Th2 balance when 
compared to APO-UNSUS rats (Kavelaars et al., 1997). Thus, the rats appear to 
differ in host resistance or susceptibility to inflammation and infection. We recently 
identified a gene-dosage imbalance of the γ-secretase component Aph-1b in the APO-
SUS/-UNSUS rat model (Coolen et al., 2005). The γ-secretase enzyme complex 
cleaves a variety of type I transmembrane proteins, including Notch1-4, β-amyloid 
precursor protein, sialophorin (CD43), HLA-A2 and syndecan-3 (Andersson et al., 
2005; Parks and Curtis, 2007). 
Intrigued by the findings with the rat model, we wondered whether an association 
between APH1B and susceptibility to HIV-1 infection would exist and thus whether 
γ-secretase signalling should be considered as a new susceptibility pathway for 
HIV-1 infection. Intriguingly, we recently discovered a SNP (rs1047552, T>G, 
Phe217Leu) in exon 6 of the human APH1B gene (located on chromosome 15q22.2 
and spanning 28.3 kb; MIM# 607630, also known as presenilin stabilization factor-
like, PSFL) that was found to be functional in transfection studies on Phe217Leu-
mutated APH1B (van Loo et al., 2008). In the present study, we therefore tested for 
association of this non-synonymous SNP with HIV-1 infection in both an African 
and a Caucasian case-control study.
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Materials and Methods
Subjects
The South African study representing unrelated Africans of Xhosa ethnic descent 
and residing in the Western Cape of South Africa has been described previously 
(Hayes et al., 2002). We analysed a total of 198 HIV-1-seropositive (61 males and 
137 females) and 112 HIV-1-seronegative individuals (42 males and 70 females). 
The Ethics Review Committee of the University of Stellenbosch approved the study 
protocol (#98/158). The Dutch cohort consisted of 1210 Caucasian male subjects: 
335 HIV-1-seropositive individuals recruited via the Amsterdam Cohort on HIV-1 
infection and AIDS between October 1984 and March 1986 (de Roda Husman et al., 
1997) and 875 randomly selected Dutch controls from the Sanquin Common Control 
Collection (SANQUIN-CCC): a Dutch national repository of common controls set 
up in 2007 as part of the Bloodomics project by Sanquin. Volunteers were recruited 
at their blood donation session at one of the collection sites of the Sanquin Blood 
Bank covering the north west of the Netherlands. Therefore more than >95% of these 
donors lived in the Dutch postal code area 1000-4000. This area was chosen while 
the Amsterdam cohort of HIV-1 individuals geographically overlaps the region of 
the blood donor cohort serving as control donors. Informed consent was obtained 
from all study participants. 
APH1B genotyping
Following the isolation of genomic DNA according to standard procedures, APH1B 
Phe217Leu genotyping was performed via denaturing gradient gel electrophoresis 
(DGGE) of PCR fragments, a Taqman assay (Applied Biosystems, Foster City, CA, 
USA) or allele-specific PCR using primers specific for SNP rs1047552 (primers and 
conditions available on request). The presence of the SNP was confirmed by Sanger 
sequencing.
Statistical analysis
Genotype frequencies were tested for the Hardy-Weinberg equilibrium. Differences 
between cases and controls were analysed using two-tailed χ2 probabilities, and 95% 
confidence intervals (95% CIs) were calculated for the odds ratios (ORs). A p-value 
< 0.05 was considered statistically significant (GraphPad Software Inc, San Diego, 
CA, USA). 
Results
In search for potential association of the non-synonymous Phe217Leu polymorphism 
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(rs1047552) of human APH1B with HIV-1 infection, we tested a case-control cohort 
of individuals belonging to the Xhosa ethnic group of South Africa (198 HIV-1-
seropositive patients and 112 non-infected individuals). Interestingly, we found a 
trend towards an association (χ2 = 2,94, df = 1, p =0.087; odds ratio [OR] for G-allele 
= 2.33; CI = 0.86-6.30) (table 1). Subdivision of the sample based on gender showed 
a slightly higher prevalence of the minor allele variant in the males compared to 
females (OR in males: 2.88; OR in females: 2.09). Since the size of the African 
cohort was restricted and we are dealing here with a relatively low frequency of the 
risk allele (2.2% in the African controls), making reliable association difficult to 
establish, we decided to extend our analysis by testing a second case-control cohort. 
Our second study comprised 1210 Dutch males, consisting of 335 HIV-1-seropositive 
patients and 875 non-infected controls. Intriguingly, a significant association of SNP 
Phe217Leu was found in this male cohort with an OR of 1.67 (χ2 = 3.86, df = 1, 
p =0.049; CI = 1.00-2.81) (table 1). All genotype distributions tested (cases and 
controls) fulfilled the Hardy-Weinberg criteria. 
Discussion
In this study, we found a higher prevalence of the APH1B Phe217Leu risk allele 
among HIV-1-infected individuals. The increase of the risk allele in the Xhosa ethnic 
group from South Africa barely failed to reach significant levels, probably due to the 
low number of individuals tested, whereas the increase of the risk allele as observed 
in the larger Caucasian study represented a statistically significant association. Since 
the first transmission from simian primates to humans (Gao et al., 1999), HIV-1 and 
HIV-2 have differentiated into several subtypes (McCutchan, 2006). These subtypes 
Genotype 
Frequencies (%)
Allele 
Frequencies (%)
n TT TG GG  T G p OR
South Africa
   HIV- 112 95.5 4.5 0 97.8 2.2
   HIV+ 198 90.4 9.1 0.5 94.9 5.1 0.087 2.33
The Netherlands
   HIV- 875 95.7 4.3 0 97.8 2.2
   HIV+ 335 92.8 7.2 0 96.4 3.6 0.049* 1.67
Table 1. Genotype and allele frequencies for the APH1B Phe217Leu variation in two case-control 
studies on susceptibility for HIV-1 infection
Standard Chi-square tests were applied to evaluate the association with HIV-1 infection. OR = odds 
ratio; *p<0.05.
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can be related to geographic areas, with HIV-1 subtype B predominating in Western 
Europe and HIV-1 subtype C in South Africa. Together with viral diversity, host 
genetic diversity has also proven to be an important factor contributing to HIV-1 
susceptibility. In this respect, one of the most relevant observations was the absence 
in the Xhosa population of the common Caucasian CCR5 32-base pair deletion 
mutation, known to be generally protective against HIV-1 infection and disease 
progression (Petersen et al., 2001). We thus conclude from our findings that the 
APH1B Phe217Leu polymorphism may be a susceptibility factor for HIV-1 infection 
in both Caucasian and African populations, and under the influence of different 
subtypes of HIV-1 infection (subtype B and subtype C infection, respectively). 
γ-Secretase and APH1B have not been considered before in relation to HIV-1 
infection. Interestingly, at least three γ-secretase substrates may be linked to the 
mechanism involved in HIV-1 infection, namely the substrates HLA-A2, CD43 and 
syndecan-3. HLA-A2 is a major histocompatibility complex class I protein involved 
in immune control of HIV-1 infection (reviewed by Carlson and Brumme, 2008), 
CD43 may lower the threshold necessary for HIV-1 viral replication and as such 
modulate HIV-1 progression (Barat and Tremblay, 2002), and syndecans may act as 
in trans HIV-1 receptors to allow HIV-1 pathogens to enter into host cells (Bobardt et 
al., 2003). Detailed studies are however necessary to unravel the pathological process 
in HIV-1-seropositive individuals carrying the APH1B Phe217Leu polymorphism. 
In this connection, it is important to note that transfection of the Leu217 variant 
of the APH1B protein into Aph-1abc-/- mouse embryonic fibroblasts resulted in a 
reduced γ-secretase cleavage activity towards syndecan-3, indicating that the APH1B 
Phe217Leu polymorphism represents a functional SNP (van Loo et al., 2008).
In conclusion, our results show that the Phe217Leu polymorphism in the APH1B gene 
has a higher prevalence among HIV-1 infected individuals, linking the γ-secretase 
pathway to susceptibility for HIV-1 infection.
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Abstract
A hallmark of the pathogenesis of Alzheimer’s disease (AD) is an affected γ-secretase 
pathway. The γ-secretase enzyme cleaves multiple transmembrane proteins involved 
in a variety of developmental processes. We have recently found that a functional non-
synonymous single-nucleotide polymorphism (SNP) in the γ-secretase component 
APH1B (Phe217Leu; rs1047552) is associated not only with AD but also with 
atherosclerosis, epilepsy and HIV-1 infection. We now find that this SNP associates 
with colorectal cancer as well. In addition, a higher prevalence of the risk allele 
was observed in patients with bipolar disorder, autism, attention deficit hyperactivity 
disorder, dyslexia, rheumatoid arthritis, celiac disease, throat cancer, prostate cancer 
and lung cancer. However, probably due to the low numbers of cases and the low 
frequency of the risk allele, these associations proved not to be statistically different 
from the respective controls. No higher prevalence of the risk allele was found for 
schizophrenia and depression. Based on our study, involving 7,062 patients and 5,872 
controls, we conclude that the γ-secretase pathway contributes not only to AD, but 
may also play a role in the pathogenesis of a number of other complex disorders. 
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Introduction
The γ-secretase enzyme complex is best known for its involvement in the sequential 
cleavage of amyloid-β precursor protein (APP) in the neurodegenerative disorder 
Alzheimer’s disease (AD). The complex consists of four different integral membrane 
proteins, namely presenilin (either presenilin 1 or presenilin 2), nicastrin, presenilin-
enhancer 2 and Aph1 (Fortini, 2002; Francis et al., 2002; Goutte et al., 2002; Kimberly 
and Wolfe, 2003). The enzyme is responsible for the proteolytic processing of a 
wide variety of type I transmembrane proteins, including APP and its relatives the 
APP-like proteins APLP1 and APLP2, Notch1-4, neuregulin, N- and E-cadherin, 
and ErbB4 (reviewed by Parks and Curtis, 2007). 
Recently, we observed a disturbed γ-secretase cleavage activity in a rat model with 
a complex phenotype (Coolen et al., 2005). The disturbance was caused by a gene-
dosage imbalance of the gene encoding the γ-secretase component Aph-1b. Whereas 
apomorphine unsusceptible (APO-UNSUS) rats harbour three copies of the Aph-
1b gene, their phenotypic counterparts (APO-SUS rats) have only one or two gene 
copies. Interestingly, the number of gene copies was associated with a number of 
phenotypic APO-SUS and -UNSUS characteristics (Coolen et al., 2005). 
Since the APO-SUS and -UNSUS rats display a complex phenotype (reviewed by 
Ellenbroek and Cools, 2002), affected γ-secretase activity may modulate a number of 
phenotypes and contribute to the pathogenesis of disorders with a complex aetiology. 
Association of a functional non-synonymous single-nucleotide polymorphism (SNP) 
in the human APH1B gene (rs1047552; Phe217Leu) has previously been found with 
AD (Poli et al., 2008), atherosclerosis (van Loo et al., 2008), epilepsy and HIV-1 
infection (chapters B2-B3). In the present study, we wondered whether the APH1B 
polymorphism may also contribute to the susceptibility of other complex disorders. 
Therefore, we searched in Caucasian case-control cohorts for association of the 
APH1B Phe217Leu variation with a number of disorders with a complex aetiology.
Materials and methods
Subjects
Schizophrenia 
Norway. The Norwegian study represented 324 Caucasian individuals and has been 
described previously (Birkenaes et al., 2007). Briefly, patients were recruited from 
the Oslo TOP (Thematic Organized Psychoses Research) Study, an ongoing study 
from the University and University Hospital of Oslo (Norway), and were selected 
according the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition 
(DSM-IV). Two senior clinicians continuously trained and supervised a group 
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of research fellows in order to secure the quality of the clinical assessments. The 
majority (90%) of the patients were ethnical Norwegian, i.e. the patient and both 
parents were born in Norway, while in a minor fraction of the cases (10%) one parent 
was born outside Norway in another North-western European country. Controls (n 
= 192) were randomly selected from statistical records of persons from the same 
catchments area as the patient groups. Only subjects born in Norway were contacted 
by letter and invited to participate. All controls were of Caucasian origin; about 
85 % had two Norwegian parents, the rest one parent from other European origin. 
Moreover, all participants had to have Norwegian as their first language or have 
received their compulsory schooling in Norway. The control subjects were screened 
by clinical interviews and with the Primary Care Evaluation of Mental Disorders 
(PRIME-MD). None of the control subjects had a history of moderate/severe head 
injury, neurological disorder, mental retardation or an age outside the range of 18-
60 years. Healthy subjects were excluded if they or any of their close relatives had 
a lifetime history of a severe psychiatric disorder (schizophrenia, bipolar disorder 
and major depression), a history of medical problems thought to interfere with brain 
function (hypothyroidism, uncontrolled hypertension and diabetes), or significant 
illicit drug use. All subjects had given written informed consent of participation and 
the study has been approved by The Norwegian Scientific-Ethical Committees and 
the Norwegian Data Protection Agency.
Sweden. The first Swedish cohort for schizophrenia (denoted as Sweden1) consisted 
of 220 schizophrenic patients and 281 non-psychiatric controls (all Caucasian 
individuals) selected from the northwestern part of Stockholm County (Gustavsson 
et al., 1999). Patients were recruited according to DSM-III-R. Control subjects were 
either re-examined healthy individuals, mainly staff and medical students, or subjects 
drawn from the general population for biological psychiatric studies performed at 
the Karolinska Institute. The study was approved by the Ethics Committee of the 
Karolinska Hospital. All subjects participated after giving informed consent. The 
second Swedish cohort for schizophrenia (Sweden2) was comprised of 450 unrelated 
SZ patients from the Northern part of Sweden (mean age at inclusion 53.1 ± 15.1). 
The individuals were thereafter examined at multiple time points, a majority up to 
the year 2005, by research psychiatrists and nurses. Relevant parts of semi-structured 
interview instrument i.e. the Mini-International Neuropsychiatric Interview-MINI 
(Sheehan et al., 1998), the Diagnostic Interview for Genetic Studies-DIGS (http://
zork.wustl.edu/nimh/home/m_DIGS2.0_Interview.html), the Family Interview for 
Genetic Studies-FIGS (http://zork.wustl.edu/nimh/home/FIGSInterview.html) and 
the Schedules for Clinical Assessment in Neuropsychiatry-SCAN (Wing et al., 
1990) were used when deemed necessary. The diagnoses were made according to 
the DSM-IV criteria. The mean age of disease-onset for the patients was 24.8 ± 
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7.3. The control individuals were randomly selected from the Betula project, a large 
population-based prospective study that is described in detail elsewhere (Nilsson et 
al., 1997). The random unrelated control population (n = 450; mean age at inclusion = 
58.0 ± 13.0) was recruited from the same geographical region of Northern Sweden as 
the patients. All control individuals and SZ patients were Caucasians and their mother 
tongue was Swedish. Participants were only included in the study after signing an 
informed consent, and the study was approved by the Medical Ethical Committees 
of the universities of Umeå and Antwerp. The association sample was controlled 
for population stratification by genotyping 37 microsatellite (STR) markers using 
standard genotyping and scoring methods. Statistical tests for population stratification 
were performed with the program STRUCTURE (http://pritch.bsd.uchicago.edu/
structure.html). No population substructure was observed in the association sample 
(data not shown).
Denmark. The Danish cohort consisted of 407 Caucasian schizophrenic patients and 
811 unrelated Caucasian controls. Patients were recruited to the Danish Psychiatric 
Biobank from the psychiatric departments at the six hospitals in the Copenhagen 
region, and were clinically diagnosed with schizophrenia or schizoaffective disorder 
according to ICD-10. An experienced research- and consultant psychiatrist verified 
high reliability of the clinical diagnoses using OPCRIT semi-structured interviews. 
The mean duration of hospitalization was 12.8 (± 8.6) years. The majority (87%) 
of the patients were ethnical Danish, i.e. the patients and both parents were born in 
Denmark, while in a minor fraction of the cases (13%) one parent was born outside 
Denmark in another North-western European country. The healthy control subjects 
were recruited among 15.000 blood-donors from the Danish Blood Donor Corps in 
the Copenhagen area. The Donor corps includes >5% of the Danish population who 
donate blood on a voluntary and unpaid basis. Apparent behavioural abnormality 
was an exclusion criterion and all individuals stated that they felt completely healthy 
with a possibility to discuss any health-related issues with a physician. Two unrelated 
healthy control subjects of Danish Caucasian origin were matched to each patient on 
gender, year of birth and month of birth. The study was approved by the Danish 
Scientific-Ethical Committees and the Danish Protection Agency. All patients had 
given written informed consent before inclusion into the project. 
The Netherlands. The Dutch group consisted of 335 schizophrenic patients recruited 
through mental health services and relatives’ support groups in the Netherlands 
(selected according DSM-IV) and 314 non-psychiatric Dutch controls. 
Belgium. The Belgium sample consisted of 515 schizophrenic patients and 246 
randomly selected controls from the same geographic region (Leuven, Belgium). 
Patients were selected according the DSM-IV criteria (schizophrenia: disorganized 
type (295.1): 10 patients; paranoid type (295.3): 213 patients; schizophreniform 
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disorder (295.4): 58 patients; residual type (295.6): 2 patients; schizoaffective 
disorder (295.7): 106 patients; undifferentiated type (295.9): 126 patients). 
USA. A total of 793 Caucasian individuals were derived from the PrecisionMed 
Sample Bank collection (San Diego, California, USA). Controls (n=300) had no 
(family) history of neuropsychiatric disease and were recruited from the same 
geographic region as the patients with schizophrenia (n=493). All subjects had given 
written informed consent of participation.
Bipolar disorder
The Norwegian cohort consisted of 116 Caucasian patients with bipolar disorder 
(recruited from the Oslo TOP Study described above) and 192 non-psychiatric 
Caucasian controls selected from statistical records of persons from the same area 
as the patient groups (see above). The Belgium cohort consisted of 60 Caucasian 
patients and 246 selected Caucasian controls from the same geographic region 
(Leuven, Belgium). Informed consent was obtained from all individuals.
Autism
The Belgium cohort consisted of 98 patients with autism and 246 randomly selected 
controls from the same geographic region (Leuven, Belgium). 
Attention deficit hyperactivity disorder (ADHD) and dyslexia
The Dutch neurodevelopmental group (ADHD and dyslexia) consisted of 84 patients 
with ADHD, 91 patients with dyslexia and 314 non-psychiatric Dutch controls.
Depression
For the depression cohort, 300 patients with depression and 300 controls with no 
(family) history of neuropsychiatric disease and recruited from the same geographic 
region as the patients were derived from the PrecisionMed Sample Bank collection 
(San Diego, California, USA). All subjects had given written informed consent of 
participation.
Rheumatoid arthritis
The Swedish cohort for rheumatoid arthritis consisted of 393 Caucasian sporadic 
rheumatoid arthritis patients and 424 Caucasian controls from the same geographical 
region (Umeå, Northern part of Sweden), matched for age, sex and area of residence. 
Informed consent of participation was obtained from all individuals.
Celiac disease
The Dutch case-control cohort for celiac disease consisted of 404 independent 
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celiac disease patients and 277 independent controls, all of Dutch Caucasian origin. 
Patients were diagnosed according to the ESPGHAN criteria and only patients with 
a biopsy-proven Marsh III lesion were included (Van Belzen et al., 2003). The study 
was approved by the Medical Ethics Committee of the University Medical Centre in 
Utrecht and informed consent was obtained from all individuals.
Cancer
The first Dutch cancer group (Nijmegen) consisted of 362 colorectal cancer (CRC) 
patients, 284 throat cancer patients and 591 Dutch controls. All subjects studied were 
Caucasians of Dutch origin. Cases were recruited at the University Medical Centre St 
Radboud (Nijmegen, The Netherlands) and were classified according to the location 
of the tumour. CRC patients have been described in more detail elsewhere (van der 
Logt et al., 2006). The control subjects were from the Dutch blood bank (Utrecht and 
Amsterdam). The study was approved by the local medical ethical review committee 
and all subjects gave their written informed consent. The second Dutch cancer group 
(Maastricht) consisted of 700 CRC patients and 1772 matched controls from The 
Netherlands Cohort Study on diet and cancer (NLCS), which has been described in 
detail elsewhere (van den Brandt et al., 1990; Brink et al., 2004). 
Subjects for the prostate cancer study were participants in the Melbourne and Perth 
arms of the Risk Factors for Prostate Cancer (RFPC) study, an Australian population-
based case-control study of prostate cancer conducted between 1994 and 1998 and 
described in detail elsewhere (Giles et al., 2001; Severi et al., 2003). 820 Patients 
with prostate cancer (histopathologically-confirmed adenocarcinoma of the prostate 
diagnosed before age 70 years) and 733 healthy controls (randomly selected from 
males on the State Electoral Rolls and matched to the age distribution of the prostate 
cancer cases) were included. 
For the lung cancer group, 798 patients with non-small cell lung carcinoma (NSCLC) 
were selected from patients treated at The Prince Charles Hospital (Brisbane, 
Australia) from 1980 to 2003 (Larsen et al., 2005, 2006). Controls consisted of 
healthy female smokers (n = 72) attending a smoking cessation clinic held at the 
hospital from 2000 to 2003 and male controls from the prostate study described 
above (n = 733). 
APH1B genotyping
Following the isolation of genomic DNA, APH1B Phe217Leu genotyping 
was performed via Taqman assays (Applied Biosystems, Foster City, CA, 
USA), denaturing gradient gel electrophoresis (DGGE) of PCR fragments or 
allele-specific PCR using primers specific for SNP rs1047552 (outer/general 
primers: forward: 5’-TGCCTTCTAGGGTTACCATCTGA-3’ and reverse: 
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5’-AGTCGGCTTTACACTGTCCCA-3’. Inner/specific primers: forward specific 
for the “T-allele”: 5’-AATAAACCTGGCGTCAGCATTT-3’ and reverse specific for 
the “G-allele”: 5’-GCCCATGAGCACCAGGATTATC-3’).
Statistical analysis
Genotype frequencies were tested for the Hardy-Weinberg equilibrium. Standard 
contingency table analysis using two-tailed χ2 test probabilities were used to compare 
allele frequencies between cases and controls. Odds ratios (95% confidence intervals 
(CI)) were calculated as an index of the association of the APH1B genotypes with 
the diseases (GraphPad Software Inc, San Diego, CA, USA). Heterogeneity between 
schizophrenia cohorts was assessed using Cochran’s Q statistic, and meta-analysis 
was performed using fixed-effects models (EasyMa2001). A p-value < 0.05 was 
considered statistically significant. 
Results
APH1B Phe217Leu polymorphism in schizophrenia
To examine a possible association between the APH1B Phe217Leu polymorphism and 
disorders with a complex aetiology, we first tested seven cohorts for susceptibility to 
schizophrenia (cohorts from Norway, Sweden (2 cohorts), Denmark, the Netherlands, 
Belgium and California, USA). The total sample comprised 2,552 individuals affected 
with schizophrenia and 2,594 controls (for a detailed description of the samples, see 
Materials and Methods). Despite a positive tendency in the initial screening of a 
small cohort in the early stages of the project, analysis of the seven case-control 
groups showed no statistically significant difference in any of the cohorts tested 
(table 1 and figure 1). In addition, a meta-analysis of the seven cohorts or simply 
pooling revealed no excess of the risk allele (meta-analysis: χ2 = 0.025, df = 1, p = 
0.87; common relative risk = 0.98; CI = 0.77-1.25; pooling: χ2 = 0.03, df = 1, p = 
0.86; odds ratio (OR) = 0.98; CI = 0.77-1.25).
APH1B Phe217Leu polymorphism in bipolar disorder
We then studied whether the Phe217Leu variation associates with bipolar disorder. 
First, we tested a bipolar disorder cohort from Norway (116 Caucasian patients with 
bipolar disorder and 192 Caucasian controls). The minor allele (G-allele) was more 
frequent in the bipolar disorder patients than in the control population, albeit not 
statistically different (χ2 = 0.55, df = 1, p = 0.55; OR for G-allele = 1.34; CI = 
0.52-3.43) (table 2). Our second sample comprised a Belgium case-control cohort 
consisting of 60 patients with bipolar disorder and 246 controls. Interestingly, 
allele frequencies were significantly different between the control population and 
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the bipolar disorder patients (χ2 = 5.45, df = 1, p = 0.041; OR = 2.86; CI = 1.14-
7.16), with a higher prevalence of the risk allele in the patients, as was seen in the 
Norwegian cohort. Pooling the Norwegian and Belgium samples showed a tendency 
for association (χ2 = 3.46, df = 1, p = 0.063; OR = 1.85; CI = 0.96-3.56) (table 2).
APH1B Phe217Leu polymorphism in autism, ADHD, dyslexia and depression
Next, we performed preliminary association studies on four other complex disorders, 
Genotype 
Frequencies (%)
Allele 
Frequencies (%)
n TT TG GG  T G HWE p OR
Norway
   Patients 132 93.9 5.3 0.8 96.6 3.4 0.025^ 0.55 1.32
   Controls 192 94.8 5.2 0 97.4 2.6 0.71
Sweden1
   Patients 220 91.8 8.2 0 95.9 4.1 0.53 0.66 1.16
   Controls 281 92.9 7.1 0 96.4 3.6 0.54
Sweden2
   Patients 450 94.9 4.9 0.2 97.3 2.7 0.22 0.88 1.05
   Controls 450 95.1 4.7 0.2 97.4 2.6 0.18
Denmark
   Patients 407 95.8 4.2 0 97.9 2.1 0.67 0.45 0.80
   Controls 811 94.9 4.9 0.1 97.4 2.6 0.53
The Netherlands
   Patients 335 97.0 2.7 0.3 98.4 1.6 0.0021^ 0.76 1.15
   Controls 314 97.1 2.9 0 98.6 1.4 0.80
Belgium
   Patients 515 96.5 3.5 0 98.3 1.7 0.69 0.36 0.71
   Controls 246 95.1 4.9 0 97.6 2.4 0.69
USA
   Patients 493 93.1 6.5 0.4 96.3 3.7 0.086 0.99 1.00
   Controls 300 92.6 7.3 0 96.3 3.7 0.51
Pooled
   Patients 2552 95.0 4.8 0.2 97.4 2.6 0.011^ 0.86 0.98
   Controls 2594 94.8 5.2 0.08 97.3 2.7 0.90
Table 1. Genotype and allele frequencies for APH1B Phe217Leu polymorphism in schizophrenia 
case-control studies 
Standard Chi-square tests were applied to evaluate the association with schizophrenia. HWE = Hardy-
Weinberg equilibrium; OR = odds ratio; ^ = deviation from Hardy-Weinberg (p<0.05).
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namely autism, ADHD, dyslexia and depression. For each disorder, one cohort was 
tested. Three of the four cohorts showed a higher prevalence of the risk allele in the 
patient populations (autism: OR = 2.15; ADHD: OR = 1.68; dyslexia: OR = 1.55), 
whereas the depression cohort displayed a lower prevalence of the risk allele in the 
patients (OR = 0.86). However, the cohorts consisted of only a limited number of 
patients and the associations were not statistically different (table 2). 
Genotype 
Frequencies (%)
Allele 
Frequencies (%)
n TT TG GG  T G HWE p OR
Bipolar disorder
Norway
   Patients 116 93.1 6.9 0 96.6 3.4 0.70 0.55 1.34
   Controls 192 94.8 5.2 0 97.4 2.6 0.71
Belgium
   Patients 60 86.7 13.3 0 93.3 6.7 0.58 0.041* 2.86
   Controls 246 95.1 4.9 0 97.6 2.4 0.69
Pooled
   Patients 176 90.9 9.1 0 95.5 4.5 0.53 0.063 1.85
   Controls 438 95.0 5.0 0 97.5 2.5 0.59
Autism (Neth.)
   Patients 98 90.8 8.2 1.0 94.9 5.1 0.12 0.073 2.15
   Controls 246 95.1 4.9 0 97.6 2.4 0.69
ADHD (Neth.)
   Patients 84 95.2 4.8 0 97.6 2.4 0.82 0.50 1.68
   Controls 314 97.1 2.9 0 98.6 1.4 0.80
Dyslexia (Neth.)
   Patients 91 95.6 4.4 0 97.8 2.2 0.83 0.51 1.55
   Controls 314 97.1 2.9 0 98.6 1.4 0.80
Depression (USA)
   Patients 300 93.7 6.3 0 96.8 3.2 0.57 0.63 0.86
   Controls 300 92.6 7.3 0 96.3 3.7 0.51
Table 2. Genotype and allele frequencies for APH1B Phe217Leu polymorphism in bipolar disorder, 
autism, ADHD, dyslexia and depression case-control studies 
Standard Chi-square tests were applied to evaluate the association with bipolar disorder, autism, 
ADHD, dyslexia and depression. HWE = Hardy-Weinberg equilibrium; OR = odds ratio; * = p<0.05.
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APH1B Phe217Leu polymorphism in rheumatoid arthritis
To examine a possible association between the APH1B polymorphism and 
rheumatoid arthritis, we tested a Swedish case-control cohort consisting of 393 
sporadic rheumatoid arthritis patients and 424 matched controls. Interestingly, the 
risk allele was more frequent in the rheumatoid arthritis patients than in the control 
population (2.3% and 1.8%, respectively), but not statistically different (χ2 = 0.56, df 
= 1, p = 0.45; OR = 1.30; CI = 0.65-2.60).
APH1B Phe217Leu polymorphism in celiac disease
We then tested whether the APH1B Phe217Leu polymorphism may also contribute 
to the autoimmune disorder celiac disease. We therefore tested a Dutch case-control 
cohort consisting of 404 patients with celiac disease and 277 controls. The results 
showed a higher prevalence of the risk allele in the celiac disease patients, but no 
significance was reached (χ2 = 0.55, df = 1, p = 0.46; OR = 1.38; CI = 0.59-3.24).
APH1B Phe217Leu polymorphism in cancer 
To explore a possible association of the APH1B genetic variation with cancer, we 
first tested a Dutch cohort for CRC, consisting of 362 CRC patients and 591 controls. 
Interestingly, allele frequencies were significantly different between the Dutch CRC 
patients and the control population (χ2 = 9.44, df = 1, p = 0.0021; OR = 2.55; CI 
= 1.38-4.74), with a higher prevalence of the risk allele in the patients (table 3). 
Next, we decided to screen a second Dutch cohort for CRC. This second cohort 
also showed a higher frequency of the risk allele, albeit not statistically different 
(χ2 = 0.83, df = 1, p = 0.36; OR = 1.20; CI = 0.81-1.80). Pooling the CRC samples 
(1062 Dutch individuals with CRC and 2363 Dutch controls) revealed a significant 
association (χ2 = 5.99, df = 1, p = 0.014; OR = 1.50; CI = 1.08-2.07) (table 3). 
Finally, we tested the hypothesis that the genetic variation also contributes to the 
pathogenesis of other cancers, including throat, prostate and lung cancer. For each 
of the cancers, one cohort was examined. Interestingly, all three cohorts showed 
a higher prevalence of the risk allele in the cancer populations (throat cancer: OR 
= 1.86; prostate cancer: OR = 1.21; lung cancer: OR = 1.13), but the associations 
proved not to be statistically different (table 3). 
Discussion
The tetrameric γ-secretase enzyme complex displays intramembrane proteolysis of 
more than 30 type I transmembrane proteins that play a role in a large variety of 
signalling pathways (reviewed by Boulton et al., 2008). Recently, we found substrate-
specific alterations in γ-secretase cleavage activity in rats with a complex phenotype, 
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the so-called APO-SUS rats. The affected γ-secretase cleavage activity was caused 
by a gene-dosage imbalance of the Aph-1b gene (Coolen et al., 2005; Coolen et 
al., 2006). Furthermore, we found substrate-specific alterations in γ-secretase 
cleavage activity for a variation in human APH1B. Presence of a leucine instead of 
a phenylalanine at position 217 of the human APH1B protein resulted in a reduced 
cleavage of syndecan-3, whereas cleavage of APP and N-cadherin were unaffected 
(van Loo et al., 2008). Interestingly, this polymorphism was associated with AD, 
epilepsy, atherosclerosis and HIV-1 infection (Poli et al., 2008, van Loo et al., 2008, 
chapters B2-B3). We now find a higher prevalence of the APH1B risk allele in a 
number of complex disorders (figure 1). 
Genotype 
Frequencies (%)
Allele 
Frequencies (%)
n TT TG  T G HWE p OR
Colorectal cancer
Nijmegen (Neth.)
   Patients 362 93.4 6.1 0.6 96.4 3.6 0.020^ 0.0021** 2.55
   Controls 591 97.1 2.9 0 98.6 1.4 0.72
Maastricht
   Patients 700 95.1 4.6 0.3 97.4 2.6 0.020^ 0.36 1.20
   Controls 1772 95.7 4.3 0 97.9 2.1 0.36
Pooled
   Patients 1062 94.5 5.1 0.4 97.1 2.9 0.0008^ 0.014* 1.50
   Controls 2363 96.1 3.9 0 98.0 2.0 0.33
Throat cancer (Neth.)
   Patients 284 94.7 5.3 0 97.4 2.6 0.65 0.079 1.86
   Controls 591 97.1 2.9 0 98.6 1.4 0.72
Prostate cancer (Aus.)
   Patients 820 93.9 6.0 0.1 96.9 3.1 0.81 0.39 1.21
   Controls 733 95.2 4.4 0.4 97.4 2.6 0.0002^
Lung cancer (Aus.)
   Patients 798 94.2 5.6 0.1 97.1 2.9 0.70 0.56 1.13
   Controls 805 95.2 4.5 0.4 97.4 2.6 0.0007^
Table 3. Genotype and allele frequencies for APH1B Phe217Leu polymorphism in cancer case-
control studies 
Standard Chi-square tests were applied to evaluate the association with cancer. HWE = Hardy-
Weinberg equilibrium; OR = odds ratio; * = p<0.05; ** = p<0.01; ^  = deviation from Hardy-Weinberg 
(p<0.05).
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Although the presence of the Leu217 allele was enriched in patients with bipolar 
disorder, autism, ADHD and dyslexia, no higher occurrence of the risk allele was 
found for schizophrenia and depression, two other neurodevelopmental disorders 
with a complex aetiology. Yet, the identification of genetic susceptibility factors 
for neurodevelopmental disorders is complicated, especially when considering 
the complex interactions of such factors with the environment, the relatively low 
frequency of the risk allele and heterogeneity within the samples (reviewed by van 
Loo and Martens, 2007). More extensive analyses based on clinical subtypes and 
endophenotypically defined patients are necessary for a more definitive conclusion. 
Intriguingly, analysis of the four cancer subtypes showed a higher frequency of 
the Leu217 allele in all patient groups when compared to their healthy controls, 
but significant association was found only for CRC. At least six of the γ-secretase 
substrates, namely deleted in colorectal cancer (DCC), Notch, Ephrin-B2, growth 
hormone receptor (GHR), tyrosinase-related protein-2 (TYRP2) and human leucocyte 
antigen-A2 (HLA-A2), appear to be involved in the development of intestinal fate 
and CRC. DCC is located on chromosome 18q, a locus affected by allelic losses in 
almost 70% of all CRC cases (Vogelstein et al., 1988). Furthermore, DCC expression 
was often reduced or even absent in tissues from patients with colorectal cancer 
Figure 1. Odds ratios for the association between the risk allele of the APH1B Phe217Leu polymorphism 
and a number of complex disorders. Indicated are individual odds ratio (OR) estimates for schizophrenia, 
bipolar disorder (BD), autism, ADHD, dyslexia, depression, rheumatoid arthritis (RA), celiac disease 
(CD), colorectal cancer (CRC), throat cancer (Thr-ca), prostate cancer (Pr-ca) and lung cancer (Lu-
ca). Vertical lines represent 95% confidence intervals (CIs); *p <0.05.  
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(Fearon et al., 1990; Itoh et al., 1993) and was consequently proposed as a putative 
tumor suppressor gene (Tanaka et al., 1991). The Notch cascade plays a central role in 
developmental processes, controls many cell fate decisions and represents a pathway 
that regulates intestinal homeostasis (Stanger et al., 2005; van Es and Clevers, 2005). 
Multiple Notch cascade components are expressed in intestinal tissue, including the 
transcription factor gene Hath1 (Artavanis-Tsakonas et al., 1999). Studies on Hath1 
have revealed a strong decrease in its expression in colon tumor tissues (Leow et 
al., 2005). Furthermore, expression analyses of colon carcinoma samples and 
normal mucous tissue have shown a higher expression of the γ-secretase substrates 
Ephrin-B2, GHR and TYRP2 (Liu et al., 2002; Yang et al., 2004; Ying-Tao et al., 
2005), whereas expression of the substrate HLA-A2 was lost in a subset of colorectal 
carcinomas (Rees et al., 1988). These data thus imply that the γ-secretase pathway 
may represent a predisposition pathway for CRC susceptibility.
No significant association of the APH1B polymorphism was found with throat, prostate 
and lung cancer, the other three cancer subtypes studied. Nevertheless, all cohorts 
showed a higher prevalence of the risk allele in the patients, pointing to a disturbed 
regulation of a common signalling pathway involved in cancer pathogenesis. More 
detailed analyses in additional cancer case-control cohorts will learn whether the 
APH1B Phe217Leu polymorphism is indeed a risk factor for a wide variety of cancer 
subtypes. 
Besides cancer and a number of neurodevelopmental disorders, also patients with 
rheumatoid arthritis and celiac disease had a higher prevalence of the Phe217Leu risk 
allele compared to their control populations. Rheumatoid arthritis and celiac disease 
are autoimmune diseases in which both genetic and environmental factors may play 
a role. As in other diseases with a complex aetiology, the genetic component of the 
two diseases is largely undefined. Our results may imply that APH1B constitutes 
a novel susceptibility gene for autoimmune disorders. Furthermore, celiac disease 
patients sometimes show neurological complications, such as epileptic seizures, and 
are thought to share predisposition factors for epilepsy (Gobbi, 2005; Grossman, 
2008). Since we previously found association of the Phe217Leu allele with epilepsy 
(chapter B2) and we now find a higher prevalence of the Leu217 allele in celiac 
disease patients, we conclude that the Phe217Leu polymorphism may interfere with 
common signalling pathways for both epilepsy and celiac disease. 
Since of the eleven disorders with a complex aetiology nine showed a higher 
prevalence of the APH1B Leu217 allele in the patients compared to the healthy 
control populations, together our data suggest that the risk allele may increase the 
susceptibility for developing multiple complex disorders. If indeed true, collecting a 
proper control group for studying this SNP will be challenging, because the chances 
are high that a considerable number of individuals carrying the SNP will not be free 
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of disease. Thus, the control risk allele frequencies we found may in fact constitute 
an overrepresentation. 
In conclusion, the Phe217Leu polymorphism in the human APH1B gene may 
constitute a risk factor for the pathogenesis of a wide variety of disorders with a 
complex aetiology. 
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Disorders with a complex aetiology, including neurodevelopmental disorders, are 
thought to result from a combination of genetic and environmental factors. Although 
many genes and pathways have been suggested to be linked to disorders with a 
complex aetiology, the identities of the causal genes are mostly still unknown. The 
aim of the research described in this thesis was to provide a contribution to a better 
understanding of the genes and pathways involved in the pathogenesis of complex 
disorders, especially the neurodevelopmental disorders. To get a better insight into 
the genetic causes, we initially used the APO-SUS/-UNSUS rat model with features 
reminiscent of complex phenotypes and subsequently employed human case-control 
cohorts in genetic association analyses. In the following paragraphs, the major 
findings of these studies are discussed and placed into a broader context. 
APO-SUS and –UNSUS rats and the Aph-1b locus
The APO-SUS/-UNSUS rats constitute an animal model with a complex phenotype, 
including features that are similar to those seen in patients with schizophrenia 
(Ellenbroek and Cools, 2002). Microarray analysis (mRNA expression profiling) 
of brain regions from APO-SUS and –UNSUS rats revealed only one reproducible 
difference between the two rat lines (chapter A1); APO-SUS rats exhibit lower 
Aph-1b mRNA levels when compared to those in APO-UNSUS rats. Interestingly, 
the difference in Aph-1b mRNA expression level was found in both the original 
APO-SUS/-UNSUS rat lines (breeding started in 1985) and the replicate APO-SUS/-
UNSUS lines (started in 1995). The two breeding lines showed a similar distribution 
of the Aph-1b genotypes: three gene copies in APO-UNSUS rats and one or two gene 
copies in APO-SUS rats, indicating that the pharmacological selection that was used 
to establish the APO-SUS and –UNSUS lines had resulted in a similar genotypic 
distribution in both the original and replicate lines. 
Along with single-nucleotide polymorphisms (SNPs), such differences in gene copy 
number (copy number variations; CNVs) are considered key genetic variations 
contributing to phenotypic variation, complex traits and disease. Mainly during the 
last decade, a number of CNVs have been identified that affect expression levels of 
genes critical for normal development and consequently are responsible for abnormal 
behavioural phenotypes. For example, a microdeletion of ~1.6 Mb on chromosome 
7q11.23 results in Williams-Beuren syndrome (OMIM# 194050); a ~4 Mb deletion 
on chromosome 15q11-q13 in Angelman (OMIM# 105830) or Prader-Willi syndrome 
(OMIM# 176270); and deletion of 22q11.2 causes DiGeorge (OMIM# 188400) or 
velo-cardio-facial syndrome (OMIM# 192430).
Detailed genomic analysis of the rat Aph-1b locus (on chromosome 8q24) revealed 
a segmental duplication (also referred to as low-copy repeat) within the Aph-1b 
region, creating a genomic architectural structure favourable for rearrangements. 
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Rearrangements (duplication, deletions and inversions) especially occur if segmental 
duplications (i) are > 10 kb in size, (ii) have a >97% sequence identity, (iii) are 
oriented in the same direction and (iv) are within 5 Mb of each other (Lupski, 1998). 
Since the rat Aph-1b gene copies each span ~20 kb, have a high degree of identity 
surrounding exon 5 (> 98.2% identity over 2377 nucleotides), are oriented in the 
same direction and are separated by only ~24 kb, the Aph-1b locus in the rat is 
susceptible to rearrangement events.
Normal Wistar rats from the Nijmegen outbred population (the original rat source 
used for the APO-SUS/-UNSUS breeding) have three copies of the Aph-1b gene 
(chapter A4). Hence, the reduction in copy number in the APO-SUS rats in both 
original and replicate lines was likely induced during breeding of the rat lines. 
Such a genomic rearrangement could have been caused by the injection of the rats 
with the dopamine receptor agonist apomorphine. For the generation of the APO-
SUS/-UNSUS lines, this compound was used to select Wistar rats with a low and 
high apomorphine susceptibility. Apomorphine and, more specifically, its oxidation 
derivative 8-oxo-apomorphine-semiquinone (8-OASQ), have been found to induce 
cytotoxic and genotoxic effects, including oxidative DNA damage and frameshift 
mutations (Moreira et al., 2003; Picada et al., 2003b; Picada et al., 2003a). By 
injecting the rats with this neurotoxic compound, the rearrangement event might 
have been triggered, leading to rats with reduced Aph-1b copies. To test whether 
the Aph-1b recombination event can indeed be induced by apomorphine, Wistar rats 
with a low and a high apomorphine susceptibility (all harbouring three copies of the 
Aph-1b gene) were injected with oxidized apomorphine for five consecutive days 
(1.5 mg/kg s.c.). A reduction in Aph-1b copy number was observed in the offspring 
of parents with high as well as parents with low apomorphine susceptibilities 
(data not shown). Thus, the Aph-1b recombination event can indeed be induced by 
oxidized apomorphine and appears to be independent of the degree of apomorphine 
susceptibility of the rats. 
The apomorphine-induced recombination event in the Aph-1b locus suggests that 
other genomic regions could also be affected by (oxidized) apomorphine injections. 
Preliminary analysis of the genomes of the offspring of the apomorphine-injected 
rats showed two other genomic regions to be affected by the apomorphine injections 
(a CNV locus located within the Ncam2 gene and a CNV locus located within the 
Spna1 gene; for localisation of the CNVs, see chapter A5). It would be of interest 
to investigate whether a consensus sequence is shared by these genomic regions. 
Such a consensus may represent a hot spot for apomorphine-induced genomic 
rearrangements. Of note is the fact that subcutaneous injections of apomorphine are 
also performed in humans (for example for the treatment of Parkinson’s disease and 
erectile dysfunction), even upto 200 mg/day (=2.5 mg/kg based on an individual 
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of ~80 kg). It is thus worthwhile to further investigate the effect of (oxidized) 
apomorphine on human genome stability.
Is Aph-1b the only causative factor of the complex APO-SUS phenotype? 
If the gene-dosage imbalance of the Aph-1b gene is the only causative factor for 
the phenotypical differences between the APO-SUS and –UNSUS rats, the number 
of Aph-1b gene copies (1, 2 or 3) should segregate with the APO-SUS/-UNSUS 
characteristics. Chapter A1 indeed shows a gene-dosage effect for some APO-
SUS/-UNSUS-related features (e.g. locomotor activity in the open field and open 
arm entries in the elevated plus maze). Yet, for a detailed gene-dosage dependency 
of the complex phenotypical features, crossbreeding experiments are necessary, 
such that the genetic background of the APO-SUS and –UNSUS rats is first mixed 
and subsequently reselected for the Aph-1b genotypes. If, following crossbreeding, 
the number of Aph-1b gene copies is still linked to the APO-SUS/-UNSUS-specific 
features, Aph-1b should be considered the causal factor of the complex APO-SUS 
phenotype.
As described in chapter A2, APO-SUS rats with one copy of the Aph-1b gene (I/I) 
were crossed with APO-UNSUS rats with three copies (III/III). Using a reselection 
procedure based on the Aph-1b genotypes, animals were obtained with a genetically 
identical background, except for the Aph-1b locus (termed Aph-1b I/I and Aph-1b 
III/III rats). Analysis of the apomorphine susceptibility of the Aph-1b I/I and III/III 
rats showed in both rat lines individuals with low and high gnawing scores (figure 
1). If the number of Aph-1b gene copies would be responsible for the apomorphine 
susceptibility, Aph-1b I/I rats should have shown gnawing scores as observed in 
APO-SUS rats (>500 counts/45 min) and Aph-1b III/III rats as seen in APO-UNSUS 
rats (<10 counts/45 min). Since we now find individuals with low and high gnawing 
scores in both the Aph-1b I/I and III/III lines, we conclude that the number of Aph-1b 
gene copies is not directly linked to apomorphine susceptibility. In addition, analysis 
of the Aph-1b I/I and III/III rats for their exploratory behaviour on the open field and 
elevated plus maze also failed to show a correlation with the number of Aph-1b gene 
copies (data not shown). Since apomorphine susceptibility and exploratory behaviour 
represent two phenotypes that are different between APO-SUS and -UNSUS rats, 
Aph-1b is likely not the only genetic factor determining the difference between the 
two rat lines. Nevertheless, these data do not exclude the possibility that an interplay 
of Aph-1b with some other (epi)genetic factor is responsible for the characteristics 
seen in the APO-SUS/-UNSUS model. Such a factor would then have been mixed 
among the various rats during the crossbreeding of the animals. 
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Other genetic variations in APO-SUS and –UNSUS rats 
Our recent experiments thus suggest that the Aph-1b gene-dosage imbalance is not 
solely responsible for the complex APO-SUS phenotype. As shown in chapters 
A4 and A5 more genetic and also epigenetic variations are present between the 
APO-SUS and –UNSUS rats, with similar (epi)genetic distributions in both the 
original and replicate lines. We observed at least five additional genetic variations 
(chapter A4), one epigenetic variation (chapter A4) and eight CNVs (CNVs 
located on chromosomes 1, 5, 10, 11 and 17; chapter A5) between the APO-SUS 
and –UNSUS (epi)genomes. Since rat CNVs have been found to overlap with CNV 
regions in human (Guryev et al., 2008), our findings may well be of significance for 
understanding complex human disorders.
Preliminary SNP analysis of the genomes of the replicate APO-SUS and –UNSUS 
rat lines (sequencing analysis of ~288.000 bp per rat genome) showed that in the 
coding regions of the APO-SUS and –UNSUS genomes one SNP exists in every 
~7 kb (in collaboration with Prof. Dr. E. Cuppen, Hubrecht Institute, Utrecht, The 
Netherlands; data not shown). When analysing also the non-coding regions, an even 
higher SNP frequency would probably be observed. Given the fact that approximately 
2.75 billion base pairs constitute the rat genome (Gibbs et al., 2004), the genomes 
of APO-SUS and –UNSUS rats are expected to contain at least 400.000 SNPs. In 
general, it appears that two individuals from the Wistar population are genetically 
closer than APO-SUS and –UNSUS rats.  
A number of the (epi)genetic variations (SNPs, CNVs and DNA methylation 
variations) may thus contribute to the phenotypical differences observed between 
APO-SUS and –UNSUS rats. For a better understanding of the significance of any 
Figure 1. Distribution of the gnawing scores in Aph-1b III/III and Aph-1b I/I rats following 1.5 mg/kg 
apomorphine injection (s.c.). The percentages of animals are scored based on the gnawing counts per 
45 minutes: 0-10, 11-100, 101-500 and more than 500 times.
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of the genetic differences in the complex APO-SUS phenotype, it may be helpful to 
analyse the (epi)genetic variations in phenotypically well-defined Wistar rats (e.g. 
Wistar rats with known apomorphine susceptibility levels, locomotor activity in the 
open field and open arm entries in the elevated plus maze). If a (epi)genetic variation 
is found to be associated with any of the traits, then this (epi)genetic variation should 
be considered a factor presumably involved in the complex APO-SUS phenotype. For 
a more definitive link between any of the (epi)genetic differences and the complex 
APO-SUS phenotype, it will also be necessary to perform crossbreeding experiments, 
with a subsequent reselection for the (epi)genetic variation, similar as we have been 
performing for the Aph-1b gene-dosage imbalance. Detailed phenotypical analysis 
of the new lines will be necessary to understand the functional consequence of the 
(epi)genetic variation. The complex APO-SUS phenotype may also be the result of 
multiple genetic alterations instead of only a single-gene variation. Therefore it might 
be interesting to examine whether combinations of genetic variations (SNPs, CNVs 
and DNA methylation variations) are linked to the complex APO-SUS phenotype.
Despite the fact that many genetic variations were found between the APO-SUS and 
–UNSUS rats (chapters A4 and A5), only one reproducible difference at the mRNA 
expression level was observed when comparing the gene expression profiles of the 
two rat lines (chapter A1). A number of possibilities may explain this surprising 
situation. First, at that time, only one third of all gene transcripts were represented on 
the microarrays. Moreover, the detection sensitivity of the arrays was rather limited. 
To allow detection above background, mRNA expression differences of at least 
~1.4-fold were necessary. Hence, additional APO-SUS/-UNSUS-specific mRNA 
expression differences may have been missed because they represented only small 
expression differences or the corresponding gene transcripts were not represented 
on the arrays. Application of one of the currently available microarray platforms 
with most genes represented and with a relatively high resolution may lead to the 
identification of new genes and pathways that underlie the differences in the APO-
SUS/-UNSUS phenotypes.  
Second, in our microarray analysis hippocampal tissue was used. The hippocampus 
is a relatively large structure with many different cell types. By analysing the whole 
hippocampus one may thus not detect an expression difference that is present in 
only a subset of cells. Isolation of a specific hippocampal region consisting of a 
smaller subset of cells (e.g. CA1, CA3 or dentate gyrus) may increase the chances 
of finding APO-SUS/-UNSUS-specific differences. Furthermore, analysis of brain 
regions other than the hippocampus (e.g prefrontal cortex, nucleus accumbens 
(ventral striatum), caudate-putamen (dorsal striatum), amygdala, ventral tegmental 
area, substantia nigra pars compacta and hypothalamus) may give new insights into 
the genes and pathways linked to the complex APO-SUS phenotype. 
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Third, brain tissues from postnatal day 9 and 60 rats were used. Future studies may 
include mRNA expression profiling in other, including earlier, developmental stages. 
Histopathological findings in schizophrenia patients, such as dilation of the lateral 
ventricles (Johnstone et al., 1976), a decreased brain weight, length and volume 
(Brown et al., 1986; Pakkenberg, 1987; Bruton et al., 1990), a decreased volume 
of the thalamus (Pakkenberg, 1990) and enlarged basal ganglia (Heckers et al., 
1991), are thought to arise early in development. Thus, the causal processes for 
schizophrenia pathogenesis are present long before the diagnosis is actually made. 
Such a neurodevelopmental hypothesis for the background of complex disorders 
would therefore ask for analysis of embryonic stages rather than of time points later 
in life. Future spatial and temporal expression analysis may reveal whether additional 
mRNA expression differences exist and whether they have a functional contribution 
to the APO-SUS/-UNSUS-specific features. 
The human APH1B gene and complex human disorders 
In contrast to rodents, humans have only one copy of the APH1B gene (located 
on chromosome 15q22.2), so an unequal crossing-over event of the APH1B gene 
cannot occur. Preliminary Southern blot analysis of schizophrenic patients and 
healthy controls did not reveal any duplications, deletions or rearrangements within 
the APH1B locus (data not shown). Interestingly, BLAST analyses revealed the 
presence of exons 1, 5 and 6 of the APH1B gene (without any intronic sequences) 
on chromosome 7q21.11. This chromosomal region may be considered a so-called 
processed pseudogene likely derived from alternatively spliced APH1B mRNA that 
was subsequently reverse transcribed and inserted into the nuclear genome. Although 
the biological effect of pseudogenes is still unclear, it has been shown that at least 
20% of the pseudogenes is transcribed (either by using its own promoter or by using 
the promoter of a nearby gene) (Zheng et al., 2007). In addition, pseudogenes have 
been found to regulate the expression of its homologues (Hirotsune et al., 2003). To 
explore if the APH1B pseudogene regulates the expression of the intact APH1B on 
chromosome 15, future studies on this pseudogene in both patients and controls are 
warranted (e.g. expression analysis and mutation analysis). 
Besides a gene-dosage imbalance as seen in the rat, other variations could influence 
APH1B mRNA and protein expression levels as well, such as small insertions and 
deletions, SNPs, mutations and also epigenetic alterations. In the human APH1B 
gene (including the 5’- and 3’-untranslated regions (UTRs)), 151 SNPs have been 
identified (based on NCBI SNP database). Non-synonymous SNPs that lead to 
an amino acid change are of special interest, since a considerable amount of non-
synonymous SNPs have been linked to human diseases (Krawczak et al., 2000). To 
date, in the commonly used SNP databases (NCBI, Ensembl and HapMap databases) 
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only one non-synonymous APH1B SNP (Phe217Leu; rs1047552) has been recorded 
as being validated (by multiple independent submissions to the refSNP cluster).
The Phe217Leu polymorphism was found to be a risk factor for premature coronary 
atherosclerosis (chapter B1), epilepsy (chapter B2), HIV-1 infection (chapter B3), 
colorectal cancer (chapter B4) and Alzheimer’s disease (AD) (Poli et al., 2003; 
Poli et al., 2008). In addition, of the eleven additional complex disorders examined 
nine showed a higher prevalence of the risk allele in the patients compared to the 
healthy control populations (chapter B4 and table 1), which is higher than expected 
by chance. 
Interestingly, some of the human disorders showing a significant association with 
the Phe217Leu SNP had phenotypical traits similar to those found in the APO-
SUS/-UNSUS model (table 2): (i) APO-SUS rats display an increased incidence 
of bursts of bilateral synchronous spike wave discharges (de Bruin et al., 2000), 
as can be seen in patients with epilepsy (Hughes and Fino, 2004), (ii) APO-SUS 
rats display an impaired vasorelaxation to adrenergic stimuli, increasing the risk 
for the development of hypertension and vascular diseases such as atherosclerosis 
(Smits et al., 2002; Riksen et al., 2003), and (iii) APO-SUS rats display a stronger T 
helper 2 (Th2)-dependent IgE response upon worm infection, a lower Th1-mediated 
autoimmune encephalomyelitis response and, like in patients with HIV-1 infection, a 
disturbed Th1/Th2 balance (Kavelaars et al., 1997). Thus, a subtle effect on APH1B 
expression or function (Aph-1b copy number variation in rat or APH1B Phe217Leu 
variation in human, respectively) may be involved in a number of complex traits and 
diseases (figure 2).
γ-Secretase signalling in complex disorders  
Together with its paralogue Aph-1a, Aph-1b is part of the γ-secretase enzyme 
complex. Aph-1 (either Aph-1a or -1b) can form with presenilin (either PS1 or PS2), 
nicastrin and presenilin enhancer 2 (Pen2) a functional γ-secretase enzyme complex 
that can cleave many type I transmembrane proteins within their membrane domain. 
Upon cleavage, the active cytoplasmic domains can (i) travel to the nucleus where 
they may regulate gene expression (Okamoto et al., 2001; LaVoie and Selkoe, 2003; 
Marambaud et al., 2003) or (ii) bind to their partners in the cytoplasm to exert their 
specific functions (Schulz et al., 2003). As reviewed recently, at least 30 γ-secretase 
substrates have been identified; amyloid-β (Aβ) precursor protein (APP), Aβ 
precursor-like protein 1 and 2 (APLP1 and APLP2), low density lipoprotein-related 
protein 1, 2 and 8 (LRP1, LRP2 (Megalin) and LRP8 (APOER2)), N- and E-cadherin, 
γ-Protocadherin, Notch1-4 and the ligands Delta1 and Jagged, Neuregulin-1 and 
-2 (NRG1 and 2), ErbB4, Sialophorin (CD43), CD44, colony stimulating factor 
1 (CSF1), deleted in colorectal carcinoma (DCC),  Ephrin-B1 and -B2, growth 
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Disorder Country
MAF
controls 
(%)
MAF
patients
(%)
OR p RR
↑ or ↓
Neurodevelopmental disorders
Schizophrenia Norway 2.6 3.4 1.32 0.55 ↑
Schizophrenia Sweden 3.6 4.1 1.16 0.66 ↑
Schizophrenia Sweden 2.6 2.7 1.05 0.88 ↑
Schizophrenia Denmark 2.6 2.1 0.80 0.45 ↓
Schizophrenia The Netherlands 1.4 1.6 1.15 0.76 ↑
Schizophrenia Belgium 2.4 1.7 0.71 0.36 ↓
Schizophrenia USA 3.7 3.7 1.00 0.99 =
Epilepsy The Netherlands 1.4 3.4 2.42 0.048 ↑
Epilepsy UK 2.4 2.9 1.19 0.65 ↑
Bipolar disorder Norway 2.6 3.4 1.34 0.55 ↑
Bipolar disorder Belgium 2.4 6.7 2.86 0.041 ↑
Autism Belgium 2.4 5.1 2.15 0.073 ↑
ADHD The Netherlands 1.4 2.4 1.68 0.50 ↑
Dyslexia The Netherlands 1.4 2.2 1.55 0.51 ↑
Depression USA 3.7 3.2 0.86 0.63 ↓
Cancer
Colorectal cancer The Netherlands 1.4 3.6 2.55 0.0021 ↑
Colorectal cancer The Netherlands 2.1 2.6 1.20 0.36 ↑
Throat cancer The Netherlands 1.4 2.6 1.86 0.079 ↑
Prostate cancer Australia 2.6 3.1 1.21 0.39 ↑
Lung cancer Australia 2.6 2.9 1.13 0.56 ↑
Other complex diseases
Premature atherosclerosis The Netherlands 2.0 2.7 1.35 0.15 ↑
HIV-1 infection The Netherlands 2.2 3.6 1.67 0.049 ↑
HIV-1 infection South Africa 2.2 5.1 2.33 0.087 ↑
Rheumatoid arthritis Sweden 1.8 2.3 1.30 0.45 ↑
Celiac disease The Netherlands 1.4 2.0 1.38 0.46 ↑
Alzheimer’s disease* Italy 1.4 3.2 2.34 0.01 ↑
MAF = minor allele frequency; OR = odds ratio; RR = relative risk; * = Poli et al., 2008.
Table 1. APH1B Phe217Leu variation in a number of diseases with a complex aetiology
hormone receptor (GHR), glutamate receptor 3 (GluR3), human leucocyte antigen-A2 
(HLA-A2), Nectin-1α, neurotrophin receptor associated death domain (NRADD), 
nerve growth factor receptor (p75NTR), sodium channel, voltage-gated, type II, beta 
197
General discussion
(Scnb2), Alcadein α-γ, Syndecan-3, Tyrosinase (TYR) and tyrosinase-related protein 
1 and 2 (TYRP1 and TYRP2) (Kopan and Ilagan, 2004; Parks and Curtis, 2007). 
Because for most γ-secretase substrates the biological relevance of intramembrane 
cleavage is still unclear, most cellular roles that are fulfilled by γ-secretase are not 
yet understood. Nevertheless, it is clear that with every new substrate discovered, the 
physiological relevance of the γ-secretase complex widens.
Figure 2. Model of affected γ-secretase signalling in rat and human. The affected expression or function 
of Aph-1b (Aph-1b copy number variation in rat and Phe217Leu variation in human, respectively) can 
lead to substrate-specific alterations in γ-secretase cleavage activity. Subsequent differences in the 
amount of released intracellular domain (ICD) may result in complex traits or diseases. 
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For understanding AD, the γ-secretase complex has long been of interest since it 
cleaves the AD-related APP protein. Since we now find a possible link of the γ-secretase 
complex with a number of complex traits, γ-secretase signalling may not only be 
involved in AD, but also in a variety of other diseases (atherosclerosis, epilepsy, 
HIV-1 infection and colorectal cancer; chapters B1-B4). Interestingly, a number of 
γ-secretase substrates have been reported to be implicated in the pathogenesis of one 
or more of these associated diseases (table 2). Obviously, further studies are required 
to completely understand the role of γ-secretase and its substrates in the pathogenesis 
of disorders with a complex aetiology. 
Complicating factors in association studies for disorders with a complex 
aetiology
Although a number of significant associations have been found, it is clear that our 
human genetic associations ask for replication in additional cohorts to understand 
the contribution of the γ-secretase signalling pathway to the pathogenesis of complex 
disorders. Unfortunately, such genetic association analyses for complex disorders 
are greatly complicated by a number of factors that are described below.
Population stratification 
Genetic variations often occur among (geographically or ethnically) different 
populations and this fact may thus increase the difficulty in data interpretation as well. 
For correct stratification and successful replication, it is therefore highly important 
that samples are clinically, geographically and ethnically well characterized. 
Definition of phenotype
In the genetics of psychiatric disorders, the definition of a phenotype is one of the 
main problems. Most genetic studies use patient characterization according to the 
Diagnostic and Statistical manual for mental disorders version IV (DSM-IV, 2000) 
or the International Classification of Disease version 10 (ICD-10, 1992) criteria. 
However, investigators nowadays believe that the phenotype should be specified 
in more detail, since most neurodevelopmental disorders include a number of 
intermediate clinical subtypes and distinct phenotypical parameters (endophenotypes) 
(Gottesman and Gould, 2003), presumably each with a different genetic background. 
Such endophenotypes may help in the identification of risk factors, although the 
effectiveness of this approach has recently been questioned (Flint and Munafo, 
2007). Nevertheless, analysis of an endophenotypically defined group of patients 
may increase replication efficacy.
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human APH1B 
Phe217Leu 
variation
rat Aph-1b gene-
dosage imbalance
γ-secretase substrates possibly involved in 
complex trait or disease
↑↓ risk for 
developing a 
neurodevelopmental 
disorder (NS; 
chapter B4)
↑ risk for 
neurodevelopmental 
features (reviewed by 
Ellenbroek and Cools, 
2002)
APP (Sokol et al., 2006)
DCC (Flores et al., 2005)
ErbB4 (reviewed by Mei and Xiong, 2008)
GluR3 (Ibrahim et al., 2000)
HLA-A2 (Ozcan et al., 1996)
LRP8 (Barr et al., 2007)
Notch4 (Wei and Hemmings, 2000) 
NRG 1 (reviewed by Mei and Xiong, 2008)
P75NTR (Rajakumar et al., 2004)
↑ risk for developing 
epilepsy (chapter 
B2)
↑  incidence of bursts of 
bilateral synchronous 
spike wave discharges 
(de Bruin et al., 2000)
GluR3 (Rogers et al., 1994) 
HLA-A2 (Fontana et al., 1978)
Scnb2 (Chen et al., 2002)
↑ risk for developing 
premature coronary 
atherosclerosis 
(male-specific 
association; chapter 
B1)
↑ risk for developing 
atherosclerosis due 
to reduced relaxation 
of mesenteric arteries 
upon α2 and β2-agonist 
stimulation (Smits et al., 
2002; Riksen et al., 2003)
APP (Nelson and Alkon, 2005)
CD44 (Vendrov et al., 2006)
CSF-1 (Rajavashisth et al., 1998)
Ephrin-B1 and -B2 (Sakamoto et al., 2008)
ErbB4 (Gassmann et al., 1995) 
LRP (Hiltunen et al., 1998; Schulz et al., 2002)
NRG (Clement et al., 2007)
↑ risk for HIV-1 
infection (chapter 
B3)
↑ TH2 response upon 
infection and a disturbed 
Th1/Th2 balance 
(Kavelaars et al., 1997)
CD43 (Barat and Tremblay, 2002)
HLA-A2 (Papasteriades et al., 1993)
Syndecan-3 (Bobardt et al., 2003)
↑ risk for developing 
colorectal cancer 
(chapter B4)
↓ angiogenesis and tumor 
growth (Teunis et al., 
2002)
DCC (Fearon et al., 1990; Itoh et al., 1993)
Ephrin-B1 and B2 (Tang et al., 1999; Liu et al., 
2002)
GHR (Yang et al., 2004)
HLA-A2 (Rees et al., 1988)
Notch (Stanger et al., 2005; van Es and Clevers, 
2005)
TYRP2 (Ying-Tao et al., 2005)
↑ risk for developing 
rheumatoid arthritis 
(NS; chapter B4)
↓ sensitivity for 
rheumatoid arthritis (van 
de Langerijt et al., 1994)
CD43 and CD44 (Humbria et al., 1994)
CSF1 (Cupp et al., 2007)
Ephrin-B1 (Kitamura et al., 2008)
HLA-A2 (Ford et al., 1984)
LRP2 (Ooka et al., 2003)
Notch and the ligands Delta1 and Jagged (Naka-
zawa et al., 2001; Yabe et al., 2005)
Syndecan-3 (Patterson et al., 2005)
↑ risk for celiac 
disease (NS; 
chapter B4)
- CD44 (Kemppainen et al., 2005)
CSF1 (Desreumaux et al., 1998)
E-cadherin (Perry et al., 1999)
HLA-A2 (Kedzierska and Turowski, 2000)
Table 2. Risk effects for human APH1B Phe217Leu variation and rat Aph-1b gene-dosage imbalance
NS: not significant 
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Gene-environment interactions
Another complicating factor in the identification of susceptibility genes for 
complex disorders concerns the possibility of multifactorial gene-plus-environment 
interactions. Unfortunately, such interactions are still difficult to quantify and 
interpret. 
Multiple genes hypothesis
The search for susceptibility genes is further complicated when the aetiology of a 
complex neurodevelopmental disorder can not be explained by a single genetic variant 
with a relatively large effect but is rather caused by an interplay of a number of genes 
with small (additive) effects. For the complex disorders, the essential parameters for 
single- and multiple-locus models have been calculated and an interaction of about 
three different genes together with the environment was predicted to underly this 
disorder (Risch, 1990). Not surprisingly, in general the greater the number of genes 
involved the more difficult their identification will be and larger (or additional) cohorts 
will be necessary to reach significant association. In addition, besides the possibility 
that multiple susceptibility genes are involved, individuals may be affected by the 
absence of protective alleles, while epistasis may also play a role. 
Common disease-common variant or rare-variant hypothesis
At present, it is not clear whether only a relatively small number of common genetic 
variants are linked to the aetiology of complex disorders (known as the “common 
disease-common variant hypothesis”, often abbreviated CD-CV) (Reich and Lander, 
2001; Peng and Kimmel, 2007), or if a large number of rare genetic variants is 
involved (“rare-variant-hypothesis” or heterogeneity hypothesis) (Pritchard, 2001). 
In case of CD-CV, association analyses (e.g. GWA studies) may detect genetic 
variants if the studies contain enough power. It is clear that association analyses will 
be more difficult in rare-variant cases (Slager et al., 2000). 
Future perspectives
The data described in this thesis illustrate the way science often works. While new 
insights concerning the genetics of complex disorders have been obtained, our results 
lead to new opportunities and hypotheses for further research. Our data implicate 
that diseases with a complex aetiology may be the result of an affected γ-secretase 
signaling. However, additional (epi)genetic factors will be involved as well. 
The APO-SUS/-UNSUS rat model provides an interesting model to analyze the 
genetic background of disorders with a complex aetiology. The precise molecular 
basis underlying the model remains to be elucidated. Extensive genome-wide genetic 
screening (for example by using high throughput SNP array analysis or complete 
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sequencing of the two genomes) will be valuable to get a better insight into the 
genetic differences between the two rat lines. Furthermore, genome-wide tissue- 
and time-specific mRNA and protein expression analyses should be performed (for 
example by using microarray analyses or 2D-gel electrophoresis on blood, spinal 
fluid or brain tissues). Besides differences at the mRNA and protein expression 
levels, changes in microRNA (miRNA) levels have also been found to correlate with 
diseases (reviewed by Guarnieri and DiLeone, 2008). Currently, microarray chips 
for rat miRNA expression profiling are on the market and might thus be instrumental 
to examine whether miRNAs are involved in the development of the complex APO-
SUS phenotype.
Besides genetic and expression analyses, it might be worthwhile to obtain more 
detailed insights into the anatomical differences between the brains of APO-SUS and 
–UNSUS rats. For this purpose, histological stainings of the brain may be helpful. 
Furthermore, neuroimaging (e.g. functional magnetic resonance imaging (fMRI) or 
positron emission tomography (PET)) may help assessing any differences in APO-
SUS and –UNSUS brain functioning. Together, such approaches will be helpful to 
identify new genes and pathways involved in a specific complex trait. Alternatively, 
tracking down behavioral outliers within the APO-SUS and –UNSUS populations 
(e.g. APO-SUS rats with low apomorphine susceptibilities or APO-UNSUS rats 
with high apomorphine susceptibilities), and subsequent analysis of the parameters 
described above may be rewarding.
Regarding the gene * environment interactions that clearly occur in the APO-SUS/-
UNSUS model system (Ellenbroek et al., 2000; Degen et al., 2004), it might be 
interesting to study the effect of early-life experiences (e.g. maternal deprivation or 
cross-fostering) on the behavioral abnormalities in adulthood. Subsequent genetic 
and expression profiling may be a fruitful approach to further investigate the genes 
and molecular pathways involved. We expect that the degree of maternal care may 
influence the degree of vulnerability to develop behavioral abnormalities later in 
life. Upon exposure to a stressful experience during adulthood, the abnormalities 
may become apparent (so-called three hit model of stress-induced psychopathology; 
a disease results from an interaction between (i) genetic factors, (ii) early-life 
events and (iii) late environmental factors (Ellenbroek, 2003; Ellenbroek et al., 
2005)). Therefore, it will be interesting to see whether APO-SUS and –UNSUS rats 
exposed to early-life events and late environmental stressors show differences in 
their behavioral phenotypes and whether this is coupled to their genetic/molecular 
build-up.
The objective of using the APO-SUS/-UNSUS model is to translate the results 
by validating the susceptibility pathways in human. The data from our human 
association studies have to be replicated and should be followed up to understand the 
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contribution of γ-secretase to disorders with a complex aetiology. In addition, future 
studies may include Aph-1b Phe217Leu analysis in complex disorders that have 
not been tested in our studies (e.g. mental retardation, addiction, anxiety disorders 
and posttraumatic stress disorder). For a better understanding of the aetiologies 
involved in complex disorder pathogenesis, it will be helpful to obtain detailed 
clinical, ethnical and geographical information on large groups of individuals. In 
addition, the environmental factors need to be well defined and documented. In 
general, knowledge of the relevant environmental risk factors is rather limited. Close 
collaborations between psychiatrists and genetic researchers are therefore required. 
Currently, the first genome-wide association studies with high-throughput SNP arrays 
have been reported for a number of complex disorders (Steer et al., 2007; Baum et al., 
2008; Meaburn et al., 2008). Undoubtedly, in the near future many more studies with 
the 500K and even larger SNP arrays can be expected. Such studies will however 
not cover all genetic variations in the genome (Wollstein et al., 2007), because 
SNPs with a low minor allele frequency (MAF) (<0.05) are usually not included 
on the arrays, thereby excluding analysis of rare genetic variants, like the Aph-1b 
Phe217Leu SNP. This is unfortunate, since the rare genetic variants are generally 
considered to have a higher chance of being causative (Cargill et al., 1999). Thus, 
candidate gene approaches on selected SNPs with a low prevalence may increase 
the chances to identify functional genetic variants. Because one would expect that 
causal SNPs have an effect in any population, a further consideration may involve 
a choice of SNPs with a low MAF in all ethnical populations. In this connection, 
one has to be aware of the possibility that such a SNP may need an additional 
polymorphism(s) to explain the phenotype (multiple genes hypothesis), while the 
additional genetic variation(s) may not be present in a particular ethnical population. 
One of the practical problems in dealing with low-MAF SNPs concerns the sample 
size necessary to obtain reliable association data, i.e. the lower the MAF the more 
samples are required to reach statistical significance. It is likely that inclusion of 
potentially functional SNPs (non-synonymous SNPs and SNPs in gene promoter 
regions or exon-intron boundaries) will increase the success rate in the analysis. 
Clearly, many questions remain unanswered with respect to the pathogenesis of 
disorders with a complex aetiology. Nevertheless, it is to be expected that within 
the next years the tsunami of genetic research, in combination with the use of well-
defined animal models, will result in the identification of susceptibility genes for 
these disorders. Eventually, the acquired understanding of the molecular mechanisms 
underlying complex disorders may lead to translational research, including the design 
of gene/pathway-specific drugs and the application of disease-preventing strategies.
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Nearly all diseases have a genetic component. Some diseases are caused by 
alterations in a single gene (monogenic diseases), but for most conditions and 
diseases the causes are much more complex since they are thought to result from 
a combination of (more than one) genetic and environmental factors. The group of 
these so-called complex disorders (or multifactorial disorders) include diseases like 
asthma, diabetes, heart disease, rheumatoid arthritis, hypertension, atherosclerosis 
and cancer, the neurodegenerative diseases (such as Alzheimer’s disease, AD) and 
the neurodevelopmental disorders (e.g. schizophrenia, attention deficit hyperactivity 
disorder-ADHD and autism). Complex disorders often cluster in families, but have a 
relatively low heritability when compared with the monogenic diseases. Due to the 
low level of inheritance, the influence of environmental factors and the possibility of 
an interplay of a number of genes (instead of a single gene), it is often still elusive 
which gene (or genes) is responsible for the pathogenesis of these disorders. Therefore, 
treatment of complex disorders is usually difficult and mostly based on reducing 
the symptoms instead of curing the disease. A better understanding of the genes 
and pathways involved in complex disorders may be useful for the development of 
specific medicines and the application of disease-preventing strategies. 
The objective of this thesis was to provide a contribution to a better understanding 
of the genes and pathways involved in complex disorders. An animal model may be 
helpful to further understand such genes and pathways. An example of an animal 
model for disorders with a complex aetiology constitutes the apomorphine-susceptible 
(APO-SUS) and apomorphine-unsusceptible (APO-UNSUS) rats. Since both genetic 
and environmental factors determine the phenotype of the APO-SUS/-UNSUS rats 
and APO-SUS rats display a number of behavioural and pathophysiological features 
reminiscent of complex disorders, the model may contribute to an analysis of the 
genetic background of complex disorders. Initially, we analysed the APO-SUS/-
UNSUS rat model (part A) and subsequently translated our results by validating 
susceptibility pathways in human (part B). 
In chapter A1, microarray analysis (mRNA profiling) of the hippocampus from 
APO-SUS and –UNSUS rats revealed a reduced expression of Aph-1b in APO-SUS 
rats when compared to APO-UNSUS rats. We observed that the difference in Aph-1b 
mRNA expression was found in the original as well as in an independent replication 
of the APO-SUS and –UNSUS rat lines (the lines were developed with a ten-year 
interval). Subsequent genomic analysis of the Aph-1b locus in the APO-SUS and 
–UNSUS rats revealed a gene-dosage imbalance; APO-SUS rats have one or two 
Aph-1b gene copies, whereas APO-UNSUS rats harbour three genes. The reduced 
Aph-1b mRNA expression in APO-SUS rats segregated with the reduced number of 
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Aph-1b gene copies. Aph-1b is a component of the γ-secretase enzyme complex that 
is responsible for the proteolytic processing of a wide variety of type I transmembrane 
proteins (including the amyloid-β (Aβ) precursor protein APP, neuregulin and 
Notch1-4) and is involved in multiple (neuro)developmental signalling pathways. 
The expression levels of the other γ-secretase components (Aph-1a, presenilin 1 and 
2, nicastrin and presenilin enhancer 2) were not altered, whereas γ-secretase cleavage 
activity towards a number of substrates was found to be different between the APO-
SUS and –UNSUS rats. Furthermore, the number of Aph-1b gene copies segregated 
with a number of behavioural traits, including apomorphine susceptibility, locomotor 
activity in the open field and open arm entries in the elevated plus maze.
Chapters A2 and A3 further describe the affected Aph-1b expression and γ-secretase 
cleavage activity in the APO-SUS/-UNSUS rat model. Expression levels of Aph-
1b and its paralogues Aph-1aS and -1aL were investigated during development 
(from embryonic day 13 to postnatal day 100). These analyses revealed gene-dosage 
dependent differences in Aph-1b mRNA expression throughout development, 
whereas expression levels for Aph-1a were neither prenatally nor postnatally 
affected. Furthermore, we observed tissue-specific alterations in γ-secretase cleavage 
activity towards the APP family (APP and its relatives the APP-like proteins APLP1 
and APLP2), p75NTR, ErbB4 and neuregulin-2. We may thus conclude that when 
compared to the APO-UNSUS rats and throughout the entire developmental period 
the relatively low levels of Aph-1b mRNA and low γ-secretase activity in the APO-
SUS rats likely affected (neuro)developmental signalling pathways and, consequently, 
contributed to the development of the complex APO-SUS phenotype. Nevertheless, 
experiments based on crossing, genetic re-selection and subsequent phenotypical 
analysis revealed that the Aph-1b gene-dosage imbalance is not the only causative 
factor for the phenotypical differences between the APO-SUS and –UNSUS rats. 
In chapters A4 and A5, we identified in both the original and replicate APO-SUS/-
UNSUS rat lines a number of genetic variations other than in Aph-1b. We observed 
eight copy number variations, five small genetic variations and one epigenetic 
variation (DNA methylation) in the APO-SUS and –UNSUS rat genomes. Together 
with the Aph-1b gene defect, a number of these newly identified variations may thus 
contribute to the complex APO-SUS phenotype. 
The objective of using the APO-SUS/-UNSUS model was to translate the results 
by validating susceptibility pathways in human. We therefore performed human 
association studies to examine whether γ-secretase signalling is involved in the 
pathogenesis of disorders with a complex aetiology. In chapter B1 we showed that a 
non-synonymous single-nucleotide polymorphism (SNP) in the human APH1B gene 
(presence of a leucine instead of the evolutionarily conserved residue Phe217) causes 
a reduced γ-secretase cleavage activity towards one of its substrates, syndecan-3. Our 
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association analyses in a number of complex disorders showed a link between this 
SNP and disorders with a complex aetiology. We may thus assume that the human 
Phe217Leu polymorphism in the APH1B gene has a functional effect. Furthermore, we 
show a male-specific association of this APH1B SNP with premature atherosclerosis 
(chapter B1), as well as its association with epileptic seizures (chapter B2), HIV-1 
infection (chapter B3) and colorectal cancer (CRC; chapter B4). In addition, a higher 
prevalence of the risk allele was observed in patients with bipolar disorder, autism, 
ADHD, dyslexia, rheumatoid arthritis, celiac disease, throat cancer, prostate cancer 
and lung cancer. However, these latter associations proved not to be statistically 
different from the respective controls, probably due to the low number of cases and 
the low frequency of the risk allele (chapter B4). Thus, the γ-secretase pathway 
may play a role in the pathogenesis of a number of complex disorders, suggesting 
that a subset of disorders with a complex aetiology have a common biological 
background. 
Overall, the data presented in this thesis show that alterations in γ-secretase cleavage 
may contribute to the pathogenesis of a number of complex traits and disorders. 
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Bij het ontstaan van vrijwel alle ziekten is een genetische component betrokken. 
Sommige ziekten ontstaan door een defect in één enkel gen (monogenetische ziekten), 
maar voor de meeste ziekten en aandoeningen is de oorzaak veel complexer. De 
meeste ziekten worden namelijk veroorzaakt door een complex samenspel van een 
(of meerdere) gen(en) met omgevingsfactoren. Tot de groep van deze zogenaamde 
complexe ziekten (ook wel multifactoriële ziekten genoemd) behoren ziekten 
zoals astma, diabetes, hartfalen, hypertensie (hoge bloeddruk), reumatoïde artritis, 
atherosclerose, kanker, de neurodegeneratieve ziekten (zoals de ziekte van Alzheimer) 
en de (hersen)ontwikkelingsstoornissen (zoals schizofrenie, aandachtstekort/
hyperactiviteitstoornis-ADHD en autisme). Hoewel complexe ziekten vaak 
voorkomen in familieverband vertonen ze, in vergelijking met de monogenetische 
ziekten, een geringere mate van overerving. Vanwege deze lagere overervingsfactor, 
alsmede de invloed van omgevingsfactoren en de mogelijkheid dat een aantal genen 
samen (in plaats van één enkel gen) leiden tot de ziekte, is het vaak nog niet bekend 
welk gen (of welke genen) betrokken is bij de totstandkoming van een complexe 
ziekte. Zodoende is de behandeling van patiënten met een complexe ziekte vaak 
erg moeilijk en meestal slechts gebaseerd op het verminderen van de symptomen 
in plaats van het genezen van de ziekte. Indien we een beter begrip hebben van de 
genen en mechanismen die een rol spelen bij de totstandkoming van een complexe 
ziekte zou deze kennis gebruikt kunnen worden voor het ontwikkelen van specifieke 
medicijnen en het opzetten van testen om de ziekte te voorkomen. 
Het doel van het onderzoek beschreven in dit proefschrift was om een bijdrage te 
leveren aan het verkrijgen van een beter inzicht in deze genen en mechanismen. 
Het gebruik van een diermodel kan hierbij helpen. Een voorbeeld van een 
diermodel voor complexe ziekten is het apomorfine-gevoelige (APO-SUS) en 
apomorfine-ongevoelige (APO-UNSUS) rattenmodel. Zowel genetische- alsook 
omgevingsfactoren spelen een rol bij de totstandkoming van het fenotype van de 
APO-SUS/-UNSUS ratten. Aangezien de APO-SUS ratten bovendien een aantal 
kenmerken vertonen die ook worden aangetroffen bij mensen met een complexe 
ziekte, kan het APO-SUS/-UNSUS rattenmodel bijdragen aan de zoektocht naar de 
genetische achtergrond van deze ziekten. In deel A van het proefschrift bestuderen 
we het APO-SUS/-UNSUS rattenmodel en vervolgens gebruiken we deze resultaten 
om de situatie bij de mens te onderzoeken (deel B). 
In hoofdstuk A1 werd met behulp van microarray analyse (het vergelijken van 
mRNA expressieniveau’s) van de hippocampus van APO-SUS en –UNSUS ratten 
gevonden dat, vergeleken met APO-UNSUS ratten, APO-SUS ratten een verlaagde 
hoeveelheid Aph-1b mRNA hadden. Dit verschil in mRNA expressie werd zowel in 
215
Samenvatting
de originele APO-SUS en –UNSUS rattenlijnen als in de onafhankelijke replicatie 
van de lijnen (die tien jaar later was opgezet) waargenomen. Vervolgens toonde 
genomische analyse van het Aph-1b locus aan dat APO-SUS en –UNSUS ratten 
een verschillend aantal Aph-1b genkopieën bezitten; APO-SUS ratten hebben 
één of twee Aph-1b genen, terwijl APO-UNSUS ratten drie kopieën dragen. De 
verlaagde hoeveelheid Aph-1b mRNA correspondeerde met het verminderde aantal 
Aph-1b genkopieën. Aph-1b is een component van het g-secretase enzymcomplex 
dat betrokken is bij de klieving van een groep van transmembraaneiwitten (zoals 
het Alzheimereiwit APP, neureguline en Notch1-4) en bij vele (neuronale) 
ontwikkelingsbiologische signaaltransductieroutes. De expressieniveau’s van 
de overige γ-secretase componenten (Aph-1a, preseniline 1 en 2, nicastrine and 
preseniline-enhancer 2) waren niet verschillend, terwijl γ-secretaseklieving van een 
aantal transmembraaneiwitten wel verschillend bleek te zijn tussen de APO-SUS en 
–UNSUS ratten. Daarnaast bleek het aantal Aph-1b genkopieën te corresponderen 
met een aantal gedragskenmerken (zoals de apomorfine gevoeligheid en de activiteit 
op het open veld).
De hoodstukken A2 en A3 beschrijven in meer detail de verstoorde Aph-1b mRNA 
expressieniveau’s en g-secretase klievingsactiviteit in het APO-SUS/-UNSUS 
rattenmodel. De mRNA expressieniveau’s van Aph-1b en van de paralogen Aph-
1aS and -1aL werden tijdens de ontwikkeling bestudeerd (beginnend op embryonale 
dag 13 en eindigend op postnatale dag 100). Hieruit bleek dat gedurende de gehele 
ontwikkeling het verschillende aantal Aph-1b genkopieën leidde tot een verschillende 
mate van Aph-1b mRNA-expressie, terwijl de Aph-1a mRNA expressieniveau’s 
zowel pre- als postnataal vrijwel gelijk waren. Bovendien werden voor een aantal 
transmembraaneiwitten, te weten APP (en de twee familieleden APLP1 en APLP2), 
p75NTR, ErbB4 en neureguline-2, weefselspecifieke veranderingen in g-secretase 
klievingsactiviteit gevonden. We kunnen dus in feite concluderen dat de verlaagde 
Aph-1b mRNA expressieniveau’s en de verlaagde g-secretase klievingsactiviteit 
tijdens de gehele ontwikkeling van de APO-SUS ratten kan leiden tot verstoorde 
(neuronale) ontwikkelingsbiologische signaaltransductieroutes en daardoor kan 
resulteren in het complexe fenotype van de APO-SUS ratten. Experimenten gebaseerd 
op kruisingen, genetische selectie en daaropvolgende fenotypische analyses hebben 
echter aangetoond dat het verschil in Aph-1b genkopieën niet de enige verklaring is 
voor de fenotypische verschillen tussen de APO-SUS en –UNSUS ratten.
In de hoofdstukken A4 en A5 hebben we een aantal andere genetische variaties 
aangetoond die zowel in de originele als in de onafhankelijke replicatie van de APO-
SUS/-UNSUS rattenlijnen voorkomen. We hebben acht grote en vijf kleine DNA 
variaties alsmede een epigenetische variatie (DNA methylatie) in het DNA van de 
APO-SUS en –UNSUS ratten geïdentificeerd. Samen met het verschil in het aantal 
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Aph-1b genkopieën, zou een deel van deze nieuwe variaties dus kunnen bijdragen 
aan het complexe APO-SUS fenotype.  
Het doel van het onderzoek was verder om de resultaten verkregen met het 
APO-SUS/-UNSUS rattenmodel te gebruikem om mechanismen bij de mens te 
bestuderen. Daarom hebben we vervolgens associatiestudies bij de mens uitgevoerd 
om te onderzoeken of aantasting van de g-secretaseklieving een rol speelt bij de 
totstandkoming van complexe humane ziekten. In hoofdstuk B1 hebben we een 
polymorfisme van een enkel nucleotide (“single-nucleotide polymorphism”, SNP) 
in het humane APH1B gen beschreven (leidend tot het aminozuur leucine, L, in 
plaats van het evolutionair geconserveerde aminozuur fenylalanine, F, op positie 
217 van het eiwit). Een 217L-bevattend g-secretase bleek het  transmembraaneiwit 
syndecan-3 minder goed te klieven. We kunnen dus veronderstellen dat de F217L 
SNP van belang is voor de functie van het enzym. Onze associatiestudies lieten een 
verband zien tussen deze SNP en vroegtijdige atherosclerose bij mannen (hoofdstuk 
B1), epileptische aanvallen (hoofdstuk B2), HIV-1 infectie (hoofdstuk B3) en 
darmkanker (hoofdstuk B4). Daarnaast werd het risico-allel vaker aangetroffen 
in patiënten met een bipolaire stoornis (manisch-depressieve stoornis), autisme, 
ADHD, dyslexie, reumatoïde artritis, coeliakie (glutenenteropathie), hoofd- en 
nekkanker, prostaatkanker en longkanker. Echter, deze laatste associaties bleken niet 
significant te zijn, waarschijnlijk vanwege het relatief kleine aantal patiënten in deze 
groepen en het geringe voorkomen van de F217L SNP bij de mens (hoofdstuk B4). 
Uit bovenstaande resultaten kunnen we concluderen dat het g-secretase-enzym een 
rol kan spelen bij de totstandkoming van een aantal complexe ziekten, waaraan dus 
een vergelijkbare biologische oorzaak ten grondslag kan liggen. 
Samenvattend kan gesteld worden dat de resultaten van het onderzoek beschreven in 
dit proefschrift suggereren dat een verandering in g-secretase klievingsactiviteit kan 
leiden tot een breed scala aan complexe ziekten. 
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Jawel, het is zover. De laatste bladzijdes van dit proefschrift kunnen geschreven 
worden; de berg is beklommen. Aan de voet van de berg begonnen op 1 april 2002, 
en nu, september 2008 kan ik terugblikken op een geweldige tocht met vele mooie, 
spannende en uitdagende momenten, maar natuurlijk ook, zoals bij elke tocht, met 
soms moeilijke en frustrerende momenten. Natuurlijk kon deze tocht alleen maar 
slagen door de tomeloze inzet van velen, die ik graag middels dit dankwoord zou 
willen bedanken. 
Allereerst wil ik graag mijn promotor Gerard Martens bedanken. Beste Gerard, 
bedankt voor het vertrouwen dat je in me hebt gesteld door mij een promotieplaats 
aan te bieden op het “rattenproject”. Verder wil ik je graag bedanken voor de 
wetenschappelijke discussies, de lage drempel van je kamer, het bijsturen tijdens het 
schrijven van de artikelen en natuurlijk de begeleiding die je me de afgelopen jaren 
gegeven hebt bij het plannen en uitvoeren van de experimenten.
 
Vervolgens is er natuurlijk ook een enorm groot dank-je-wel voor Marcel. Als 
begeleider tijdens m’n eerste stage heb je me de basisvaardigheden van het moleculaire 
labwerk bijgebracht en vervolgens, toen ik terugkwam op de afdeling voor m’n 
promotieonderzoek, hebben we een paar jaar zeer nauw mogen samenwerken. Jouw 
rust en doorzettingsvermogen zorgden voor een enorm prettige samenwerking en 
inspiratie. Bedankt daarvoor! 
Na de Marcel-samenwerkings-periode volgde de Jessica-samenwerkings-periode. 
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